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As we continue to gain more insights into HDAC structures and the roles played by 
individual HDAC isoforms in tumor progression, the prospect of discovering safer HDACi therapy 
is looking brighter. An evolving strategy in the clinical application of HDACi as therapeutics for 
solid tumors involves combining HDACi with other therapeutics, with the goal of potentiating 
either of the two drugs being combined. However, dose optimization, toxicities from individual 
drugs, and possibility of drug-to-drug interactions associated with combination therapies are some 
of the bottlenecks that need to be surmounted. One way to mitigate these challenges is to make a 
single compound (referred to as “bifunctional compound” in this thesis) that can engage the two 
or more targets of interest in combination therapy. Another strategy gaining prominence in HDACi 
drug discovery field is to incorporate a targeting moiety, with affinity for receptors highly 
expressed in tumors, into the design of HDACi. Such targeted HDACi will have a higher 
propensity to accumulate in tumors relative to healthy tissues, and may also be able to access and 
localize in solid tumors easily. We explored the two approaches in my thesis projects, in addition 
to carrying out preliminary studies on drug delivery using either clarithromycin- or tamoxifen-
functionalized liposomes. 
Attempts to improve on the challenges faced by combination therapy led me to making 
bifunctional compounds capable of interacting with cyclooxygenase and HDACs. Two COX 
inhibitors, celecoxib and indomethacin, were used as structural templates on which the 
bifunctional compounds were developed. In one of the series based on celecoxib, we obtained 
compounds with low nanomolar activity towards class I and class IIB HDACs, in addition to COX-




based on the indomethacin template showed potent activity towards class I and class IIB HDACs, 
in addition to selectivity towards COX-2 (a property lacking in indomethacin).  A remarkable 
observation with some of the lead compounds is their enhanced cytotoxicity towards androgen 
dependent prostate cancer cell line (LNCaP) relative to androgen independent prostate cancer cell 
line (DU-145). Target validation in LNCaP, cell cycle analysis and inhibition of NF-kB activation 
showed that our lead compounds have unique mechanism of action in cells. Compared to 
vorinostat, these lead compounds displayed tumor-selective cytotoxicity as they have low anti-
proliferative activity towards healthy cells (VERO); an attribute that makes them attractive 
candidates for drug development. 
In chapter two, clarithromycin was incorporated into the head group of hydroxamate- and 
amino biaryl-based HDACi. Clarithromycin belongs to a class of compounds called macrolides, 
known for their preferential accumulation in the lung tissues. Hence, the goal of this project is to 
make HDACi that can localize in lung tissues with potential application in lung cancer treatment. 
Lead compounds from the hydroxamate-based series potently inhibited all the three HDAC 
isoforms they were profiled against, and showed cytotoxic effects in lung and breast cancer cell 
lines that surpass US FDA approved vorinostat. More importantly, the lead compounds were less 
cytotoxic towards the healthy cell line (Vero) compared to vorinostat. While hydroxamate-based 
compounds are known to have activity across all HDAC classes, amino biaryl-based compounds 
only show activity against HDAC 1 and HDAC 2, (class I HDACs). So, a sub-goal in this chapter 
is to make clarithromycin- amino biaryl-based HDACi that only inhibit HDAC 1 and HDAC 2, 
and also localize in lung tissues. Consistent with their selectivity for class I HDACs, all the amino 




However, their potent enzyme inhibitory activities did not translate into strong growth inhibition 
of lung- and breast cancer cell lines. 
In continuation of our efforts towards making targeted HDACi, we incorporated a 
benzamide template, with high affinity for melanin, into the design of HDACi with the goal of 
selective delivery of the HDACi to melanoma cells. This effort resulted in a new series of 
compounds with high potency towards HDAC 1 and HDAC 6. Against HDAC 1, lead compound 
obtained is about ten-fold more potent than SAHA, though with the same level of potency towards 
HDAC 6. Surprisingly, all the compounds were only modestly cytotoxic activity towards 
melanoma cell lines, B16F10 and A375. We further explored a prodrug approach, whereby we 
made a compound bearing the benzamide template linked by a labile bond to a hydroxamate-based 
HDACi.  While cytotoxicity was not significantly improved, the pro-drug compound showed some 
promise and warrants further study. 
Lastly, preliminary studies were carried out, wherein we evaluated the suitability of 
clarithromycin and tamoxifen as targeting ligands on liposomes encapsulating propidium iodide. 
Liposomes formed with a phospholipid derivatized with clarithromycin showed some promise in 
enhancing propidium iodide uptake by macrophages (RAW 264.7). Similarly, phospholipid 
derivatized with tamoxifen helped facilitate substantial uptake of liposome made from it. Further 
studies are needed to validate the observations from the two uptake studies, and optimize the 








1.1. Epigenetic regulation of gene expression and cancer 
Epigenetics, a term used to describe transfer of heritable traits that are independent of 
changes in the DNA sequence,1 play a significant role in regulation of gene expression. As such, 
homeostatic regulation of gene expression is an important factor that determines the normal 
functioning of the cells. Consequently, there is a strict requirement for an efficient cellular 
epigenetic regulation of expression to keep the cells healthy. Diseases such as cancer, 
neuropsychiatric disorder, and inflammation have been associated with a dysfunctional epigenetic 
machinery.2 This, necessitates having a thorough understanding of things/events that causes 
aberrant epigenetic regulation. The dynamics of the epigenetic regulation process involves a 
concerted regulation of events such as DNA methylation, histone modification, and chromatic 
remodeling -all epigenetic processes3-4. Among these epigenetic events, DNA methylation and 
histone modification are the most studied.  
In cancer, hypermethylation of CpG islands of promoter regions of tumor suppressor genes 
is a frequent event that often results in silencing of the associated genes.5 Suppression and/or 
mutation of genes such as P16INK4A (encodes cyclin dependent kinase inhibitor) and BRCA1 are 
often due to hypermethylation of the CpG islands of their promoters.5 One consequence of this is 
development of a dysregulated cell cycle, which enables cancer cells to evade natural cell death. 




therapeutic values in cancer, and have since been approved by the US Food and Drug 
Administration (FDA) for treating myelodysplastic syndromes.6 
Likewise, histone hypoacetylation, due to upregulation of histone deacetylase activity, is a 
common occurrence in tumors which also leads to downregulation of tumor suppressor genes. The 
sections below are devoted to discussing histone acetylation/deacetylation and their associated 
enzymes. 
 
1.2. Histone deacetylases (HDACs) 
Histone deacetylases (HDACs), commonly referred to as “erazers” because of their mode 
of action, are a family of enzymes that facilitate the removal of the acetyl group on the lysine of 
histones to influence the dynamics of the chromatin7. While their substrate appears to be just 
histone, there have been reports of some HDAC isoforms catalyzing the deacetylation of other 
proteins8. A good example of this is the cytoplasmic localized HDAC6 that also deacetylates 
tubulin and HSP909. In conjunction with histone acetyl transferases (HATs), HDACs control the 
accessibility of transcription factors to the promoter regions on the chromatin (Figure 1.1). 
Therefore, a balance in histone acetylation and deacetylation activities is required for maintaining 
a stable epigenome.10 As will be discussed copiously in Chapters 2-5, one of the survival tricks 
employed by cancer is to ensure an imbalance in the acetylation and deacetylation activities which 
ultimately leads to silencing of tumor suppressor genes. This is achieved by maintaining a high 




There are currently eighteen known isoforms of HDACs, grouped into four classes based 
on phylogenetic analysis, sequence homology and cellular localization.11-12, 14 Among these four, 
class III HDACs, consisting of seven HDAC isoforms, are non-zinc dependent but rely on NAD+ 
for their catalytic activity.11 Classes I, II and IV make up the Zn dependent HDAC isoforms. While 
Class I comprises HDACs 1, 2, 3 and 8; class II is further subdivided into class IIA (comprising 
HDACs 4, 5, 7 and 9) and class IIB (comprising HDACs 6 and 10), with class IV having HDAC 
11 as the only member of the class.  
 
Figure 1.1: Cartoon representation of HDAC and HAT function. Image courtesy of Dr. Berkeley 
Gryder (an abridged version is published in ref. 11). 
In terms of cellular localization, class I HDACs are located mainly in the nucleus, with 




in the cytoplasm. Lastly, class IV HDACs could be found either in the nucleus or cytoplasm (Table 
1.1).  
Each HDAC isoform plays different roles in driving tumorigenesis. In most cancer cases, 
elevated levels of various HDAC isoforms have been reported as shown in Table 1.2 below. 
Mechanistically, all Zn-dependent HDACs use a similar mechanism to facilitate the 
hydrolysis of acetyl groups on histone’s lysine. Acetylated lysine residue traverses the  
Table 1.1: Cellular localization of HDAC isoforms11-12 
Class Isoform Cellular localization 
I HDACs 1,2,3, and 8 Nucleus 
IIA HDACs 4, 5, 7, and 9 Nucleus/cytoplasmic 
IIB HDACs 6 and 10 Cytoplasmic 
IV HDAC 11 Nucleus/cytoplasmic 
 
hydrophobic pocket of the enzyme’s active site until it gets to an optimum distance for chelation 









Table 1.2: HDAC isoform overexpressed in various cancer types14-15 
Cancer Type HDAC isoform overexpressed 
Cutaneous T-cell lymphoma HDAC1, HDAC2 and HDAC6 
Colorectal HDAC1, HDAC2 and HDAC3 
Prostate HDAC1, HDAC2 and HDAC3 
Lung  HDAC1, HDACs4-6, and HDAC10 
Breast HDAC1, HDAC6 
Gastric HDAC1, HDAC2 and HDAC3 
Liver HDAC6 
 
nucleophilic attack on the acetamide, by a water molecule activated by surrounding histidine 
residues, to form an oxyanion transition state, which then collapses to give acetate and free lysine 





Figure 1.2: Proposed mechanism for histone deacetylation by HDAC enzymes13 
 
1.3. Histone acetyl transferases (HATs) 
HATs, often referred to as “writers” due to their mode of action, add acetyl group to the 
lysine on histone tail to disrupt the electrostatic interactions holding the DNA to histones. In 
conjunction with HDACs, HATs control access of transcription factors to promoter regions on the 




with other proteins. In contrast to HDACs, HATs utilize acetyl CoA in carrying out their catalytic 
activity.16-17 Although it is widely believed that the consequence of lysine acetylation is the 
disruption of electrostatic interaction keeping the chromatin compact, covalent modification of 
histones could also serve as an epigenetic marker for gene expression.16, 18 In addition to their 
acetylation function, HATs also have other functions, such as DNA damage repair and maintaining 
genome stability, as dictated by the protein complexes to which they are bound.19  As with HDACs, 
HATs also have non-histone proteins as substrates, specifically P53 and several other 
mitochondrial proteins.8 
The roles of HATs in the development and progression of certain malignancies have been 
a subject of recent studies.20 Increased HATs activity on genes that drive tumorigenesis has been 
observed in some cancer types,21 and this has sparked interest in developing HATs inhibitors for 
possible intervention in such types of cancer.22-24 
 
1.4. Histone deacetylase inhibitors: pan inhibitors vs class-selective inhibitors  
Since the observation that reversal of the balance in equilibrium dynamics of HDACs and 
HATs facilitates upregulation of tumor suppresor genes, hitherto silenced in cancer, efforts have 
been devoted to making small molecule inhibitors of commonly over expressed HDACs. These 
efforts paid off in 2006 with the US FDA approval of the first HDAC inhibitor, Vorinostat (also 
known as SAHA). The approval of SAHA paved the way for other HDACi (Figure 1.3A) to gain 
approval, resulting in a total of five HDACi in the clinic. Out of this five, only four (including 
SAHA) HDACi are approved for use in the US market. In addition to this, several HDACi are at 




have also stimulated interests in treatment of other disease characterized by aberrent gene 
expression25. 
A closer look at the structures of all clinically approved HDACi reveals a common 
structural feature, that could be divided into zinc binding group (ZBG), linker and surface 
recognition group (also known as cap) (Figure 1.3B). All these three components are amenable to 
structural modifications to generate a library of HDACi the could either be active across all HDAC 
isoforms (pan inhibitors) or selective towards a particular class of HDAC (isoform selctive). With 
the exception of a few (e.g tubacin and tubastatin A,26 both selective HDAC6 inhibitors), 
compounds having hydroxamic acid as their ZBG always end up as pan inhibitors. On the other 
hand, compounds with benzamides as ZBGs have selective inhibitory activity towards class I 
HDAC.27-29 While other less common ZBGs, such as ethyl carbamate (seen in santacruzamate 
A30), 3-hydroxypyridine-2-thione,31 also confer isoform-selective inhibitory activities.   
Though in vitro studies suggest that class I HDAC inhibition is essential in the anticancer 
activity of HDAC inhibitors,32 it is yet to be seen if there is an advantage to having class-selective 
inhibitors over pan inhibitors in the clinic. Among the four US FDA approved HDACi, only 
romidepsin could be considered as being class-selective in its inhibitory activity, with low 
nanomolar IC50 against class I HDACs.
33 Despite this, romidepsin shows off-target toxicities 
typical of pan inhibitors.34 Perhaps one could argue that hydroxamates (pan inhibitors) may not be 
the best due to their susceptibility to hydrolysis and glucuronidation,35-36 which adversely affect 
the pharmacokinetic profile.  
While HDACi have enjoyed tremendous successes in the clinic, off-target toxicity, poor 




challenges.11 Overall, the projects described in this thesis capture ways of mitigating the 
undesirable attributes of clinically approved HDACi. Chapters 2 and 3 cover targeted approaches 
towards discovery of novel HDACi, while Chapter 4 introduces the concept of bifunctional 
compounds active against HDAC and COX-2. With the eventual goal of achieving selectively 
delivery of HDACi, work described in Chapter 5 focuses on preliminary studies towards using 









                                             
Figure 1.3: A) Structures of clinically approved HDAC inhibitors; B) HDACi pharmacophoric 
model. 
 
1.5. Macrolide-derived HDACi 
Macrolides are a class of antibiotics recommended as first line treatment for antimicrobial 
infections of soft tissues, especially lung tissues. Structurally, most macrolides possess either a 14- 
or 15-membered macrocyclic ring structure, with two sugar moieties attached (Figure 1.4). Their 
complex ring structures make them an excellent template to generate non-peptide macrocyclic 
HDACi. In addition to this, macrolides are known to show substantial localization in lung 
tissues,37-39 making them ideal candidates to generate targeted chemotherapeutic agents specific 
for lung cancer tissues. Previous work in our lab has identified clarithromycin, azithromycin and 
TE-802 as excellent mimetics for the cap group of macrocyclic HDACi,40-41 though SAR studies 
were restricted to modifications at the desosamine sugar, and linker lengths were varied from six 
to eight methylenes separating the cap group from the ZBG. 
As a follow up, Chapter 2 of this thesis focuses on expanding the SAR studies to include 
modifications at the cladinose sugar of clarithromycin to generate a new series of HDACi with 




described previously40-41 was also expanded to generate compounds with shorter linker lengths to 
study the effect of short linkers on HDAC inhibitory activities and on anti-proliferation activity. 
Also, lead compounds generated were evaluated for their ability to downregulate NF-Kb mediated 
inflammatory activity. Lastly, considering the need for class I HDAC isoforms inhibition for the 
anticancer activity of HDACi, a bi-aryl ZBG known to confer selective inhibition of HDAC 1 and 
HDAC 2 on HDACi,42-43 was adopted as ZBG to further generate a library of clarithromycin-based 
isoform selective HDACi. 
  
 




1.6. HDACi for melanoma 
Melanoma of the skin ranks as the fifth most prevalent among estimated new cases of 
cancer in 2015.44 At the advanced stage, melanoma becomes very aggressive and resistant to 
chemotherapy. A large subset (about 60 percent) of advanced melanoma cases is believed to carry 
BRAFV600E mutation, which drive signaling in the Mitogen-Activated Protein Kinase (MAPK) 
pathway, independent of upstream signaling by RAS.45-46 Currently, the inhibitor of the 
hyperactivated BRAF, Vemurafenib,46 is the most successful drug used to treat advanced 
melanomas having BRAFV600E mutation. 




To expand the treatment options available for melanoma, there has been tremendous effort 
towards understanding other pathways believed to be involved in melanoma development and 
progression. A critical understanding of such pathways will aid our effort towards developing 
better diagnosis and therapeutics for melanoma. One of such pathways is epigenetic regulation of 
genes that drive signaling pathways in melanoma. While about ten percent of all melanoma 
incidence is linked to genetic inheritance,48 aberrant regulation of epigenetic events such as 
chromatin remodeling, DNA methylation and histone modification are believed to play significant 
roles in melanoma development.47-49 For instance, histone hypo-acetylation, a consequence of 
overexpression of HDAC, leading to downregulation of tumor suppressor genes (P21 and P53) is 
a common occurrence that has been characterized in melanoma cells in vitro.50 Recently, HDAC 
isoforms- 5 and 6 were shown to be the dominant HDAC isoforms expressed in melanoma.51 
Hence, inhibition of HDACs, with small molecules, could provide an alternative approach towards 
melanoma treatment.  
Previous attempt to study the role of HDAC 6 selective inhibitors in inhibiting the growth 
of B16F10 melanoma cell line has shown some promise, as the lead compounds tested showed 
high micromolar IC50.
32 Interestingly, a Phase 2 clinical trial study of vorinostat (SAHA) in 
metastatic uveal melanoma (ClinicalTrials.gov identifier: NCT01587352) is about to begin and is 
currently recruiting participants. 
To further evaluate the effects of HDACi in melanoma, the project described in Chapter 3 
of this thesis focuses on developing HDACi targeted towards melanoma. In doing this, a targeting 
moiety was incorporated into the surface recognition group of an hydroxamate-based HDACi 




called benzamides. These compounds are unique for their ability to bind melanin, and are currently 
being developed as diagnostic agents for melanoma.52-53 Two classes of HDACi were made in this 
study: one based on benzyl, and another based on pyridyl templates. These compounds showed 
potent inhibitory activity in HDAC assay against HDAC1 and HDAC6, though with only modest 
potency against melanoma cell lines. A prodrug approach was also employed to further exploit the 
utility of the benzamide template as a targeting group, and improve on potency in cell growth 
inhibition assay. 
  
1.7. Designed-multiple ligand approach in the design of HDACi 
Despite the clinical successes of HDACi towards different types of lymphomas, HDACi 
are currently being evaluated in combination with other chemotherapeutic agents to derive 
maximum therapeutic benefits in solid tumors. The rationale behind combining HDACi with other 
drugs could be attributed to HDAC inhibition acting in synergy with the pathways targeted by 
other drugs, to make cancer cells more susceptible to cell death.54 Although this approach is quite 
appealing, patients, in most cases, have to deal with the individual toxicities associated with the 
combined drugs.55 Likewise, dose optimization as well as differences in the pharmacokinetic 
profiles of the combined agents could be a bottle-neck in deriving maximum benefits from 
combining two different drugs.56 In addition to this, patients’ compliance to dose regimens and the 
economic implication of buying multiple drugs further complicates combination therapy. An 
emerging approach being proposed as an alternative to combination therapy in the drug discovery 
field is the designed-multiple ligand approach.57-60 This approach involves making a single 




The designed-multiple ligand approach could become beneficial in cancer and other 
diseases in which: i) Concurrent inhibition of two or more pathways relevant for the sustained 
progression of such diseases is crucial; ii) Inhibition of one pathway leads to activation of a 
different pathway that drives such diseases-hence the chances of resistance to chemotherapy 
becomes reduced; and iii) Inhibition of two pathways elicit a synergistic effect. 
With regards to HDACi drug design, the designed-multiple ligand approach has enjoyed a 
considerable amount of attention.56 Incorporation of estrogen receptor modulators,61-63 androgen 
receptor antagonist,64 topoisomerase inhibitors,65 tubulin depolymerization inhibitor,43 and kinase 
inhibitors66 unto the cap group of SAHA-like molecules all demonstrated advantages over using 
the individual components and/or physically combining the individual components in vitro (and 
in vivo in some cases).  
Given the important roles played by inflammation in driving tumorigenesis, and the fact 
that HDAC inhibition perturb most pathways relevant in inflammation induction and 
progression,66 it is reasonable to explore the benefits of combining drugs that block any of the 
inflammation development pathways and an HDACi.  
Cyclooxygenase (COX) is an enzyme that facilitates the conversion of arachidonic acid 
(obtained from distressed cell membrane through phospholipase A2 activity) to prostaglandins and 
other signaling molecules in the body68 (Figure 1.6). One of COX isoforms, COX-2, is 
ubiquitously expressed in most cancer types where it promotes inflammation development and 
progression.69 As a result, several studies are currently targeted towards repurposing COX 




shown that simultaneous blockade of COX-2 and HDAC activities results in enhanced 
antiangiogenic effects in lung cancer cells.72   
 
Figure 1.6: COX-mediated synthesis of prostaglandins from arachidonic acid73   
To further explore the benefits of simultaneous inhibition of COX-2 and HDAC in tumors, 
Chapter 4 of this thesis is focused on making bifunctional molecules, based celecoxib and 
indomethacin templates, having both COX and HDAC inhibitory activities. Lead compounds 




preferentially cytotoxicity towards androgen-dependent prostate cancer.  Some of the compounds 
made were able to downregulate activation of Nf-kB induced inflammation, making them potential 
candidates for regulation of inflammation.  
 
Figure 1.7: Structures of selected US FDA approved NSAIDs 
 
1.8. Lipid nanoparticle-based drug delivery system 
Lipid nanoparticle-based drug delivery systems are attractive for drug delivery purposes 
because of their ability to traverse the cellular membrane easily, due to their amphiphilic nature. 
Their composition, mainly phospholipids, imparts membrane-like properties on them, making the 
nanoparticles suitable for delivery of drugs with poor pharmacokinetic profile. More importantly, 
lipid nanoparticles are biodegradable,74 and could be used to mask the off-target toxicities 
associated with encapsulated drugs, if drug release can be controlled. The two most studied lipid 
nanoparticle drug delivery systems are micelles and liposomes. While micelles are composed of a 
single monolayer of phospholipid, liposomes comprise one or more phospholipid bilayers having 




     
Figure 1.8: Structural annotations of micelle and liposomes75  
Liposome formulation for drug delivery purposes is explored in chapter 5 of this thesis. 
Liposomes could be used to package hydrophilic and hydrophobic agents in their hydrophilic and 
hydrophobic compartments respectively.75 During the early stages of development, one of the 
challenges faced by liposomes in systemic circulation is rapid uptake by the mononuclear 
phagocyte system (MPS).76 To circumvent this, stealth liposomes (Figure 1.9), having PEG 
coating on the surface of the liposomes, were developed. Stealth liposomes have longer circulation 
times due to their ability to evade uptake by the MPS. This makes them highly desirable for drug 
delivery. In recognition of their impressive drug delivery capabilities, the first US FDA approved 
liposomal formulation, DOXIL (or Caelyx),77 was based on the stealth liposome design. 
 
1.8.1. Passive targeting of liposomes 
One very attractive property of liposomes as drug delivery systems for cancer therapy is 
their ability to explore the defect inherent in most cancer types to selectively accumulate in tumors. 
Cancer blood vessels have a leaky vasculature compared to those in normal tissues. This leaky 




and get trapped. This process by which nanoparticle get into tumors is known as the Enhanced 
Permeability and Retention effect (EPR),78-79 Figure 1.10. Passively targeted liposomes (e.g stealth 
liposome) get to tumors by the EPR effect. 
 
Figure 1.9: Liposomes getting to tumor via EPR effect80 
 
1.8.2. Active targeting of liposome 
In addition to the EPR effect, tumor accessibility to liposomes could be enhanced by having 
ligands with affinity for receptors, preferentially expressed in tumors, attached to the surface of 
the liposome (Figure 1.8). Due to the targeting ligands’ specificity for receptors expressed in 
tumors, it is anticipated that actively targeted liposomes will show superior therapeutic index 
compared to passively targeted ones. It is noteworthy to point out that despite DOXIL (a passively 
targeted liposome) being successful at alleviating the cardiotoxic effects associated with 
doxorubicin, off target effects such as palmar-plantar erythrodysesthesia (also known as hand and 




As promising as active targeting sounds, no actively targeted nanoparticle has received the 
approval of US FDA for clinical use, while several stealth liposomes carrying various 
chemotherapeutic drugs are in use.75 
A critical look at the literature for factors that influence choice of ligands for targeted 
liposome applications reveal that the nature of tumor microenvironment (e.g acidity) and high 
expression of cell surface receptors in tumors relative to healthy tissues play prominent roles.82 
Several small molecules and macromolecules have been studied for their suitability as targeting 
ligands on liposomes. Among the small molecules studied, folate, targeting folate receptor, is 
probably the most studied.83 Other macromolecules that have been studied include proteins and 
peptides (e.g. transferrin84 and glutathione85), antibodies,86 DNA aptamers,87 etc.  
Previously, macrolide-functionalized gold nanoparticles were demonstrated to show 
substantial accumulation in macrophage cells (RAW 264.7), consistent with the accumulation of 
the parent macrolides in macrophages.88-89 To further explore the suitability of macrolides as 
targeting ligands on lipid nanoparticles, liposomes were formulated with phospholipids having 
clarithromycin attached. These liposomes were used to encapsulate propidium iodide and 
thereafter used to study uptake of propidium iodide in RAW 264.7 cells. Preliminary results from 
this study are described in Chapter 5. Likewise, tamoxifen, a US FDA approved drug for treatment 
of estrogen receptor positive (ER+) breast cancer, was also appended on phospholipids. Liposomes 
formed with the tamoxifen-functionalized phospholipids were used for uptake experiments in ER+ 
breast cancer (MCF-7). The suitability of tamoxifen as a targeting ligand on gold nanoparticles 






Off-target toxicity ranks very high among the challenges faced by HDACi in the clinic. 
Though none of the clinically approved HDACi were designed to address this, it is believed that 
making HDACi more isoform-selective and incorporating a targeting group into the design of these 
compounds may mitigate some of the off- target effects observed in patients. By incorporating 
groups like clarithromycin, benzamide and NSAIDs into the design of HDACi ab initio, we 
obtained new sets of HDACi with very promising in vitro therapeutic index suggesting that they 
may be safer therapeutics to the compared to the clinically approved HDACi.  
Another approach that could potentially lessen the toxic effects associated with the use of 
HDACi is to package them in an appropriate drug delivery system. we explored the suitability of 
ligand-functionalized liposomes for this purpose, by first carrying out preliminary evaluation of 
clarithromycin- and tamoxifen- functionalized liposome for their ability to facilitate selective 
delivery of cargoes (in this case propidium iodide) to tumors. These two ligands showed some 
promise and warrants further investigation. 
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SYNTHESIS, ANTI-CANCER ACTIVITY EVALUATION AND ANTI-
INFLAMMATORY STUDY OF CLARITHROMYCIN-BASED HDACI 
Some of the work described in this chapter have been published in: 
Bioorganic and Medicinal Chemistry, 2015, 23 (24), 7543-7564  
 
2.1. Introduction 
Histone deacetylases (HDACs) are emerging therapeutic targets for cancer and other 
diseases such as malaria and leishmania.1,2 In conjuction  with histone acetyltransferases (HATs), 
they regulate the chromatin dynamics by controlling the acetylation state of histone proteins as 
well as non-histone proteins such as tubulin, ERα, p53, HSP90, and GATA-1.3 Histone deacetylase 
inhibitors (HDACi) have been shown to cause growth arrest, differentiation, and apoptosis in a 
variety of cancer cell lines.4 To date, several classes of small molecule HDACi exist conforming 
to a three-motif pharmacophoric model, namely, a zinc binding group (ZBG), a hydrophobic 
linker, and a recognition cap group.5 Moreover, five HDACi have been clinically approved for 
hematological malignancies (Figure 2.1a). The clinically approved HDACi include: 
suberoylanilide hydroxamic acid (SAHA)6,7 and FK2288, approved for the treatment of cutaneous 
T-cell lymphoma; Panobinostat and Chidamide, approved for multiple myeloma;9,10 and Belinostat 
granted approval for peripheral T cell lymphoma11. Among all HDACi, macrocyclic HDACi 
(Figure 2.1b) have the most complex cap group moieties capable of interacting optimally with 
amino acid residues at the surface of the HDAC active site, an attribute that is essential for the 




inhibition activity (nanomolar range), synthetic challenges posed by their complex structural 
features, as well as the disadvantages resulting from their peptide group (s) make the clinical 
development of macrocylic HDACi almost impossible.12 
 
Figure 2.1. Structures of representative HDACi: (a) Clinically approved HDACi, (b) Selected 
examples of non-peptide (5e-f, 26e-f) macrocyclic HDACi. 
Previously, we showed that macrocycles derived from two 14-membered macrolide rings 
– clarithromycin (5e and 5f) and TE-802 (26e and 26f), are excellent mimetics for the peptide 
backbone of macrocyclic HDACi.13,14,15 The replacement of the amide moiety,  by its bioisostere, 




fold.14 Drawing inspiration from the naturally occurring HDACi such as TSA (trichostatin A) we 
have hitherto studied the para-substitution pattern of the aryl-triazole cap group of these non-
peptide macrocyclic HDACi.14,15  
To gain further insight into the depth of the SAR of the class of HDAC inhibitors based on 
the 14-membered macrolide ring, clarithromycin, we investigated and disclosed herein the 
consequence of: (i) varied methylene linker lengths; (ii) point of attachment of aryl-triazole cap 
group; and (iii) having biaryl zinc binding group (ZBG), on their biological activities. We observed 
that the new compounds reported here possess anti-HDAC, anti-proliferative and anti-
inflammatory activities that are highly dependent on the point of attachment of the HDAC 
















Scheme 2.1. (a) Hünig’s base, DMSO, 85 °C, 3 h; 63 % (b) CuI (15 mol%), Hünig’s base, THF, 
rt, 12 h; (c) CsF, MeOH, rt, 30 min, 30-40 %. 
 
The syntheses of the target compounds were achieved following the reaction routes shown 
in Schemes 2.1-2.3. The crucial ethynylbenzyl moiety was installed at the desosamine sugar of 
clarithromycin to furnish the requisite alkynyl-clarithromycin 3, following the literature 
procedure.14,15,16,17 Copper (I)-catalyzed azide-alkyne-cycloaddition (CuAAC)18 reaction between 
TBS-protected azidohydroxamates 4a-f and compound 3, followed by removal of TBS-group19 





Scheme 2.2. (a) CH2Cl2, Ac2O, rt, 3 h, 100 %; (b) NCS, DMS, TEA, CH2Cl2, -15 °C, 4.5 h, 100 
%; (c) (CH3)3SOI, NaH, DMSO, THF, rt, 4 h, 38 %; (d) KI, MeOH, 60 °C, 6 h, 73 %; (e) CuI 




Introduction of the ethynylbenzyl moiety to cladinose sugar of clarithromycin 6 was 
achieved in four steps (Scheme 2.2).20b Reaction of clarithromycin 6 with acetic anhydride in 
dichloromethane gave selective 2-O-acetylclarithromycin 7. Corey-Kim oxidation of 7 and 
subsequent Corey-Chaykovsky epoxidation of intermediate 4-oxo-2-O-acetylclarithromycin 8 
yielded the epoxide 9. Diastereoselective opening of epoxide 9 with 4-ethynylbenzyl-N-
methyamine 10 in methanol, followed by a concomitant acetyl group deprotection, gave the vital 
intermediate 11. The alkynyl intermediate 11 was subjected to CuAAC reaction with the requisite 
TBS-protected azido hydroxamates 12a-f followed by TBS protection removal to furnish the target 





Scheme 2.3. (a) acetic anhydride, CH2Cl2, rt, 3 h, 95 %; (b) NCS, DMS, TEA, CH2Cl2, -15 °C, 6 
h, 45 %; (c) (CH3)3SOI, NaH, DMSO, THF, rt, 4 h, 77%; (d) KI, MeOH, 60 °C, 6 h, 96 %; (e) 





We thereafter synthesized clarithromycin-triazolyl-hydroxamic acids with dimethylamino 
methylene group placed in the C4” position of cladinose sugar (Scheme 2.3). We propose that this 
substitution should introduce extra acid-stability to the cladinose sugar glycosidic bond.20c In 
addition to this, we wanted to see if this small change will influence the HDAC inhibitory and 
growth inhibition activity profile of these compounds. The target compounds 20a-b were made 
from intermediate 3 following a similar synthetic route as described for compounds 13a-f. The 
previously synthesized compound 5f was included here as a control.  
 
2.3. Results and discussion  
To evaluate the HDAC inhibitory activity of the newly synthesized compounds, we tested 
them against class I (HDAC1 and HDAC8) and class IIb (HDAC6) HDAC enzymes. Two 
previously synthesized compounds (5e and 5f)14,15 were added as controls. HDAC inhibition was 
measured using the label-free mass spectrometry-based SAMDI assay.21 In agreement with 
previous observations, most of tested compounds were less active towards HDAC8 except for 
compounds 5f (IC50 713 nM, Table 2.1).  
A closer look at the HDACs 1 and 6 inhibitory profiles of these compounds revealed an 
interesting trend that is largely dependent on the length of the methylene spacer-group separating 
the triazolyl group from the hydroxamate moiety. We observed that an increase in the length of 
the methylene spacer resulted in gradual increase in HDAC1 and HDAC6 inhibitory activities. In 
most cases, optimum potency was obtained with compounds having six methylene spacers. In 
general, compounds having five or six methylene spacers showed low to mid nanomolar HDAC1 




compounds having one to four methylene spacers were either inactive or very poorly active (5a-
d, 13a-d).  
Table 2.1. HDAC 1, HDAC 6, and HDAC 8 Inhibition Activities (IC50 in nM) of clarithromycin 
derived hydroxamic acid compounds 
Compound n HDAC 1 HDAC 6 HDAC 8 
5a 1  10000    10000  10000 
5b 2  10000  919 ± 45 2450 ± 600 
5c 3 9910 ± 3000 70.9 ± 12.6 986 ± 81 
5d 4 4870 ± 500 120 ± 19 877 ± 125 
5e 5 533 ± 123 3.61 ± 1.01 1180 ± 310 
5f 6 207 ± 84 6.67 ± 1.23 713 ± 748 
13a 1  10000 5350 ± 190 7120 ± 2130 
13b 2  10000 3560 ± 370 10200 ± 1600 
13c 3  10000 361 ± 67 2530 ± 880 
13d 4 3690 ± 860 269 ± 100 1820 ± 400 
13e 5 652 ± 130 5.89 ± 2.73 985 ± 325 
13f 6 23.9 ± 3.3 2.85 ± 1.07 1840 ± 460 
20a 5 201 ± 17 32.9 ± 2.4 3200 ± 820 
20b 6 33.3 ± 8.1 31.4 ± 5.5 2210 ± 300 
 
Introduction of the dimethylamino methyl group at cladinose sugar C4 position had a 




analogs 5e-f. However, HDAC6 inhibition was affected substantially in all the compounds, with a 
5 to 10 fold drop in potency (20a: IC50 32.9 nM; 20b: IC50 31.4 nM compared to 5e: IC50 3.61 nM, 
5f: IC50 6.67 nM). Attachment of the aryl-triazolyl cap group to cladinose sugar (13a-f) also 
influenced HDAC1 and HDAC6 inhibitory activities. Among all the compounds, compound 13c, 
in which the hydroxamic acid moiety was separated from aryl-triazole cap by three methylene 
groups, showed a five-fold decrease in HDAC6 (IC50 361 nM) inhibitory potency compared to the 
analogous desosamine modified compound 5c (IC50 70.9 nM) and was completely inactive against 
HDAC1 (27% at 10M for 13c vs 9.91 M IC50 value for 5c). Interestingly for 13f, in which the 
hydroxamic acid moiety was separated from the aryl-triazole cap by six methylene groups, the 
HDAC6 inhibitory activity increased by two fold compared to control compound 5f (IC50 2.85 nM 
vs 6.67 nM, respectively). Moreover, the HDAC1 inhibitory activity of 13f was eight-fold higher 
than that of 5f (IC50 23.9 nM vs IC50 207 nM, respectively).  
Table 2.2. Anti-proliferative activity of selected HDACi (IC50 values in M)a 
Compound A549 MCF-7 Vero 
5f 2.29 ± 0.73 2.86 ± 0.10 4.90 ± 0.34 
13f 0.99 ± 0.08 0.69 ± 0.05 1.55 ± 0.12 
20b 3.58 ± 0.79 1.43 ± 0.17 2.08 ± 0.14 
SAHA 5.00 ± 0.24 3.27 ± 0.05 1.03  0.09 






2.4. Cell growth inhibition study 
  To verify if the potent HDAC inhibitory profiles of these clarithromycin-derived HDACi 
translate to growth inhibitory effects in cells, we tested representative members of each group 
against lung (A549) and breast (MCF-7) cancers cell lines– and normal cell line (Vero - monkey 
kidney epithelial cell). Our rationale for selecting a representative compound from each series is 
that the ideal compound should have robust activity against HDACs 1 and 6- two isoforms 
implicated in a lot of cancer cases. SAHA and the previously disclosed control compound 5f are 
both cytotoxic to the two cancer cell lines (Table 2.2). Compounds 13f and 20b, with strong HDAC 
inhibitory activities, possess varying degree of anti-proliferative activities against A549 and MCF-
7 cell lines. For analogous compounds (i.e. having same methylene-linker length), the points of 
attachment of HDACi moiety to clarithromycin is a strong determinant of potency.  However, 
installing N, N-dimethylamine at the cladinose sugar slightly enhanced the cytotoxicity of 
compound 20b compared to compound 5f in MCF-7. In fact, the cladinose ring is the optimum 
point of attachment of the HDAC inhibiting moiety to the clarithromycin template, as the resulting 
HDACi 13f is the most potent among the compounds tested for anti-proliferative activity.  
To assess tumor cell selectivity of these series of compounds, we tested them against the 
non-transformed Vero cell line. The control compound SAHA is equipotent towards healthy and 
transformed cells, as it is about 3-5 fold more cytotoxic to the Vero cell compared to the two tumor 
cell lines. In contrast, the clarithromycin-derived compounds are either significantly less cytotoxic 






2.5. Anti-inflammatory Activity Study 
Inflammation is a salient factor in cancer, particularly lung cancer and many other chronic 
lung diseases. 22,23,24 HDACs have been implicated in the regulation of inflammation and HDACi25 
such as SAHA,26 trichostatin A (TSA),27 butyrates,28 and MS-275,29 attenuate cellular 
inflammation processes through inhibition of NF-B activation and or blockage of pro-
inflammatory cytokine release.30 In addition to its antibiotic activities, the macrolide template, 
clarithromycin, incorporated into the design of HDACi described herein has intrinsic anti-
inflammatory and immunostimulatory activities.  
To test if the clarithromycin-derived HDACi preserve these useful properties and 
additively or synergistically enhance the latent anti-inflammatory activity of HDACi, we evaluated 
their anti-inflammatory activities in BEAS-2B cell infected with nontypeable Haemophilus 
influenza (NTHi) using NF-B luciferase assay.31 NTHi is a Gram-negative bacterium which 
causes infection in the human respiratory tract.32,33 Upon infection by NTHi, transcriptional 
regulator, NF-B, in human epithelial cell is strongly activated by translocating from cytoplasm 
to nucleus and consequently up-regulating certain pro-inflammatory cytokines such as IL-1β, IL-
6, and TNF-α. To pre-screen these compounds for their effect on NF-B activity, we treated NTHi 
infected BEAS-2B cells with the compounds at 1 M. We observed the compounds lacking or 
those with weak anti-HDAC activities did not suppress NF-B activation while those compounds 
with potent anti-HDAC activities suppressed NF-B activation to varying degrees which closely 
correlate with their HDAC inhibition potency. 
We then determined the IC50 values of selected compounds which suppressed NF-B 




compounds suppressed the NTHi-induced NF-B activation with IC50 ranging from low to high 
nanomolar. Compounds 5f, 13f and 20b have slightly lower Imax value compared to SAHA (Table 
2.3), implying that at maximum concentration of 1 M, these compounds suppressed NF-B 
activity SAHA. Interestingly, the starting clarithromycin did not exhibit any anti-inflammatory 
activity in this assay as their relative percentage luciferase activity was indistinguishable from no 
drug treatment in presence of NTHi (100%).  





5e 785 45.1 
5f 243 35.9 
13e 785 50.7 
13f 197 35.6 
20b 260 33.4 
SAHA 88 37.4 
*Imax (%) at 1 M 
To further confirm the mechanism of anti-inflammatory activities of this class of macrolide 
HDACi, we performed Q-PCR analysis to determine the effect of these HDACi on the expression 
levels of mRNAs of inflammatory cytokines known to be NTHi-inducible.35,36 We observed that 
compound 13f more significantly suppressed NTHi-induced TNF-α, IL-1α, IL-1β mRNA 




suggest that the suppression of NF-B activation induced by these compounds is derived from 
their HDAC inhibition activities. 
 
Figure 2.2. HDACi suppress NTHi-induced expression of Cytokines. BEAS-2B cells were 
pretreated with HDACi (26f, 13f; 1 μM) or SAHA (1 μM) or DEX (0.1 μM) for 2 h followed by 
1.5 h stimulation with NTHi, and cytokines mRNA (TNF-α, IL-1 α and IL-1β) expressions were 
analyzed. Data are mean ± std (n=3); **p<0.01, ***p<0.005. Data are representative of three 
independent experiments. CON = BEAS-2B cells treated with PBS control; NTHi = BEAS-2B 
cells treated with NTHi. 
 
2.6. Targeted and isoform-selective HDACi 
In furtherance of our quest to making safer small molecule HDACi, we extended our SAR 
studies to the ZBG of clarithromycin-based HDACi, with the goal of achieving class 1 selective 
HDACi. High expression levels of class 1 HDACs is a common feature in many tumors,37-38 hence 
class 1-selective inhibitors could be beneficial as safer therapeutics to mitigate some of the adverse 
effects seen with pan-HDACi.39 
Structurally, both HDAC 1 and HDAC 2 possess an internal cavity (about 14 Å), adjacent 




upon hydrolysis from acetylated lysine substrate.40 Miller et. al. carried out extensive SAR studies 
on the ZBG portion of the HDAC pharmacophoric model, and came up with compounds having 
biaryl groups as ZBG41 (Figure 2.4). In their study, compounds having thiophene attached at the 
para anilinic position gave optimal inhibition and selectivity towards HDAC 1 and HDAC 2. 
      
Figure 2.3: Docked structure of macrolide-based HDACi with benzamide ZBG in HDAC1 active 
site.  
The rationale behind having biaryl ZBG is to achieve tighter chelation to Zn2+, and occupy the 
14Å internal cavity using the bulky thiophene attached at the para anilinic position. 
In our approach, we adopted 2-amino-5-(thiophene phenyl) as ZBG in the design of a new 
series of clarithromycin-based HDACi. We propose that these series of compounds will be capable 
of selective localization in lung tissues, and show selectivity towards HDAC 1 and HDAC 2 in 
their HDAC isoforms inhibitory activity. Hypothetically, this approach should result in HDACi 





Figure 2.4: HDACi having a benzamide ZBG as reported by Miller et al41 
 
2.6.1. Chemistry 
 Linkers used in this study were made as previously described.42 Previous SAR studies in 
our lab identified compounds having six methylenes separating the cap group from the ZBG to 
give the optimum enzyme inhibitory effects.43-44 Hence, linkers used in this study were restricted 
to those having five, six and seven methylenes separating the azido end from the ZBG. Using Cu 
(I)-catalyzed cycloaddition reaction between azido compounds (21a-c) and compound 3, the 





Scheme 2.4: (a) CuI (15 mol%), Hünig’s base, THF, rt, 12 h. 
 
2.6.2. HDAC inhibition study 
 We then profiled compounds 22a-c against all class I (HDAC 1, HDAC 2, HDAC 3 and 
HDAC 8) and class IIB (HDAC 6) HDAC isoforms. These isoforms were chosen to evaluate the 
extent of selective inhibition within the class I HDACs, as well as across other HDAC classes. 
Consistent with literature observation for compounds having 2-amino-5-(thiophene phenyl) as 
ZBG45-46, all the three compounds showed preferential inhibitory effects towards HDAC 1 and 
HDAC 2, with no activity towards HDAC 3, HDAC 6 and HDAC 8. Hence, they not only show 
sub-class selectivity, they also showed selectivity across HDAC classes. 
 Compounds 22a and 22b are equipotent towards HDAC 1 and HDAC 2, and there is no 
obvious selectivity towards either isoform.  This is not surprising, as HDAC 1 and HDAC 2 have 
structural similarities that make it difficult for small molecules to distinguish between the two.47 
The same pattern is seen with compound 22c against HDAC 1 and HDAC 2, although it is less 
potent towards the two HDAC isoforms compared to compounds 22a and 22b. 
Table 2.4. HDAC inhibitory activity of 2-amino-5-(thiophene phenyl)-based HDACi 
Compound HDAC 1 HDAC 2 HDAC 3 HDAC 6 HDAC 8 
22a 118 ± 24 101 ± 9 NI NI NI 
22b 112 ± 20 146 ± 73 NI NI NI 
22c 428 ± 111 279 ± 54 NI NI NI 




2.6.3. Antiproliferation study and target validation  
 Impressed by the anti-HDAC activity of the newly synthesized compounds, we then tested 
compounds 22a-c in A549 and MCF-7 cancer cell lines. To our surprise, none of the three 
compounds showed any growth inhibitory effect against the two cancer cell lines (Table 2.5). 
While we do not have a clear explanation for the observed lack of activity, we thought it may be 
due to lack of cell penetration by these compounds. To justify this, we tested a similar compound 
(compound 23), based on the azithromycin template, made by a colleague in our lab (Shaghayegh 
Fathi). Compound 23 showed potent growth inhibitory activity in A549 and MCF-7 cancer cell 
lines, and is about six-fold less toxic towards healthy cells Vero. This suggests that the observed 
lack of activity may be peculiar to the clarithromycin-based compounds, and is not due to lack of 
cell penetration. 
Table 2.5: Growth inhibitory activity of 2-amino-5-(thiophene phenyl)-based HDACi in cell lines 
Compound A549 MCF-7 Vero 
22a NI NI NT 
22b NI NI NT 
22c NI NI NT 
23 1.72 ± 0.09 0.83 ± 0.07 6.46 ± 1.15 





To unravel the reason behind the observed lack of cellular activity seen with compounds 
22a-c as compared with the robust activity of the azithromycin analogue, 23, we used western blot 
to verify target engagement intracellularly. Class I HDAC inhibition in the cells results in 
accumulation of acetylated histones in the cells.9 We treated MCF-7 cells with compounds 22b 
and 23 at varying concentrations, using SAHA as a positive control. We observed substantial 
accumulation of acetyl H4 as expected for SAHA. To our surprise, we did not observe significant 
level of accumulation of acetyl H4 at the maximum tested concentration (5 µM) for the potent 
compound 23.  The same effect was seen for compounds 22b, suggesting that there may be an 
alternative pathway perturbed by compound 23, or that the test concentrations used in this study 
were too low to elicit significant accumulation of acetyl H4. 
 
Figure 2.5: Western blot analysis of accumulation of acetylated H4. Lanes: 1= DMSO; 2= SAHA 
(5 µM); 3= 23 (0.8 µM); 4= 23 (5 µM); 5= 22b (5 µM); 6= 22b (10 µM). 
 
2.7. Conclusion 
We have synthesized diverse series of non-peptide macrocyclic hydroxamic acid- and 
benzamide- based HDACi derived from clarithromycin to further explore the SAR of this class of 




activity against recombinant HDAC1 and HDAC6 enzymes. The benzamide- based compounds 
also showed nanomolar activity, in addition to their selectivity towards HDAC1 and HDAC2. 
Among the lead compounds tested for antiproliferation activity, compounds 13f potently inhibited 
the growth of lung cancer cell line (A549) and breast cell line (MCF-7). Unlike SAHA which is 
much more toxic to healthy Vero cells, these clarithromycin-derived compounds are either 
significantly less cytotoxic to the Vero cells or equally cytotoxic to the transformed and normal 
cells tested. Also, some of these compounds exhibited anti-inflammatory activity in NTHi infected 
BSAS-2B cells.  
 
2.8. Experimental  
2.8.1. Materials and methods  
All commercially available starting materials were used without further purification. 
Clarithromycin was purchased from Greenfield Chemicals. 2-Ethynylbenzyl alcohol, 3-
bromobenzaldehyde, and 4-ethynylbenzyl alcohol were purchased from Sigma-Aldrich. Reaction 
solvents were either high performance liquid chromatography (HPLC) grade or American 
Chemical Society (ACS) grade and used without further purification. Analtech silica gel plates (60 
F254) were used for analytical TLC, and Analtech preparative TLC plates (UV 254, 2000 µm) were 
used for purification.  UV light and anisaldehyde/iodine stain were used to visualize the spots.  
200-400 Mesh silica gel was used in column chromatography.  Nuclear magnetic resonance 
(NMR) spectra were recorded on a Varian-Gemini 400 MHz or Bruker 500 MHz magnetic 
resonance spectrometer.  1H NMR Spectra were recorded in parts per million (ppm) relative to the 




(2.49 ppm) in DMSO-d6. 
13C spectra were recorded relative to the central peak of the CDCl3 triplet 
(77.0 ppm) or CD3OD septet (49.3 ppm) or DMSO-d6 septet (39.7 ppm) and were recorded with 
complete hetero-decoupling. Original ‘fid’ files were processed using MestReNova LITE (version 
5.2.5-5780) program. High-resolution mass spectra were recorded at the Georgia Institute of 
Technology mass spectrometry facility in Atlanta. 3-Desmethylclarithromycin (1), 4-
ethynylbenzyl mathanesulfonate (2), 3-O-acetylclarithromycin (7) were synthesized as we 
previously reported.14,15,34  
(Clarithromycin-3-(N-(4-triazolylbenzyl)))-N-hydroxyacetamide (5a) 
3-N-(Desmethyl)- 3-N-(4-ethynylbenzyl) clarithromycin 3 (0.15 g, 0.18 mmol) and 2-
azido-N-((tert-butyldimethylsilyl)oxy)acetamide 4a (0.073 g, 0.318 mmol) are dissolved in 
anhydrous THF and purged with argon for 10 min. DIPEA (0.06ml, 0.35mmol) and CuI (0.017 g, 
0.088 mmol) were then added to the mixture and purged further for another 20 minutes. The 
resulting suspension was stirred at room temperature for 12 h. Reaction was quenched with a 
solution of 4:1 satd. Aqueous NH4Cl/NH4OH and extracted with a mixture of 10% MeOH in DCM. 
Combined organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo. The crude 
was subjected to next reaction without further purification. 
The crude was dissolved in anhydrous methanol (2 mL) alongside caesium fluoride (0.04g, 
0.27mmol) and left to stir under Ar until TLC showed complete conversion (1.5 h). Water was 
added to quench the reaction and the aqueous layer extracted with DCM. Combined organic layer 
was dried over Na2SO4 and concentrated in vacuo. Crude obtained was purified by preparative 
chromatography (Silica gel, 12:1:0.1 DCM-MeOH-NH4OH) to give target compound 5a as light 




Hz, 2H), 7.50 (d, J = 8.2 Hz, 2H), 5.12 (d, J = 3.7 Hz, 2H), 4.53 (d, J = 7.2 Hz, 1H), 4.08 (dq, J = 
12.6, 6.9 Hz, 3H), 3.80 – 3.68 (m, 5H), 3.42 (d, J = 7.5 Hz, 1H), 3.30 (dt, J = 3.3, 1.6 Hz, 4H), 
3.17 (s, 3H), 3.15 – 3.07 (m, 2H), 3.04 (s, 1H), 3.01 (d, J = 9.5 Hz, 2H), 2.94 – 2.86 (m, 1H), 2.59 
(d, J = 9.0 Hz, 1H), 2.44 (s, 3H), 2.38 (d, J = 15.2 Hz, 1H), 2.15 (s, 1H), 2.04 – 2.00 (m, 2H), 1.98 
– 1.82 (m, 4H), 1.67 (d, J = 13.0 Hz, 1H), 1.52 (ddd, J = 18.2, 13.3, 6.1 Hz, 3H), 1.38 (d, J = 17.4 
Hz, 4H), 1.24 (dq, J = 12.9, 8.0 Hz, 13H), 1.13 (dt, J = 12.5, 8.6 Hz, 16H), 0.85 (dd, J = 8.4, 6.3 
Hz, 3H). 13C NMR (126 MHz, CDCl3) δ (ppm) 175.8, 147.2, 130.0, 125.8, 122.2, 102.5, 96.1, 
81.2, 78.5, 78.3, 74.2, 72.7, 70.8, 69.1, 68.2, 65.7, 64.3, 57.7, 50.6, 49.4, 45.1, 39.2, 39.1, 37.3, 
36.7, 34.9, 29.7, 22.7, 21.3, 21.0, 19.9, 18.7, 18.0, 16.0, 12.3, 10.6, 9.3. HRMS (ESI) m/z Calcd. 
for C48H78N5O15 [M+H
+]: 964.5494, found 964.5541. 
(Clarithromycin-3-(N-(4-triazolylbenzyl)))-N-hydroxypropanamide (5b) 
Reaction of 3-N-(desmethyl)- 3-N-(4-ethynylbenzyl) clarithromycin 3 (0.15 g, 0.18 
mmol) with 3-azido-N-((tert-butyldimethylsilyl)oxy)propanamide 4b (0.065 g, 0.265 mmol) 
followed by TBS deprotection with caesium fluoride as described for the synthesis of compound 
5a, gave 5b as a light yellow solid (0.067 g, 39%). 1H NMR (400 MHz, CD3OD) δ (ppm) 8.25 (s, 
1H), 7.78 (d, J = 8.1 Hz, 2H), 7.46 (d, J = 8.1 Hz, 2H), 5.13 (dd, J = 11.1, 2.1 Hz, 1H), 4.74 (t, J 
= 6.5 Hz, 2H), 4.51 (d, J = 7.2 Hz, 1H), 4.11 (dd, J = 9.4, 6.3 Hz, 1H), 3.93 (d, J = 13.2 Hz, 1H), 
3.79 – 3.69 (m, 5H), 3.68 – 3.62 (m, 1H), 3.38 – 3.32 (m, 2H), 3.30 (dt, J = 3.3, 1.6 Hz, 3H), 3.18 
(s, 3H), 3.11 (d, J = 7.8 Hz, 1H), 3.03 (d, J = 7.3 Hz, 4H), 3.01 (d, J = 9.5 Hz, 2H), 2.94 – 2.84 
(m, 2H), 2.77 (t, J = 6.3 Hz, 2H), 2.64 – 2.53 (m, 1H), 2.40 (s, 1H), 2.34 (s, 4H), 1.96 – 1.78 (m, 
5H), 1.67 (d, J = 13.0 Hz, 1H), 1.60 – 1.47 (m, 2H), 1.39 (d, J = 14.0 Hz, 4H), 1.25 (q, J = 7.8 Hz, 
5H), 1.21 (d, J = 6.0 Hz, 7H), 1.18 – 1.08 (m, 17H), 0.85 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, 




78.3, 77.8, 76.7, 74.3, 72.6, 70.8, 69.1, 69.0, 68.4, 65.7, 63.8, 57.6, 50.6, 49.4, 46.2, 45.2, 45.1, 
39.3, 39.1, 37.3, 36.9, 34.8, 33.1, 29.9, 29.7, 21.4, 21.2, 21.0, 19.8, 18.6, 18.0, 16.0, 12.3, 10.6, 
9.2. HRMS (ESI) m/z Calcd. for C49H79N5O15Na [M+Na
+]: 1000.5454, found 1000.5479. 
(Clarithromycin-3-(N-(4-triazolylbenzyl)))-N-hydroxybutanamide (5c)  
Reaction of 3-N-(desmethyl)-3-N-(4-ethynylbenzyl) clarithromycin 3 (0.15g,0.18mmol)  with 4-
Azido-N-((tert-butyldimethylsilyl)oxy)butanamide 4c (0.082 g, 0.318 mmol) followed by TBS 
deprotection with caesium fluoride as described for the synthesis of compound 5a, gave 5c as a 
light yellow solid (0.075 g, 43%). 1H NMR (500 MHz, CDCl3) δ (ppm) 7.85 (s, 1H), 7.74 (d, 2H), 
7.34 (d, 2H), 5.03 (d, J = 11.2 Hz, 1H), 4.88 (d, J = 4.1 Hz, 1H), 4.41 (d, J = 6.9 Hz, 4H), 4.01 – 
3.89 (m, 3H), 3.81 (d, J = 10.8 Hz, 1H), 3.77 – 3.69 (m, 4H), 3.67 – 3.55 (m, 3H), 3.46 (dd, J = 
8.1, 5.3 Hz, 3H), 3.37 – 3.27 (m, 2H), 3.18 (d, J = 13.1 Hz, 1H), 3.15 (d, J = 16.9 Hz, 5H), 3.06 – 
2.92 (m, 8H), 2.89 – 2.80 (m, 2H), 2.57 (dd, J = 11.0, 6.5 Hz, 3H), 2.35 – 2.13 (m, 11H), 1.90 (dd, 
J = 14.4, 7.3 Hz, 3H), 1.80 (dd, J = 26.9, 14.6 Hz, 3H), 1.68 (d, J = 13.9 Hz, 2H), 1.58 – 1.43 (m, 
3H), 1.43 – 1.36 (m, 5H), 1.31 – 1.20 (m, 14H), 1.16 (d, J = 7.1 Hz, 5H), 1.14 – 0.99 (m, 23H), 
0.96 – 0.85 (m, 1H), 0.87 – 0.77 (m, 5H). 13C NMR (126 MHz, CDCl3) δ (ppm) 176.0, 147.6, 
129.8, 125.8, 120.3, 102.8, 96.0, 81.2, 78.4, 78.0, 74.4, 72.7, 70.9, 69.2, 68.7, 65.9, 64.0, 57.7, 
50.8, 49.3, 45.4, 39.3, 37.4, 36.9, 35.1, 29.8, 29.7, 21.6, 21.0, 19.7, 18.9, 18.4, 16.0, 12.4, 10.7, 
9.3. HRMS (ESI) m/z Calcd. for C50H83N5O15 [M+H
+]: 992.5807, found 992.5839. 
(Clarithromycin-3-(N-(4-triazolylbenzyl)))-N-hydroxypentanamide (5d) 
 Reaction of 3-N(desmethyl)- 3-N-(4-ethynylbenzyl) clarithromycin 3 (0.15 g, 0.18 mmol)  
with 5-Azido-N-((tert-butyldimethylsilyl)oxy)pentanamide 4d (0.072g, 0.265mmol) followed by 




as a light yellow solid (0.068 g, 45%). 1H NMR (500 MHz, CDCl3) δ (ppm) 7.86 (s, 1H), 7.75 (s, 
2H), 7.35 (s, 2H), 5.03 (dd, J = 11.1, 1.6 Hz, 1H), 4.87 (d, J = 3.7 Hz, 1H), 4.41 (t, J = 9.4 Hz, 
1H), 4.35 (s, 2H), 3.99 – 3.89 (m, 2H), 3.83 (d, J = 10.5 Hz, 1H), 3.78 – 3.68 (m, 2H), 3.62 (d, J 
= 6.9 Hz, 1H), 3.54 – 3.41 (m, 2H), 3.38 – 3.29 (m, 1H), 3.17 (d, J = 20.3 Hz, 1H), 3.12 (s, 3H), 
3.04 – 2.91 (m, 5H), 2.91 – 2.81 (m, 1H), 2.64 (s, 1H), 2.56 (dd, J = 10.3, 7.4 Hz, 1H), 2.24 (d, J 
= 40.5 Hz, 6H), 1.88 (dt, J = 26.6, 13.4 Hz, 4H), 1.85 – 1.73 (m, 2H), 1.71 – 1.56 (m, 3H), 1.56 – 
1.41 (m, 2H), 1.42 – 1.33 (m, 3H), 1.33 – 1.27 (m, 2H), 1.30 – 1.18 (m, 8H), 1.16 (d, J = 7.0 Hz, 
3H), 1.13 – 1.00 (m, 15H), 0.82 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ (ppm) 175.8, 
170.3, 147.3, 129.6, 125.7, 120.1, 102.6, 95.9, 80.9, 78.3, 74.2, 72.5, 70.7, 69.0, 68.4, 65.6, 63.8, 
57.6, 50.5, 49.8, 49.3, 45.9, 45.1, 45.0, 39.2, 39.0, 37.2, 36.8, 34.7, 31.7, 29.8, 29.6, 29.3, 22.1, 
21.4, 21.2, 20.9, 19.8, 18.6, 17.9, 15.9, 12.2, 10.5, 9.1, 8.5. HRMS (ESI) m/z Calcd for 
C51H83N5O15Na [M+Na
+]: 1028.5783, found 1028.5795. 
4-Oxo-3-O-acetylclarithromycin (8) 
A solution of N-chlorosuccinimide (2.00 g, 14.97 mmol) in anhydrous DCM (30 mL) was 
stirred at -15 C for 10 min. Dimethyl sulfide (1.10 mL, 14.97 mmol) was then added drop wise to 
the solution. After stirring for 20 minutes at the same temperature a DCM solution (10 mL) of 
acetylated clarithromycin 7 (5.91 g, 7.49 mmol) was added over a period of 30 min to the 
suspension and the resulting suspension was stirred at -15 C for another 30 min, afterward TEA 
(2.09 mL, 14.97 mmol) was added. The resulting solution was stirred at -10 C for another 2 h. 
The reaction was quenched by adding saturated aqueous NaHCO3 solution (50 mL), the organic 
layer was separated. The aqueous layer was extracted with DCM (2 x 25 mL) and the combined 




compound 8 (6.35 g) was sufficiently pure to be used for the next step without further purification. 
1H NMR (400 MHz, CDCl3) δ (ppm) 5.11 – 5.02 (m, 1H), 4.97 (d, J = 10.7 Hz, 1H), 4.75 (dd, J = 
10.3, 7.6 Hz, 1H), 4.39 (t, J = 6.1 Hz, 1H), 4.29 (q, J = 6.7 Hz, 1H), 3.67 – 3.53 (m, 3H), 3.38 (td, 
J = 15.1, 5.0 Hz, 2H), 3.30 (d, J = 1.3 Hz, 4H), 3.15 (t, J = 9.1 Hz, 3H), 2.93 – 2.82 (m, 4H), 2.78 
(dd, J = 16.9, 7.3 Hz, 1H), 2.68 (d, J = 1.3 Hz, 1H), 2.65 (d, J = 2.7 Hz, 1H), 2.60 (d, J = 1.2 Hz, 
1H), 2.56 (d, J = 1.3 Hz, 1H), 2.49 – 2.37 (m, 8H), 2.29 – 2.14 (m, 3H), 2.07 – 2.02 (m, 2H), 1.97 
(t, J = 8.3 Hz, 3H), 1.94 – 1.73 (m, 15H), 1.60 – 1.47 (m, 1H), 1.41 – 1.33 (m, 2H), 1.32 – 1.23 
(m, 8H), 1.21 (d, J = 9.9 Hz, 3H), 1.12 (dd, J = 11.2, 6.4 Hz, 7H), 1.07 – 0.93 (m, 10H), 0.78 (t, J 
= 9.6 Hz, 3H), 0.70 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ (ppm) 221.0, 210.6, 175.6, 
170.4, 99.6, 96.4, 80.0, 78.7, 78.1, 78.0, 76.7, 76.0, 74.2, 72.9, 72.7, 69.8, 69.2, 67.5, 61.7, 51.2, 
50.2, 49.9, 45.1, 44.4, 39.0, 38.4, 38.1, 37.9, 37.6, 37.2, 30.8, 30.4, 29.5, 28.3, 26.5, 21.3, 21.3, 
20.9, 20.5, 20.4, 20.0, 19.5, 18.9, 17.8, 16.2, 16.1, 15.5, 14.7, 13.0, 12.2, 10.4, 8.9. HRMS 
(MALDI) m/z Calcd. for C40H70NO14 [M+H
+]: 788.4791, found 788.4781. 
4-Epoxy-3-O-acetylclarithromycin (9) 
NaH (60% in mineral oil) (0.73 g, 17.7 mmol) was added to an oven dried three-neck round 
bottom flask and was washed with petroleum ether. The flask was immediately flushed with Ar 
and 5mL of anhydrous DMSO added through the septum. The mixture was stirred at room 
temperature under Ar and trimethyloxosulfonium iodide (3.90 g, 17.7 mmol) was added over a 
period of 5 min. When hydrogen evolution ceased and a clear solution obtained, a solution of 
compound 8 (6.35 g, 8.06 mmol) in anhydrous THF (10 mL) was added over a period of 10 min 
and left to stir for 2 h. Once TLC showed 100% conversion, THF was removed under vacuum and 
ethyl acetate was added to the remaining solution. The solution was washed severally with H2O to 




was purified by column chromatography using EtOAc: Acetone (5:1) to give compound 9 as a 
white solid (2.43g, 38%). 1H NMR (400 MHz, CDCl3) δ (ppm) 5.06 (dq, J = 6.2, 4.6 Hz, 2H), 4.77 
– 4.59 (m, 4H), 3.95 (s, 1H), 3.76 – 3.66 (m, 3H), 3.55 (s, 1H), 3.45 (dd, J = 9.3, 6.0 Hz, 1H), 3.34 
– 3.28 (m, 4H), 3.19 (s, 1H), 3.01 (d, J = 7.0 Hz, 1H), 3.01 – 2.95 (m, 4H), 2.94 – 2.90 (m, 1H), 
2.86 (dd, J = 9.9, 7.1 Hz, 1H), 2.69 – 2.63 (m, 1H), 2.61 (dd, J = 9.8, 4.4 Hz, 2H), 2.53 (dd, J = 
9.6, 7.1 Hz, 1H), 2.34 (s, 1H), 2.27 – 2.20 (m, 7H), 2.19 – 2.13 (m, 2H), 2.06 – 2.00 (m, 4H), 1.95 
– 1.83 (m, 3H), 1.72 – 1.61 (m, 2H), 1.56 (d, J = 1.6 Hz, 1H), 1.53 (s, 1H), 1.49 – 1.36 (m, 1H), 
1.33 (d, J = 7.2 Hz, 3H), 1.28 (s, 1H), 1.26 – 1.12 (m, 11H), 1.14 – 0.99 (m, 16H), 0.92 (t, J = 8.2 
Hz, 3H), 0.81 (dd, J = 9.8, 4.9 Hz, 3H). 13C NMR (101 MHz, CDCL3) δ (ppm) 221.1, 175.3, 170.0, 
100.1, 96.4, 96.3, 80.3, 78.9, 78.3, 78.2, 76.6, 76.1, 74.2, 73.7, 71.7, 69.1, 67.8, 64.3, 63.2, 60.4, 
60.2, 50.4, 49.6, 46.6, 45.3, 44.8, 40.7, 38.6, 38.1, 37.2, 36.0, 30.8, 29.2, 21.6, 21.3, 21.0, 20.2, 
19.7, 18.2, 18.0, 16.1, 15.9, 14.9, 14.2, 14.2, 12.4, 10.5, 9.1. HRMS (MALDI) m/z Calcd. for 
C41H77NO14 [M+H
+]: 802.4947, found 802.4938. 
(4-(Methylamino)-N-(methyl)(4-ethynylbenzyl))clarithromycin (11) 
1-(4-Ethynylphenyl)-N-methylmethanamine 10 (1.52 g, 10.47 mmol) was added to a 
solution of compound 9 (2.80 g, 3.49 mmol) in MeOH (20 mL). The solution was heated at 60 C 
for 6 h. Excess MeOH was evaporated off and the crude was purified by column chromatography 
using Hexanes:EtOAc:MeOH:NH4OH (2:1:0.6:0.1) to give compound 11 as a light yellow solid 
(2.41g, 73%). 1H NMR (400 MHz, CDCl3) δ (ppm) 7.33 (d, J = 8.1 Hz, 2H), 7.13 (d, J = 8.1 Hz, 
2H), 4.98 – 4.86 (m, 2H), 4.35 – 4.28 (m, 1H), 4.06 (q, J = 5.9 Hz, 1H), 3.66 (d, J = 11.1 Hz, 2H), 
3.57 (d, J = 7.0 Hz, 2H), 3.34 (s, 1H), 3.20 (s, 3H), 3.09 (dd, J = 10.0, 7.3 Hz, 2H), 3.02 (d, J = 




(d, J = 7.4 Hz, 1H), 2.34 (dd, J = 15.6, 6.7 Hz, 1H), 2.24 (s, 1H), 2.20 (s, 6H), 2.10 (s, 3H), 2.04 
(d, J = 3.6 Hz, 1H), 2.00 (s, 1H), 1.96 (s, 1H), 1.93 – 1.87 (m, 1H), 1.84 – 1.70 (m, 3H), 1.57 (dd, 
J = 19.0, 11.8 Hz, 2H), 1.41 – 1.31 (m, 1H), 1.30 (d, J = 11.1 Hz, 3H), 1.15 – 1.07 (m, 10H), 1.05 
(s, 4H), 0.97 (dd, J = 17.3, 7.0 Hz, 10H), 0.71 (dd, J = 13.8, 6.6 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ (ppm) 220.8, 175.7, 139.1, 132.1, 128.6, 121.2, 102.7, 96.4, 83.2, 80.9, 78.9, 78.0, 76.3, 
76.1, 75.9, 74.2, 70.9, 70.6, 68.9, 68.2, 67.4, 65.4, 63.1, 56.9, 50.6, 49.5, 45.2, 44.8, 43.2, 40.2, 
39.3, 38.8, 37.1, 31.3, 28.7, 21.7, 20.9, 20.2, 19.6, 19.1, 18.7, 18.0, 15.9, 15.3, 14.8, 14.6, 13.0, 





Reaction of (4-(Methylamino)-N(methyl)(4-ethynylbenzyl)) clarithromycin 11 (0.15 g, 
0.17 mmol) with 2-azido-N-((tert-butyldimethylsilyl)oxy)acetamide 12a (0.057 g, 0.249 mmol) 
followed by TBS removal with caesium fluoride as described for the synthesis of compound 5a, 
gave 13a as a light yellow solid (0.057 g, 38%). 1H NMR (400 MHz, CD3OD) δ (ppm) 8.37 (d, J 
= 5.4 Hz, 1H), 7.82 (d, J = 8.1 Hz, 2H), 7.41 (d, J = 8.3 Hz, 2H), 5.50 (d, J = 5.4 Hz, 1H), 5.12 (d, 
J = 14.2 Hz, 2H), 5.00 – 4.95 (m, 1H), 4.43 (d, J = 7.3 Hz, 1H), 4.22 (d, J = 6.4 Hz, 1H), 3.85 – 
3.65 (m, 5H), 3.61 (s, 1H), 3.50 (s, 1H), 3.32 – 3.25 (m, 5H), 3.13 – 3.00 (m, 5H), 2.96 – 2.85 (m, 
1H), 2.76 (d, J = 10.3 Hz, 1H), 2.58 (s, 1H), 2.53 (s, 1H), 2.48 (s, 5H), 2.35 (s, 1H), 2.32 – 2.25 
(m, 3H), 2.24 (s, 1H), 2.21 (s, 1H), 2.16 (d, J = 7.6 Hz, 1H), 2.14 (d, J = 5.4 Hz, 1H), 2.01 (s, 1H), 
1.98 – 1.74 (m, 5H), 1.66 (d, J = 12.7 Hz, 1H), 1.57 – 1.44 (m, 1H), 1.40 (s, 3H), 1.31 – 1.15 (m, 
17H), 1.12 (dt, J = 11.4, 4.9 Hz, 10H), 0.85 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 




65.4, 62.9, 53.5, 50.7, 49.6, 45.2, 45.0, 43.4, 40.3, 39.1, 37.3, 31.5, 29.7, 21.5, 21.0, 19.8, 18.9, 
18.0, 16.0, 15.4, 14.9, 14.8, 13.1, 12.3, 11.5, 10.7, 10.6, 9.3.  HRMS (MALDI) m/z Calcd. for 
C51H86N6O15 [M+H
+]: 1021.6073, found 1021.6095. 
(Clarithromycin-4(methylamino)-N(methyl)(4-benzyltriazolyl))-N-hydroxypropanamide 
(13b) 
Reaction of (4-(methylamino)-N(methyl)(4-ethynylbenzyl)) clarithromycin 11 (0.15 
g,0.17 mmol) with 3-azido-N-((tert-butyldimethylsilyl)oxy) propanamide 12b (0.061 g, 0.249 
mmol) followed by TBS removal with caesium fluoride as described for the synthesis of compound 
5a, gave 13b as a light yellow solid (0.07g, 47%). 1H NMR (400 MHz, CD3OD) δ (ppm) 8.22 (s, 
1H), 7.75 (d, J = 7.7 Hz, 2H), 7.36 (d, J = 7.9 Hz, 2H), 5.13 – 5.06 (m, 1H), 4.97 – 4.90 (m, 1H), 
4.69 (d, J = 18.5 Hz, 2H), 4.40 (d, J = 7.0 Hz, 1H), 4.19 (d, J = 6.5 Hz, 1H), 3.81 – 3.64 (m, 5H), 
3.47 (s, 1H), 3.30 – 3.20 (m, 5H), 3.09 – 3.03 (m, 2H), 3.00 (d, J = 8.3 Hz, 3H), 2.94 – 2.82 (m, 
1H), 2.73 (t, J = 19.8 Hz, 3H), 2.56 (d, J = 7.6 Hz, 1H), 2.41 (s, 6H), 2.31 (s, 1H), 2.25 (d, J = 12.9 
Hz, 4H), 2.18 (s, 1H), 2.16 – 2.12 (m, 1H), 2.14 – 2.09 (m, 7H), 1.95 – 1.80 (m, 4H), 1.76 (d, J = 
12.9 Hz, 1H), 1.62 (d, J = 14.9 Hz, 1H), 1.53 – 1.41 (m, 1H), 1.36 (s, 3H), 1.27 – 1.13 (m, 16H), 
1.09 (td, J = 13.0, 8.1 Hz, 11H), 0.83 (t, J = 12.0, 5.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
(ppm) 175.7, 146.9, 137.8, 129.2, 125.5, 121.0, 102.2, 96.2, 80.9, 80.9, 78.7, 78.4, 78.1, 77.9, 76.4, 
75.9, 75.4, 74.1, 71.2, 70.9, 70.5, 68.8, 67.8, 67.3, 65.1, 62.6, 56.3, 50.8, 50.5, 50.5, 49.4, 46.0, 
45.0, 44.7, 44.6, 43.1, 40.2, 39.1, 38.8, 37.0, 31.2, 29.9, 29.5, 25.4, 21.3, 20.8, 20.1, 19.8, 19.5, 
18.9, 18.6, 18.1, 17.8, 15.8, 15.2, 14.7, 14.5, 12.9, 12.1, 11.3, 10.4, 10.3, 10.3, 9.3, 9.2. HRMS 
(MALDI) m/z Calcd. for C52H87N6O15 [M+H







Reaction of (4-(methylamino)-N(methyl)(4-ethynylbenzyl)) clarithromycin 11 (0.15 g, 
0.17 mmol) with 4-azido-N-((tert-butyldimethylsilyl)oxy)butanamide 12c (0.064 g, 0.245 mmol) 
followed by TBS removal with caesium fluoride as described for the synthesis of compound 5a, 
gave 13c as a light yellow solid (0.060g, 40%). 1H NMR (400 MHz, CD3OD) δ (ppm) 8.32 (s, 
1H), 7.77 (d, J = 7.7 Hz, 2H), 7.36 (d, J = 7.9 Hz, 2H), 5.09 (d, J = 9.2 Hz, 1H), 4.46 (s, 2H), 4.39 
(d, J = 7.2 Hz, 1H), 4.19 (d, J = 6.4 Hz, 1H), 3.82 – 3.61 (m, 5H), 3.48 (s, 1H), 3.29 – 3.21 (m, 
4H), 3.05 (t, J = 4.8 Hz, 2H), 3.00 (d, J = 9.9 Hz, 3H), 2.92 – 2.82 (m, 1H), 2.67 (s, 1H), 2.54 (s, 
1H), 2.41 (s, 5H), 2.30 (s, 1H), 2.26 – 2.18 (m, 6H), 2.11 (t, J = 7.4 Hz, 3H), 1.95 – 1.79 (m, 4H), 
1.75 (d, J = 13.0 Hz, 1H), 1.62 (d, J = 14.6 Hz, 1H), 1.52 – 1.40 (m, 1H), 1.36 (s, 3H), 1.18 (dt, J 
= 11.1, 7.0 Hz, 15H), 1.13 – 1.02 (m, 11H), 0.81 (t, J = 7.2 Hz, 3H). 13C NMR (126 MHz, CDCl3) 
δ (ppm) 176.1, 171.4, 147.5, 138.4, 129.8, 129.5, 125.9, 120.8, 102.7, 102.4, 96.9, 96.6, 81.2, 81.2, 
80.3, 79.1, 78.8, 78.5, 78.2, 76.3, 76.2, 75.7, 74.4, 71.5, 71.1, 70.8, 70.1, 69.2, 68.3, 68.1, 67.9, 
67.7, 65.6, 63.1, 60.6, 56.9, 53.6, 51.2, 50.8, 49.7, 49.5, 45.4, 45.1, 44.9, 43.4, 40.5, 39.4, 39.1, 
37.4, 31.6, 29.8, 29.5, 26.2, 21.7, 21.2, 21.1, 20.4, 20.1, 19.9, 19.3, 19.0, 18.5, 18.2, 16.1, 15.6, 
15.0, 14.9, 14.3, 13.2, 12.5, 11.7, 10.8, 9.6, 9.5. HRMS (MALDI) m/z Calcd. for C53H89N6O15 









Reaction of (4-(methylamino)-N(methyl)(4-ethynylbenzyl)) clarithromycin 11 (0.15 g, 
0.17 mmol) with 5-azido-N-((tert-butyldimethylsilyl)oxy)peantanamide 12d (0.068 g, 0.249 
mmol) followed by TBS removal with caesium fluoride as described for the synthesis of compound 
5a, gave 13d as a light yellow solid (0.067g, 44%). 1H NMR (400 MHz, CD3OD) δ (ppm) 8.30 (s, 
1H), 7.76 (d, J = 8.0 Hz, 2H), 7.36 (d, J = 8.1 Hz, 2H), 5.12 – 5.03 (m, 1H), 4.47 – 4.36 (m, 3H), 
4.19 (d, J = 6.4 Hz, 1H), 3.81 – 3.59 (m, 5H), 3.48 (s, 1H), 3.29 – 3.18 (m, 4H), 3.04 (dd, J = 10.3, 
4.5 Hz, 2H), 3.00 (d, J = 9.6 Hz, 4H), 2.92 – 2.82 (m, 1H), 2.66 (s, 1H), 2.55 (d, J = 7.3 Hz, 1H), 
2.40 (s, 6H), 2.30 (s, 1H), 2.23 (s, 4H), 2.16 (d, J = 9.6 Hz, 1H), 2.15 – 2.06 (m, 4H), 1.86 (ddd, J 
= 20.9, 14.7, 7.6 Hz, 6H), 1.75 (d, J = 13.2 Hz, 1H), 1.62 (d, J = 12.2 Hz, 3H), 1.50 – 1.41 (m, 
1H), 1.35 (s, 3H), 1.26 – 1.12 (m, 16H), 1.09 (td, J = 12.8, 7.9 Hz, 11H), 0.81 (t, J = 7.3 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ (ppm) 176.5, 147.8, 138.7, 130.3, 129.9, 126.3, 121.0, 103.1, 97.0, 
81.6, 79.5, 79.2, 78.9, 78.7, 76.7, 74.9, 71.5, 71.2, 69.6, 68.7, 68.1, 66.0, 63.6, 57.3, 51.6, 51.2, 
50.4, 50.1, 45.8, 45.5, 43.8, 40.9, 39.9, 39.5, 37.8, 32.0, 30.2, 29.9, 22.7, 22.2, 21.5, 20.8, 20.3, 
19.4, 18.9, 18.6, 16.5, 15.9, 15.4, 15.3, 13.6, 12.9, 12.1, 11.2, 11.1, 10.0, 9.9. HRMS (MALDI) 
m/z Calcd. for C54H91N6O15 [M+H
+]: 1063.6542, found 1063.6588. 
(Clarithromycin-4-(methylamino)-N(methyl)(4-benzyltriazolyl))-N-hydroxyhexanamide 
(13e) 
Reaction of (4-(methylamino)-N(methyl)(4-ethynylbenzyl)) clarithromycin 11 (0.135 g, 
0.149 mmol) with 6-azido-N-((tert-butyldimethylsilyl)oxy)hexanamide 12e (0.077 g, 0.268 mmol) 




gave 13e as a light yellow solid (0.053g, 35%). 1H NMR (500 MHz, CDCl3) δ (ppm) 7.86 (s, 1H), 
7.77 (d, J = 7.4 Hz, 2H), 7.31 (d, J = 7.8 Hz, 2H), 5.06 – 4.95 (m, 2H), 4.43 – 4.30 (m, 2H), 4.19 
– 4.11 (m, 1H), 3.81 – 3.71 (m, 2H), 3.65 (dd, J = 13.3, 6.4 Hz, 2H), 3.48 – 3.39 (m, 1H), 3.29 (s, 
3H), 3.21 (dd, J = 12.4, 6.3 Hz, 3H), 3.06 (d, J = 6.5 Hz, 1H), 3.05 – 2.93 (m, 4H), 2.92 – 2.82 (m, 
1H), 2.58 – 2.45 (m, 2H), 2.31 (dd, J = 28.6, 7.4 Hz, 6H), 2.20 (d, J = 14.3 Hz, 3H), 2.11 (dd, J = 
35.3, 9.4 Hz, 5H), 2.00 – 1.83 (m, 5H), 1.75 – 1.57 (m, 6H), 1.57 – 1.49 (m, 2H), 1.41 – 1.27 (m, 
7H), 1.28 – 1.11 (m, 16H), 1.13 – 1.01 (m, 11H), 0.90 – 0.85 (m, 1H), 0.85 – 0.74 (m, 3H). 13C 
NMR (126 MHz, CDCl3) δ (ppm) 176.0, 147.4, 138.4, 129.8, 129.4, 125.8, 120.1, 102.7, 96.6, 
96.5, 81.1, 81.0, 78.4, 78.2, 77.3, 77.1, 76.8, 76.6, 76.2, 76.1, 76.0, 74.3, 71.1, 70.7, 69.1, 68.3, 
67.6, 65.4, 63.1, 57.0, 51.2, 51.0, 50.7, 50.1, 49.6, 45.3, 45.0, 43.2, 40.3, 39.4, 39.0, 37.2, 31.5, 
29.8, 29.7, 29.3, 28.5, 26.2, 25.6, 24.9, 24.5, 21.7, 21.0, 19.7, 18.9, 18.1, 16.0, 16.0, 15.4, 14.9, 
14.8, 13.1, 12.3, 11.5, 10.6, 9.3. HRMS (MALDI) m/z Calcd. for C55H93N6O15 [M+H
+]: 
1077.6699, found 1077.6692. 
(Clarithromycin-4-(methylamino)-N(methyl)-4-benzyltriazolyl))-N-hydroxyheptanamide 
(13f) 
Reaction of (4-(methylamino)-N(methyl)(4-ethynylbenzyl)) clarithromycin 11 (0.15 g, 
0.17 mmol) with 7-azido-N-((tert-butyldimethylsilyl) oxy) heptanamide 12f (0.075 g, 0.249 mmol) 
followed by TBS removal with caesium fluoride as described for the synthesis of compound 5a, 
gave 13f as a light yellow solid (0.060g, 40%). 1H NMR (400 MHz, CD3OD) δ (ppm) 8.34 (s, 1H), 
7.81 (d, J = 8.2 Hz, 2H), 7.40 (d, J = 8.2 Hz, 2H), 5.16 – 5.08 (m, 1H), 4.96 (d, J = 5.2 Hz, 1H), 
4.45 (t, J = 6.5 Hz, 3H), 4.22 (d, J = 6.4 Hz, 1H), 3.85 – 3.64 (m, 5H), 3.52 (s, 1H), 3.33 – 3.23 




6H), 2.35 (s, 1H), 2.31 – 2.23 (m, 4H), 2.21 (s, 1H), 2.18 – 2.12 (m, 3H), 2.12 – 2.04 (m, 4H), 1.99 
– 1.85 (m, 6H), 1.83 (d, J = 13.2 Hz, 2H), 1.69 – 1.53 (m, 7H), 1.44 – 1.31 (m, 12H), 1.28 – 1.18 
(m, 15H), 1.12 (dt, J = 11.4, 4.9 Hz, 12H), 0.90 (s, 1H), 0.85 (t, J = 7.3 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ (ppm) 176.2, 147.6, 138.4, 130.1, 129.7, 126.1, 120.3, 102.8, 96.8, 81.4, 78.6, 
78.4, 74.6, 71.3, 71.0, 69.3, 68.4, 67.9, 65.7, 63.3, 57.1, 51.6, 51.0, 50.4, 49.9, 45.5, 45.2, 43.5, 
40.7, 39.6, 39.2, 37.5, 31.8, 30.1, 30.0, 28.9, 28.8, 28.2, 26.6, 26.0, 25.6, 25.3, 21.9, 21.3, 20.6, 
20.0, 19.5, 19.1, 18.3, 16.3, 15.7, 15.2, 15.0, 12.6, 10.9, 9.7. HRMS (MALDI) m/z Calcd. for 
C56H95N6O15 [M+H
+]: 1091.6815, found 1091.6869. 
((3-O-Acetyl)-4-N-(4-ethynylbenzyl)) clarithromycin (14) 
(4-Ethynylbenzyl) clarithromycin 3 (0.15 g, 0.177 mmol) was dissolved in anhydrous 
DCM (5 mL) and acetic anhydride (0.04 mL, 0.442 mmol) added to the solution. The mixture was 
left to stir at room temperature under Ar for 3 days after which TLC shows full consumption of 
the starting material. The reaction was washed with NaHCO3, brine and H2O, theorganic layer was 
dried with anhydrous Na2SO4 and concentrated in vacuo to give compound 14 (128 mg, 81%). 
1H 
NMR (400 MHz, CDCl3) δ 7.38 (d, J = 8.2 Hz, 2H), 7.19 (d, J = 8.1 Hz, 2H), 5.01 (dd, J = 11.1, 
2.2 Hz, 1H), 4.87 (d, J = 4.8 Hz, 1H), 4.74 (dd, J = 10.6, 7.4 Hz, 1H), 4.48 (d, J = 7.4 Hz, 1H), 
3.94 (s, 1H), 3.86 (dt, J = 12.1, 6.1 Hz, 1H), 3.66 (t, J = 11.1 Hz, 2H), 3.63 (s, 1H), 3.52 (d, J = 
6.5 Hz, 1H), 3.46 (s, 1H), 3.40 (dd, J = 11.3, 6.7 Hz, 1H), 3.18 (s, 1H), 3.07 (s, 3H), 3.02 (d, J = 
6.2 Hz, 1H), 2.99 – 2.91 (m, 5H), 2.80 (dt, J = 14.2, 7.2 Hz, 1H), 2.73 (d, J = 4.5 Hz, 1H), 2.59 – 
2.47 (m, 2H), 2.29 – 2.24 (m, 1H), 2.20 – 2.15 (m, 9H), 2.06 – 2.01 (m, 4H), 1.93 – 1.76 (m, 3H), 
1.71 (t, J = 12.8 Hz, 1H), 1.62 (d, J = 11.6 Hz, 1H), 1.57 – 1.47 (m, 3H), 1.42 (ddd, J = 13.2, 8.3, 




Hz, 3H), 1.08 (t, J = 6.0 Hz, 8H), 0.85 (t, J = 7.5 Hz, 3H), 0.79 (t, J = 7.4 Hz, 2H). HRMS (ESI) 
m+z Calcd. for C48H76NO14 [M + H
+]: 890.5260, found 890.5256. 
((4-Oxo)-3-O-acetyl)-4-N-(4-ethynylbenzyl)) clarithromycin (15) 
A solution of N-chlorosuccinimide (0.034 g, 0.23 mmol) in DCM (5 mL) was stirred at -
15 C for 10 min then dimethyl sulfide (0.020 mL, 0.26 mmol) was added drop wise to form a 
white turbid solution. After stirring for 20 min, a DCM (5 mL) solution of compound 14 (0.128 g, 
0.144 mmol) was added over a period of 30 min and the resulting suspension was stirred at -15 C 
for 30 min.  Subsequently, TEA (0.030 mL, 0.23 mmol) was added and the suspension cleared up 
within a min. Stirring continued at -10 C for 2 h and the reaction was quenched with saturated 
NaHCO3 (10 mL). The organic layer extracted with DCM (50 mL), dried with anhydrous Na2SO4, 
filtered, and concentrated in vacuo. Residue was purified by preparative chromatography (Silica 
gel, Hexanes/EtOAc/MeOH (3:2:0.05) to give compound 15 as a yellow solid (0.055 g, 45%). 1H 
NMR (400 MHz, CD3OD) δ (ppm) 8.32 (s, 1H), 7.77 (d, J = 7.7 Hz, 2H), 7.36 (d, J = 7.9 Hz, 2H), 
5.09 (d, J = 9.2 Hz, 1H), 4.96 – 4.91 (m, 1H), 4.46 (s, 2H), 4.39 (d, J = 7.2 Hz, 1H), 4.19 (d, J = 
6.4 Hz, 1H), 3.81 – 3.60 (m, 5H), 3.48 (s, 1H), 3.28 – 3.19 (m, 4H), 3.10 – 2.95 (m, 5H), 2.92 – 
2.82 (m, 1H), 2.67 (s, 1H), 2.54 (s, 1H), 2.41 (s, 6H), 2.30 (s, 1H), 2.27 – 2.16 (m, 7H), 2.13 (dd, 
J = 20.0, 10.6 Hz, 4H), 1.94 – 1.69 (m, 6H), 1.62 (d, J = 14.6 Hz, 1H), 1.50 – 1.41 (m, 1H), 1.42 
– 1.31 (m, 4H), 1.26 – 1.13 (m, 16H), 1.13 – 1.01 (m, 12H), 0.86 – 0.76 (m, 3H). 13C NMR (126 
MHz, MeOD) δ (ppm) 212.0, 177.2, 172.2, 142.0, 133.0, 129.9, 122.5, 101.8, 97.9, 84.5, 81.5, 
80.5, 79.8, 78.5, 78.2, 76.0, 74.2, 73.9, 73.1, 70.7, 69.9, 62.6, 59.1, 51.8, 51.1, 50.9, 46.6, 46.0, 




16.7, 16.3, 15.1, 13.7, 12.8, 11.1, 10.1, 9.9. HRMS (ESI) m/z Calcd. for C48H74NO14 [M+H
+]: 
888.5104, found 888.5113. 
((4-Epoxy)-3-O-acetyl)-4-N-(4-ethynylbenzyl))clarithromycin (16) 
Compound 15 (0.40 g, 0.45 mmol) was reacted with NaH (60% dispersion in mineral oil) 
(0.040 g, 0.99 mmol) and trimethyloxosulfonium iodide (0.218 g, 0.99 mmol) as described for the 
synthesis of compound 9 to give compound 16 after purification by preparative chromatography 
(Silica gel, Hexanes/EtOAc/EtOH (4:1:0.5), as yellow solid (0.35 g, 77%). 1H NMR (400 MHz, 
CDCl3) δ (ppm) 7.40 (d, J = 8.1 Hz, 2H), 7.20 (d, J = 8.1 Hz, 2H), 4.88 (d, J = 3.5 Hz, 1H), 4.84 
– 4.73 (m, 2H), 4.56 (d, J = 7.5 Hz, 1H), 3.98 – 3.91 (m, 1H), 3.69 (s, 1H), 3.67 – 3.61 (m, 2H), 
3.49 (d, J = 14.0 Hz, 2H), 3.34 (s, 1H), 3.06 (s, 3H), 3.04 (s, 2H), 2.90 (d, J = 4.1 Hz, 1H), 2.81 – 
2.67 (m, 3H), 2.64 (d, J = 4.1 Hz, 1H), 2.49 (dt, J = 21.9, 7.4 Hz, 1H), 2.38 (dt, J = 9.9, 4.9 Hz, 
1H), 2.35 – 2.25 (m, 2H), 2.21 (s, 3H), 2.18 (s, 1H), 2.15 (s, 1H), 2.08 (s, 3H), 1.83 (d, J = 4.8 Hz, 
1H), 1.81 – 1.71 (m, 2H), 1.43 – 1.32 (m, 3H), 1.30 – 1.22 (m, 9H), 1.19 (t, J = 5.8 Hz, 7H), 1.12 
(t, J = 9.0 Hz, 4H), 1.04 – 0.97 (m, 10H), 0.92 (d, J = 6.5 Hz, 3H), 0.88 (dd, J = 10.4, 4.7 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ (ppm) 216.1, 178.8, 171.3, 169.8, 140.7, 131.9, 128.4, 120.6, 99.7, 
96.0, 83.7, 79.7, 78.7, 73.8, 71.5, 68.2, 63.1, 61.5, 60.4, 58.2, 50.3, 49.4, 46.7, 41.6, 41.1, 38.3, 
37.0, 36.4, 35.7, 33.4, 31.3, 29.7, 24.6, 21.3, 21.1, 20.2, 19.2, 17.9, 14.3, 14.1, 10.9, 10.7, 7.8. 
HRMS (ESI) m/z Calcd. for C49H76NO14 [M+H
+]: 902.5260, found 902.5260. 
((4-(N,N-Dimethylaminomethyl)-4-N-(4-ethynylbenzyl))clarithromycin (18) 
N,N-Dimethylmethylamine 17 (4.22 mL, 8.46 mmol, 2M in THF) was added to a solution 
of compound 16 (0.10 g, 0.11 mmol) in MeOH (20  mL). The solution was heated at 60 C for 6 




dissolved in MeOH (10 mL) and heated at 90 C for three days after which TLC showed complete 
conversion. Excess MeOH was evaporated off to give compound 18 as yellow solid (0.08 g, 83%). 
1H NMR (400 MHz, CDCl3) δ (ppm) 7.43 (d, J = 8.2 Hz, 3H), 7.26 – 7.20 (m, 2H), 5.04 (dd, J = 
11.0, 2.2 Hz, 1H), 4.98 (d, J = 5.0 Hz, 1H), 4.37 (d, J = 7.2 Hz, 1H), 4.07 – 4.00 (m, 1H), 3.94 (s, 
1H), 3.79 (s, 1H), 3.75 (s, 2H), 3.73 – 3.69 (m, 2H), 3.66 (dd, J = 8.5, 5.8 Hz, 1H), 3.62 (dd, J = 
6.6, 3.6 Hz, 1H), 3.61 – 3.57 (m, 1H), 3.50 – 3.42 (m, 2H), 3.39 (dd, J = 12.3, 7.7 Hz, 3H), 3.29 
(dd, J = 10.2, 7.2 Hz, 1H), 3.21 (d, J = 3.9 Hz, 1H), 3.16 (d, J = 3.7 Hz, 2H), 3.09 (s, 3H), 3.06 (t, 
J = 4.5 Hz, 4H), 3.05 – 3.01 (m, 4H), 2.99 (d, J = 8.0 Hz, 1H), 2.91 – 2.80 (m, 1H), 2.66 (s, 1H), 
2.62 (s, 1H), 2.52 (dd, J = 15.6, 7.6 Hz, 2H), 2.36 (s, 9H), 2.23 (d, J = 4.3 Hz, 4H), 2.18 – 2.15 (m, 
1H), 2.07 (s, 1H), 2.03 (s, 2H), 1.99 (d, J = 6.8 Hz, 1H), 1.90 (dt, J = 30.0, 10.5 Hz, 6H), 1.64 – 
1.52 (m, 2H), 1.49 – 1.42 (m, 1H), 1.41 – 1.33 (m, 6H), 1.31 – 1.22 (m, 10H), 1.22 – 1.17 (m, 5H), 
1.15 – 1.01 (m, 25H), 0.91 (dt, J = 14.0, 5.6 Hz, 3H), 0.87 – 0.78 (m, 5H). 13C NMR (126 MHz, 
CDCl3) δ (ppm) 175.7, 169.9, 167.8, 132.3, 132.0, 130.9, 128.8, 128.5, 121.1, 102.8, 96.4, 83.4, 
81.3, 78.3, 78.0, 76.5, 76.0, 74.3, 70.9, 70.3, 69.0, 68.3, 68.2, 67.6, 63.6, 58.0, 57.8, 50.8, 50.6, 
49.4, 47.3, 45.3, 44.9, 39.3, 38.8, 38.7, 37.2, 36.9, 31.3, 30.4, 29.7, 28.9, 23.7, 23.0, 21.6, 21.0, 
19.8, 18.5, 18.1, 16.0, 16.0, 15.1, 14.1, 12.4, 11.0, 10.6, 9.3. HRMS (ESI) m+2/2z Calcd. for 
C49H82N2O13 [M+2H
+]: 453.2903 found 453.2892. 
(Clarithromycin-(4-N-(4-benzyltriazolyl))-4-(N,N-dimethylaminomethyl))-N-
hydroxyhexanamide (20a) 
Reaction of compound 18 (0.05 g, 0.06 mmol)  with 6-azido-N-((tert-
butyldimethylsilyl)oxy)hexanamide 19e (0.075 g, 0.249 mmol) followed by TBS removal with 




(0.02 g, 44%).1H NMR (400 MHz, CD3OD) δ (ppm) 8.36 (s, 1H), 7.81 (d, J = 8.2 Hz, 2H), 7.46 
(d, J = 8.3 Hz, 2H), 5.12 (d, J = 10.8 Hz, 1H), 4.45 (t, J = 6.9 Hz, 3H), 4.31 (d, J = 7.2 Hz, 1H), 
4.09 (d, J = 6.5 Hz, 1H), 3.90 (d, J = 13.4 Hz, 1H), 3.72 (d, J = 13.5 Hz, 2H), 3.59 (d, J = 12.8 Hz, 
2H), 3.20 (dd, J = 19.5, 9.0 Hz, 3H), 3.11 (d, J = 15.2 Hz, 2H), 3.00 (d, J = 8.4 Hz, 6H), 2.89 (s, 
1H), 2.65 (s, 1H), 2.59 (s, 3H), 2.42 (s, 6H), 2.34 (s, 4H), 2.28 (s, 1H), 2.21 (s, 1H), 2.10 (t, J = 
7.4 Hz, 4H), 1.96 (dd, J = 15.3, 7.4 Hz, 5H), 1.82 (s, 7H), 1.73 – 1.60 (m, 5H), 1.44 – 1.33 (m, 
9H), 1.27 (d, J = 10.6 Hz, 7H), 1.22 (dd, J = 12.4, 6.3 Hz, 7H), 1.21 – 1.16 (m, 6H), 1.17 – 1.09 
(m, 17H), 1.06 (d, J = 7.5 Hz, 4H), 0.91 (d, J = 10.9 Hz, 5H), 0.84 (dd, J = 9.5, 5.1 Hz, 5H). 13C 
NMR (101 MHz, CDCl3) δ (ppm) 175.7, 147.5, 129.7, 125.8, 102.9, 96.8, 94.9, 78.3, 76.1, 74.3, 
71.3, 70.9, 69.0, 68.3, 67.5, 51.3, 50.7, 50.7, 50.1, 50.5, 49.4, 47.2, 45.3, 45.3, 44.6, 39.4, 37.5, 
36.8, 33.7, 31.9, 29.7, 28.6, 23.2, 22.7, 21.6, 21.3, 19.7, 18.1, 16.0, 15.9, 15.1, 14.1, 12.3, 10.6, 
9.2, 7.8. HRMS (ESI) m/z Calcd. for C55H93N6O15 [M+H
+]1077.6693, found 1077.6692. 
(Clarithromycin-(4-N-(4-benzyltriazolyl))-4-(N,N-dimethylaminomethyl))-N-
hydroxyheptanamide (20b) 
Reaction of compound 18 (0.024 g, 0.022 mmol)  with 7-Azido-N-((tert-
butyldimethylsilyl)oxy)heptanamide 19f (0.075 g, 0.249 mmol) followed by TBS removal with 
caesium fluoride as described for the synthesis of compound 5a, gave 20b as a light yellow solid 
(0.021 g, 83%).1H NMR (400 MHz, CD3OD) δ 8.37 (s, 1H), 7.82 (d, J = 8.2 Hz, 2H), 7.46 (d, J = 
8.2 Hz, 2H), 5.14 – 5.07 (m, 1H), 4.45 (t, J = 7.0 Hz, 2H), 4.30 (d, J = 7.2 Hz, 1H), 4.09 (d, J = 
6.5 Hz, 1H), 3.92 (d, J = 13.0 Hz, 1H), 3.72 (d, J = 12.3 Hz, 2H), 3.64 – 3.57 (m, 2H), 3.34 (d, J 
= 2.4 Hz, 2H), 3.09 (s, 1H), 3.04 – 2.97 (m, 7H), 2.89 (s, 2H), 2.59 (s, 3H), 2.49 (s, 7H), 2.36 (s, 
3H), 2.28 (s, 1H), 2.15 (s, 1H), 2.11 – 2.03 (m, 5H), 1.92 (dd, J = 13.5, 6.7 Hz, 6H), 1.83 (d, J = 




5H), 1.19 (d, J = 7.2 Hz, 4H), 1.17 – 1.08 (m, 16H), 1.05 (d, J = 7.5 Hz, 4H), 0.97 (s, 1H), 0.91 (d, 
J = 11.7 Hz, 4H), 0.84 (t, J = 7.4 Hz, 4H). 13C NMR (101 MHz, cd3od) δ 223.5, 179.1, 149.8, 
132.2, 127.7, 123.6, 105.6, 99.1, 83.2, 80.8, 79.1, 77.0, 73.5, 71.6, 70.5, 69.7, 63.3, 60.6, 53.5, 
52.2, 51.4, 48.7, 47.8, 47.4, 41.5, 38.1, 33.1, 32.2, 31.5, 30.9, 30.6, 28.2, 27.6, 23.1, 20.0, 19.8, 
18.1, 17.7, 16.9, 13.7, 12.2, 11.3 HRMS (ESI) m+2/2z Calcd. for C56H97N6O15 [M+2H
+]: 
546.3461, found 546.3469. 
(Clarithromycin-3-(N-(4-triazolylbenzyl)))-N-(2-amino-5-(thiophen-2-yl)phenyl)-
hexanamide (22a) 
3-N-(desmethyl)- 3-N-(4-ethynylbenzyl) clarithromycin 3 (0.08 g, 0.09 mmol) and 2-N-
(2-amino-5-(thiophen-2-yl)phenyl)-6-azidohexanamide 21a (0.03 g, 0.10 mmol) are dissolved in 
anhydrous THF and purged with argon for 10 min. DIPEA (0.03ml, 0.19mmol) and CuI (0.01 g, 
0.05 mmol) were then added to the mixture and purged further for another 20 minutes. The 
resulting suspension was stirred at room temperature for 12 h. Reaction was quenched with a 
solution of 4:1 satd. Aqueous NH4Cl/NH4OH and extracted with a mixture of 10% MeOH in DCM. 
Combined organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo. The crude 
was purified by prep. TLC using Hexanes: EtOAc: iPrOH: NH4OH (10:10:0.2:0.01) to give 
compound 22a as a brown solid (0.064g, 57%). 1H NMR (400 MHz, cdcl3) δ 7.80 – 7.71 (m, 3H), 
7.53 (s, 1H), 7.43 (s, 1H), 7.37 – 7.26 (m, 3H), 7.14 (dd, J = 12.4, 4.3 Hz, 2H), 7.04 – 6.97 (m, 
1H), 6.77 (d, J = 8.2 Hz, 1H), 5.04 (d, J = 11.1 Hz, 1H), 4.88 (d, J = 4.6 Hz, 1H), 4.40 (t, J = 8.0 
Hz, 3H), 3.95 (d, J = 17.2 Hz, 3H), 3.80 – 3.68 (m, 3H), 3.62 (d, J = 6.9 Hz, 1H), 3.48 (s, 3H), 
3.33 (d, J = 11.4 Hz, 2H), 3.20 (d, J = 8.1 Hz, 2H), 3.11 (s, 3H), 3.04 – 2.92 (m, 6H), 2.87 (dd, J 




(s, 1H), 2.08 (d, J = 10.0 Hz, 2H), 1.96 (dd, J = 17.8, 9.8 Hz, 3H), 1.92 – 1.84 (m, 3H), 1.83 – 1.61 
(m, 7H), 1.47 (dd, J = 20.5, 17.1 Hz, 5H), 1.39 (s, 5H), 1.24 (dt, J = 21.5, 10.8 Hz, 10H), 1.19 – 
1.13 (m, 5H), 1.14 – 1.01 (m, 18H), 0.83 (t, J = 7.3 Hz, 4H). 13C NMR (126 MHz, CDCl3) δ 
175.95, 175.78, 172.59, 147.39, 145.00, 129.57, 128.02, 125.78, 124.26, 122.71, 121.07, 119.80, 
102.79, 99.96, 95.93, 88.63, 81.00, 78.32, 77.89, 74.27, 72.51, 70.76, 69.08, 65.69, 63.87, 57.67, 
50.64, 49.85, 49.42, 45.26, 45.06, 39.26, 39.08, 37.23, 36.87, 34.71, 31.88, 29.71, 29.53, 28.52, 
26.51, 25.54, 22.63, 21.48, 21.31, 21.03, 19.83, 18.64, 18.02, 16.03, 15.98, 14.14, 12.33, 10.62, 
9.16. HRMS (ESI) m+z Calcd. for C62H93O14N6S [M+H
+]: 1177.6465, found 1177.6425. 
 (Clarithromycin-3-(N-(4-triazolylbenzyl)))-N-(2-amino-5-(thiophen-2-yl)phenyl)-
heptanamide (22b) 
3-N-(desmethyl)- 3-N-(4-ethynylbenzyl) clarithromycin 3 (0.08 g, 0.09 mmol) and N-(2-
amino-5-(thiophen-2-yl) phenyl)-7-azidoheptanamide 21b (0.04 g, 0.10 mmol) are dissolved in 
anhydrous THF and purged with argon for 10 min. DIPEA (0.02ml, 0.19mmol) and CuI (0.01 g, 
0.05 mmol) and left to react as described for compound 22a above. Crude product was purified by 
prep. TLC using Hexanes: EtOAc: iPrOH: NH4OH (10:10:0.2:0.01) to give compound 22b as a 
brown solid (0.046g, 57%). 1H NMR (400 MHz, cdcl3) δ 7.79 – 7.71 (m, 3H), 7.65 (s, 1H), 7.42 
(d, J = 1.8 Hz, 1H), 7.30 (dd, J = 10.3, 4.3 Hz, 3H), 7.14 (dd, J = 11.9, 3.8 Hz, 2H), 7.03 – 6.97 
(m, 1H), 6.78 (d, J = 8.3 Hz, 1H), 5.02 (dt, J = 13.1, 6.5 Hz, 1H), 4.88 (d, J = 4.6 Hz, 1H), 4.39 
(dd, J = 10.4, 6.9 Hz, 3H), 3.99 – 3.86 (m, 3H), 3.79 – 3.68 (m, 3H), 3.61 (d, J = 7.1 Hz, 2H), 3.43 
(s, 2H), 3.31 (dd, J = 16.2, 9.0 Hz, 1H), 3.19 (d, J = 9.0 Hz, 2H), 3.11 (d, J = 11.0 Hz, 3H), 3.03 – 
2.90 (m, 6H), 2.90 – 2.81 (m, 1H), 2.58 (d, J = 31.0 Hz, 2H), 2.44 – 2.33 (m, 2H), 2.30 – 2.21 (m, 
5H), 2.18 – 2.13 (m, 6H), 1.99 – 1.83 (m, 7H), 1.81 – 1.65 (m, 6H), 1.54 – 1.33 (m, 13H), 1.31 – 




MHz, CDCl3) δ 175.79, 171.72, 147.39, 144.13, 140.46, 129.56, 129.34, 127.89, 126.21, 125.76, 
124.96, 124.59, 123.58, 122.82, 121.90, 118.60, 115.17, 113.31, 102.49, 95.93, 80.97, 78.32, 
77.92, 74.27, 72.51, 72.49, 71.29, 70.51, 70.19, 69.07, 65.66, 63.57, 61.88, 57.68, 50.63, 50.11, 
49.43, 45.26, 45.06, 39.25, 39.09, 37.23, 36.85, 36.39, 34.82, 31.94, 31.65, 30.01, 29.71, 29.67, 
29.37, 28.23, 25.84, 25.21, 22.71, 21.47, 21.29, 21.03, 19.83, 19.27, 18.64, 18.01, 16.02, 15.98, 
14.20, 14.14, 13.92, 12.33, 10.62, 9.13. HRMS (ESI) m+z Calcd. for C63H95O14N6S [M+H+]: 
1191.6621, found 1191.6620. 
(Clarithromycin-3-(N-(4-triazolylbenzyl)))-N-(2-amino-5-(thiophen-2-yl)phenyl)-
octanamide (22c) 
3-N-(desmethyl)- 3-N-(4-ethynylbenzyl) clarithromycin 3 (0.11 g, 0.09 mmol) and N-(2-
amino-5-(thiophen-2-yl)phenyl)-8-azidooctanamide 21c (0.05 g, 0.14 mmol) are dissolved in 
anhydrous THF and purged with argon for 10 min. DIPEA (0.04 ml, 0.25 mmol) and CuI (0.012 
g, 0.064 mmol) and left to react as described for compound 22a above. Crude product was purified 
by prep. TLC using DCM: MeOH: NH4OH (12:1:0.1) to give compound 22c as a brown solid 
(0.134g, 87%). 1H NMR (400 MHz, cdcl3) δ 7.76 (d, J = 7.8 Hz, 3H), 7.51 (d, J = 6.9 Hz, 1H), 
7.43 (s, 1H), 7.30 (d, J = 6.3 Hz, 3H), 7.17 – 7.10 (m, 2H), 7.04 – 6.97 (m, 1H), 6.78 (d, J = 8.1 
Hz, 1H), 5.02 (t, J = 10.3 Hz, 1H), 4.89 (d, J = 4.9 Hz, 1H), 4.44 – 4.30 (m, 3H), 4.00 – 3.85 (m, 
3H), 3.76 – 3.67 (m, 3H), 3.62 (d, J = 7.0 Hz, 1H), 3.46 (d, J = 15.2 Hz, 3H), 3.28 (d, J = 20.7 Hz, 
1H), 3.19 (d, J = 9.1 Hz, 1H), 3.12 (d, J = 14.1 Hz, 3H), 3.04 – 2.92 (m, 6H), 2.87 (dd, J = 17.9, 
9.1 Hz, 2H), 2.51 (d, J = 34.1 Hz, 2H), 2.40 (t, J = 7.4 Hz, 2H), 2.31 – 2.18 (m, 5H), 2.07 (d, J = 
9.9 Hz, 1H), 2.00 (d, J = 0.7 Hz, 1H), 1.98 – 1.85 (m, 5H), 1.83 – 1.75 (m, 2H), 1.69 (d, J = 14.4 
Hz, 6H), 1.49 (td, J = 15.2, 6.0 Hz, 2H), 1.39 (s, 10H), 1.25 (dd, J = 13.2, 6.1 Hz, 10H), 1.17 (d, J 




171.64, 157.80, 152.04, 149.69, 144.17, 129.26, 127.98, 125.85, 124.80, 124.57, 123.29, 122.75, 
122.22, 120.41, 118.29, 102.62, 99.74, 95.82, 80.91, 78.25, 74.24, 72.28, 69.10, 68.87, 65.69, 
57.60, 50.61, 50.02, 49.50, 43.21, 39.05, 36.92, 36.40, 34.59, 29.90, 28.61, 28.08, 25.94, 25.21, 
21.48, 20.74, 19.67, 18.63, 18.09, 15.73, 12.31, 10.60, 8.93. HRMS (ESI) m+z Calcd. for 
C64H97O14N6S [M+H
+]: 1205.6778, found 1205.6795. 
 
2.8.2. In Vitro HDAC Inhibition: SAMDI Assay  
The maleimide-presenting SAMs and expression of HDAC8 enzyme were prepared as 
previously reported.21 To obtain IC50 values, we incubated isoform- optimized substrates (50 μM, 
detailed below) with enzyme (250 nM, detailed below) and inhibitor (at concentrations ranging 
from .1 nM to 1.0 mM) in HDAC buffer (25.0 mM Tris-HCl, pH 8.0, 140 mM NaCl, 3.0 mM KCl, 
1.0 mM MgCl2, and 0.1 mg/mL BSA) in 96-well microtiter plates (60 min, 37 °C). Solution-phase 
deacetylation reactions were quenched with trichostatin A (TSA) and transferred to SAMDI plates 
to immobilize the substrate components. SAMDI plates were composed of an array of self-
assembled monolayers (SAMs) presenting maleimide in standard 384-well format for high-
throughput handling capability. Following immobilization, plates were washed to remove buffer 
constituents, enzyme, inhibitor, and any unbound substrate and analyzed by MALDI mass 
spectrometry using automated protocols. Deacetylation yields in each triplicate sample were 
determined from the integrated peak intensities of the molecular ions for the substrate and the 
deacetylated product ion by taking the ratio of the former over the sum of both. Yields were plotted 





Isoform-optimized substrates were prepared by traditional FMOC solid-phase peptide 
synthesis (reagents supplied by Anaspec) and purified by semi-preparative HPLC on a reverse-
phase C18 column (Waters). The peptide GRKacFGC was prepared for HDAC1 and HDAC8 
experiments, whereas the peptide GRKacYGC was prepared for HDAC6 experiments.  
 HDAC1, HDAC6, and HDAC2 were purchased from BPS Biosciences. The catalytic 
domain of HDAC8 was expressed as previously reported.21e Briefly, an amplicon was prepared by 
PCR with the following primers: forward (5′−3′) TATTCTCGAGGA- CCACATGCTTCA and 
reverse (5′−3′) ATAAGCTAGCATG- GAGGAGCCGGA. A pET21a construct bearing the 
genetic insert between the NheI and XhoI restriction sites was transformed into Escherichia coli 
BL21(DE3) (Lucigen) and expressed by standard protocols. Following purification by affinity 
chromatography, the His- tagged enzyme-containing fractions were purified by FPLC (AKTA) on 
a superdex size-exclusion column (GE), spin-concentrated, and stored at −80 °C in HDAC buffer 
with 10% glycerol.  
 
2.8.3. Cell growth inhibition study 
 A549, MCF-7 and VERO were cultured in DMEM (Lonza, GA) supplemented with 10% 
fetal bovine serum (FBS) (Atlanta Biologicals, Atlanta, GA) and 1% Penicillin-Streptomycin. 
Cells were incubated in a 96 well plate for 24 h then treated with various drug concentrations and 
incubated for another 72 h. Cell viability was measured using the MTS assay (CellTiter 96 
Aqueous One Solution and CellTiter 96 Non-Radioactive Cell Proliferation Assays, Promega, 
Madison, WI) protocol as described by the manufacturer. In all experiments, DMSO concentration 




2.8.4. Anti-inflammatory Activity Assay: 
NF-B activity was measured by luciferase assay. BEAS-2B cells were transfected with 
NF-B luciferase reporter construct in pGL3 basic vector.31 24 h after transfection, the cells were 
treated with drugs for 1 h followed by stimulation with NTHi for 5 h. Then cells were lysed with 
cell lysis buffer (250 mM Tris HCl (pH 7.5), 0.1% Triton-X, 1 mM DTT) and luciferase activity 
was measured by luciferase assay system (promega). Relative luciferase activity (RLA) was 
determined using the following equation; RLA = luciferase unit of the cells treated with NTHi and 
drug / luciferase unit of the cells treated with mock. IC50 was determined by treating the cell with 
a serial dose of the drug followed by luciferase assay. % Inhibition was calculated using the 
following equation; % inhibition = RLA of the cells treated with indicated concentration of the 
drug / RLA of the cells treated with mock.  
 
2.8.5. Real-Time quantitative RT-PCR analysis 
Total RNA was isolated with TRIzol reagent (Life Technologies) by following the 
manufacturer’s instruction. For the reverse transcription reaction, TaqMan reverse transcription 
reagents (Life Technologies) were used as described previously. For quantitative RT-PCR 
analysis, PCR amplifications were performed by using SYBR Green Universal Master Mix (Life 
Technologies). In brief, reactions were performed in triplicate containing 2×~ Universal Master 
Mix, 1 μL of template cDNA, 500 nM primers in a final volume of 12.5 μL, and they were analyzed 
in a 96-well optical reaction plate (USA Scientific). Reactions were amplified and quantified by 
using a StepOnePlus Real-Time PCR System and the manufacturer’s corresponding software 




by using the comparative Ct method and were normalized by using human cyclophilin as an 
endogenous control. For semiquantitative RT-PCR analysis, PCR amplifications were performed 
with PrimeSTAR Max polymerase (Takara) by following the manufacturer’s instruction. The 
primer for TNF-α, IL-1β were described previousery35,36. IL-1α :5’-
CGAGCCAATGATCAGTACCTC -3’ and 3’-CACCCATATATTTCACTG -5’. 
 
2.8.6. Western blot analysis 
MCF-7 cells (106 cells/dish) were seeded in petri dishes 24 hour prior to treatment with 
various concentrations of compounds for 24 hours. Thereafter, media was removed and cells were 
washed with chilled 1X PBS buffer and resuspended in CelLyticM buffer containing a cocktail of 
protease inhibitor (Sigma-Aldrich, St. Louis, MO, USA). Protein concentration was determined 
through Bradford protein assay.  Equal amount of protein was then loaded onto an SDS-page gel 
(Bio-Rad, Hercules, CA, USA) and resolved by electrophoresis at a constant voltage of 100 V for 
2 hours. The gel was transfered onto a nitrocellulose membrane and probed for H4 and acetyl H4. 
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Melanoma is one of the most prevalent cancers among skin malignancies.1 As with most 
cancer types caused by disruption in the homeostatic regulation of cellular processes, melanomas 
are typified by dysregulation of melanin-producing melanocytes by keratinocytes in the skin 
epidermis.2 This dysregulation results in uncontrolled proliferation of melanocytes, hence the high 
melanin content associated with most melanoma cases. When detected early, melanoma can be 
corrected by surgery. Therefore, sustained efforts have been on developing effective new tools for 
early diagnosis of melanoma.  
Over the past two decades, benzamides (Figure 3.1A) have emerged as promising class of 
compounds that can be developed into theranostics for early detection and treatment of 
melanomas.3 What makes this class of compounds suitable for this purpose is their high affinity 
for melanin, which affords them a high residence time in melanoma cells. In phase II clinical trial, 
N-(2-(diethylamino)ethyl)-4-iodobenzamide (Figure 3.1A) showed 100% specificity on a lesion-
site basis with little toxicity to the patients.3a When incorporated into the structure of a 
conventional alkylating agent, the resulting alkylating benzamides showed superior selectivity for 




suitability of the benzamide template for developing targeted proteasome degradation inhibitors5. 
Hence, benzamides have become “the Holy Grail” for developing melanoma-targeted therapeutics. 
Epigenetic dysregulation, exemplified by aberrant regulation of expression of histone 
deacetylases (HDAC) and histone acetyl transferase (HAT), is one of the root causes of cancer. 
Several isoforms of HDAC have been implicated in the sustained proliferation of most tumors, 
with class I and class IIb HDACs being the most prominent.6 With respect to melanomas, HDAC 
isoforms 5 and 6 were recently reported to play significant roles in melanoma progression.7 To 
further exploit the relevance of HDAC 6 in melanoma progression, Kozikowski et. al.8 made 
HDAC 6 selective HDAC inhibitors (HDACi) and studied their effects on melanoma cell growth. 
Though a promising approach, their compounds showed weak cytotoxic effects on B16F10 
melanoma cell line.  
The structures of the five clinically approved HDACi (Figure 3.1B) conform to a structural 
model comprising a surface recognition group, linker and a zinc binding group (ZBG) as shown 
for SAHA in Figure 3.1C. Previous SAR studies on the surface recognition group have identified 
this part of most HDACi to be the most amenable to modification.9  
To further demonstrate the broad scope of application of the benzamide template for 
developing targeted therapies, we designed and synthesized HDACi which have melanin binding 
benzamide group incorporated unto the surface recognition group (Figure 3.2A and B). We 
envisaged that this approach will result in selective localization of benzamide-based HDACi 
within the melanoma cells, and mitigate the off-target toxicities associated with most clinically 
approved HDACi. Following our previous reports,9a we restricted linker lengths in our design to 










Figure 3.1: A) structures of some selected benzamides for imaging tumors3b, 3c, 11; B) structures of 





Figure 3.2: General structures of designed compounds. 
 
3.2. Chemistry 
Synthesis of target compounds started with the esterification of 4-iodobenzoic acid 1 and 5-
bromopyridine-2-carboxylic acid 2, both of which are commercially, using TMSCl in MeOH to 
give methyl esters 3 and 4 (Scheme 3.1). Sonogashira coupling12 of the respective halo-methyl 
ester (compound 3 or 4) with TMS-acetylene gave the appropriate TMS-protected ethynyl 
intermediates 5 and 6. At this stage, different synthetic pathways were employed to access alkynes 
8 and 9. Subjecting TMS-protected methyl-4-(ethynyl)-benzoate 5 to alkaline hydrolysis, using 
KOH in isopropanol, resulted in TMS removal and gave the potassium salt of 4-(ethynyl) benzoate 
7. Coupling of 7 to N,N-diethyl ethane-1,2-diamine using TSTU3c afforded compound 8. In the 
case of compound 9, TMS-protected methyl-5-ethynyl picolinate 6 was refluxed with N,N-diethyl 




between alkyne 8 or 9 and O-trityl protected azido hydroxamates with appropriate linker lengths, 
followed by trityl deprotection using TFA, gave the target compounds 10a-b and 11a-b. 
 





3.3. HDAC isoform inhibition 
Considering the previously reported roles of HDAC6 in sustaining melanoma growth7-8 
and the absolute requirement of HDAC1 inhibition for HDACi to elicit robust antiproliferative 
effects of HDACi,8 we profiled compounds 10a-b and 11a-b against HDAC1 and HDAC6 in a 
cell-free assay. All the compounds showed strong inhibitory activities towards the two HDAC 
isoforms tested, with compound 10a being ten-fold more potent towards HDAC 1 compared to 
SAHA (Table 3.1). We observed these compounds to be more potent towards HDAC1 compared 
to HDAC6, suggesting that they may possess potent in vitro anticancer activities. The most potent 
compound in this series, compound 10a, showed about four-fold selectivity for HDAC 1 compared 
to HDAC 6.  While the weakest in the series, compound 11a, is almost indistinguishable in terms 
of inhibitory activity towards HDAC 1 and HDAC 6. Compounds 10b and 11b, despite having 
seven- and six methylenes, respectively, as linkers are both equipotent towards HDAC 1 and 
HDAC 6. 
Interestingly, the benzyl-based compound with six methylenes as linker, 10a, is more 
potent than the analogous pyridyl-based compound, 11b, in both HDAC1 and HDAC6.  This 
observation is similar to a previous study in our lab in which HDAC inhibitory activities of benzyl-
based HDACi and their analogous pyridyl-based HDACi were compared.14 Likewise, linker-







3.4. Growth inhibition study 
Encouraged by the potent cell-free HDAC inhibitory activities of these benzamide-based 
HDACi, we assayed their growth inhibitory effects on two melanin-producing melanoma cell 
lines, B16F10 and A375. We were surprised to observe that none of compounds 10a-b and 11a-b 
showed inhibitory effects on the growth of B16F10 and A375 cells at the maximum concentration  
Table 3.1: HDAC isoforms inhibition study 
 
Compound n IC50 (μM) * 
HDAC1 HDAC6 
10a 2 0.0038 0.016 
10b 3 0.012 0.027 
11a 1 0.100 0.170 
11b 2 0.017 0.034 
SAHA - 0.031 0.011 
*values indicate average of three independent experiments 
tested (20 μM) (Table 3.2). Previously, the intricate drug efflux system in melanoma, involving 
melanosomal sequestration and subsequent efflux of cytotoxic agents, was identified to be 
responsible for resistance of melanoma to chemotherapeutic agents.10, 16 It is quite possible that 




binding might not provide the anticipated advantage. Melanin, being a non-protein polymer,17 
might be unable to release the benzamide-based HDACi upon binding, resulting in their inability 
to engage HDACs, the therapeutic targets. Furthermore, the observed weak antiproliferative 
activity might just be a result of the inability of the tested compounds to penetrate the cell 
membrane.  
Intrigued by this observation and determined to unravel the basis for the weak in cellulo 
activities of these compounds, we extended cell growth inhibition study to LNCaP, an androgen 
dependent prostate cancer cell line not known to produce melanin. Results obtained from this study 
should provide insights into the role (s) of melanin in the observed cellular inactivity, and also 
confirm the ability of these compounds to cross the cell membrane.   
As seen in Table 3.2, all of the tested compounds inhibited the growth of LNCaP in a 
pattern similar to the HDAC inhibitory activity, confirming that these compounds can cross the 
cell membrane easily. This makes it highly probable that melanin binding or effective drug efflux 










Table 3.2: Antiproliferation study in cancer cell lines. 
 
Compound n IC50 (μM) * 
B16F10 A375 LNCaP 
10a 2 34.16 23.60 1.2 
10b 3 75.91 >100 3.0 
11a 1 >100 >100 10.5 
11b 2 55.67 47.18 1.5 
SAHA - 13.1 4.1 1.8 
*values indicate average of three independent experiments 
 
3.5. Prodrug approach 
We then considered exploiting benzamides’ affinity for melanin in a slightly different way. 
For this, a prodrug approach in which the melanin binding benzamide is attached to a hydroxamate-
based HDACi, via a labile ester bond that could provide a means of selective delivery of such 
HDACi to melanoma, was considered. When such compound binds to melanin in melanoma cells, 
the HDACi component could then be released by hydrolysis, facilitated by cellular esterase. This 




hydroxamate-based HDACi (Figure 3.3).18 In addition to this, such a design could mask potential 
off target interaction of the hydroxamate group with other biological targets in the cells.  
 
Figure 3.3: Structures of representative hydroxamate-based prodrugs. 
 
Previous work from our lab has identified triazolyl hydroxamate 7u (scheme 3.2) as a 
promising HDACi with robust growth inhibitory activity in prostate cancer cell line14. Encouraged 
by this, we incorporated compound 7u into the design of a releasable benzamide-HDACi prodrug 
(Figure 3.4).  
 




Potassium 4-((2-(diethylamino) ethyl) carbamoyl) benzoate (13) used in the synthesis of 
prodrug was made as according to Scheme 3.2 (synthesis was previously described in ref. 5c). 
Coupling of compound 13 to 7u using TSTU gave the desired prodrug 14. 
 
Scheme 3.2: Synthesis of releasable BZA-based HDACi 
  
 
While we do not anticipate any appreciable inhibition of HDAC (because the ZBG is 
masked), compound 14, when profiled against HDAC isoforms 1, 6 and 8 at 5 μM, showed 100 
percent inhibition against HDAC1, 99 percent inhibition against HDAC6, and 52 percent 
inhibition against HDAC8. The inhibitory activity shown could be due to hydrolysis of this 
compound in the HDAC assay buffer leading to the release of compound 7u, which is a very potent 




patent describing prodrugs of SAHA-like molecules,18b though no explanation was given for the 
observed potency in HDAC assay. 
Compounds 7u and 14 were tested in melanoma cell lines, A375 and B16F10, as shown in 
Table 3.3.  In B16F10, the prodrug 14, was slightly more potent than compound 10a and about 
half as potent as compound 7u. Similarly, compound 10a is about half as potent as compound 7u 
and equipotent to prodrug 14 in A375 cell line. Interestingly, prodrug 14 showed the same level 
of potency at 25 μM compared to compound 10a. The advantage to having the prodrug becomes 
more obvious at 50 μM, where prodrug 14 becomes more potent than compound 10a (Figure 3.5). 
This implies that there may be an advantage to using the benzamide template to design prodrugs 
rather than having it “permanently” incorporated into the design of compounds targeted towards 
melanin-producing melanoma cells.  
Table 3.3: Anti-proliferation study of prodrug in cancer cell lines. 
Compound IC50 (μM) * 
B16F10 A375 LNCaP 
14 27.75 25.95 6.46 
7u 10.50 12.61 5.10 
10a 34.16 23.60 1.20 
SAHA 13.44 4.31 1.80 





Figure 3.5: Comparison of growth inhibitory effects of prodrug 14 and compound 10a in 
B16F10 cell line. 
 
3.6. Cellular target engagement 
 To gain further insight into the cellular accessibility of the synthesized compounds, and 
confirm that prodrug 14 releases compound 7u upon getting into the cells, we used western blot to 
probe for accumulation of acetyl tubulin upon treating B16F10 cells with compounds 10a, 7u, 14, 
and SAHA. Accumulation of acetyl tubulin in the cytoplasm is a marker of HDAC 6 inhibition in 
cells.19 SAHA and compound 7u as expected showed significant accumulation of acetyl tubulin at 
20 μM (Figure 3.6). Likewise, compound 10a gave a similar effect at increasing drug 
concentrations (5-50 μM). Prodrug 14 increasingly shows increase in the level of acetyl tubulin 
that becomes very significant at 50 μM. This implies that the prodrug is actually releasing 


























Figure 3.6: Western blot analysis showing acetyl tubulin accumulation 
 
3.7. Conclusion 
In conclusion, we have reported a series of HDACi designed to selectively target melanoma 
cells. Although our compounds have potent HDAC inhibitory activities, they only showed modest 
cell growth inhibitory activity in melanoma cell lines. Against HDAC 1 and HDAC 6, compounds 
10a-b and 11a-b showed enzyme inhibitory activities that are largely dependent on the nature of 
the cap group and the linker length. Preliminary evaluation of the growth inhibitory effects of these 
compounds on two melanin-rich melanoma cell lines, B16F10 and A375, showed them to have 
modest effect on the proliferation of these cell lines. An observation that may be attributed to the 
inability of benzamide-HDACi to engage their HDAC targets after being bound to melanin, and/or 
the very effective efflux of cytotoxic agents commonly seen with melanoma cells10. In androgen-
dependent prostate cancer cell line (LNCaP), however, all the compounds showed anticancer 
activities consistent with their strong HDAC enzyme inhibitory effects. 
Effort to adopt a prodrug strategy using the benzamide template to selectively deliver a 
potent HDACi to melanoma cell lines showed some promise, though the anticipated enhanced 




potency is not readily obvious, the benzamide template should be further explored to develop 
and/or deliver more potent HDACi to melanoma cells. 
 
3.8. Materials and methods 
All commercially available starting materials were used without further purification. 
Indomethacin was purchased from TCI America (OR, USA). Reaction solvents were either high 
performance liquid chromatography (HPLC) grade or American Chemical Society (ACS) grade 
and used without further purification. Analtech silica gel plates (60 F254) were used for analytical 
TLC, and Analtech preparative TLC plates (UV 254, 2000 µm) were used for purification.  UV 
light was used to examine the spots. 200-400 mesh silica gel was used in column chromatography. 
For NMR spectra, Varian-Gemini 400 MHz or Bruker 500 MHz magnetic resonance spectrometer 
was used.  1H NMR spectra were recorded in parts per million (ppm) relative to the peak of CDCl3, 
(7.26 ppm), CD3OD (3.31 ppm), or DMSO-d6 (2.49 ppm). 
13C spectra were recorded relative to 
the central peak of the CDCl3 triplet (77.0 ppm), CD3OD (49.0 ppm), or the DMSO-d6 septet (39.7 
ppm) and were recorded with complete heterodecoupling. Multiplicities are described using the 
abbreviations: s, singlet; d, doublet, t, triplet; q, quartet; m, multiplet. High-resolution mass spectra 
were recorded at the Georgia Institute of Technology mass spectrometry facility in Atlanta. HPLC 
was used to establish the purity of the compounds to be >95%. The HPLC analyses were done on 
a Beckman Coulter instrument with a Phenomenex RP C-18 column (250 mm × 4.6 mm), using 
0.1% TFA in water (solvent A) and 0.1% TFA in acetonitrile (solvent B), starting with 70% B for 




detection was at 280 nm. Compounds 3, 4, 12, 13 and all O-trityl protected azido linkers were 
made according to literature protocols.5c, 15 
B16F10, A375, and LNCaP cell lines were purchased from ATCC (Manassas, VA). Cell 
cultures were maintained in an incubator at 37 0C under a 5% CO2 atmosphere. Mouse 
antiacetylated α- tubulin antibody was obtained from Invitrogen (Life Technologies, Grand Island, 
NY, USA), rabbit antiactin, and rabbit antitubulin α antibodies were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Secondary antibodies, goat antirabbit conjugated to IRDye680, 
and goat antimouse conjugated to IRDye800 were purchased from LI-COR Biosciences (Lincoln, 
NE, USA). The CellTiter 96 Aqueous One Solution Cell Proliferation assay (MTS) kit was 
purchased from Promega (Madison, WI, USA). 
 
Methyl 4-iodobenzoate (3): 4-Iodo benzoic acid (0.500 g, 2.016 mmol) in MeOH (15 mL) and 
TMSCl (0.510 mL, 4.032 mmol) was added. The reaction mixture was left to stir at room 
temperature overnight. Water (50 mL) was added to quench the reaction and extracted three times 
with DCM (50 mL). Organic layer was combined, dried over Na2SO4 and concentrated in vacuo 
to give compound 3 as a white solid (0.508g, 95%). The compound was used for the next step 
without characterization. 
Methyl 5-bromopicolinate (4): 5-Bromo picolinic acid (0.200 g, 0.990 mmol) in MeOH (5 mL) 
and TMSCl (0.500 mL, 3.960 mmol) was added. The reaction mixture was left to stir at room 
temperature overnight. Water (20 mL) was added to quench the reaction and extracted three times 




to give compound 3 as a white solid (0.205g, 94%) 1H NMR (400 MHz, cdcl3) δ 8.81 (s, 1H), 8.03 
– 7.97 (m, 2H), 3.96 (s, 3H). 
Methyl 4-((trimethylsilyl) ethynyl) benzoate (5): A suspension of p-iodo methylbenzoate 
(0.300g, 1.141 mmol), TMS-acetylene (0.240ml, 1.711mmol), Pd(PPh3)2Cl2 (0.024g, 0.034 mmol) 
and CuI (0.013g, 0.068 mmol) in a 2:1 mixture of deoxygenated Et3N (4 ml) and THF (2 ml) in a 
reaction tube was heated while stirring at 80 0C overnight. The reaction was filtered through celite 
and solid residue was washed three times with ether. Filtrate was concentrated and the crude 
residue purified by column using Hexanes: EtOAc (20:1) to give compound (5) as a brown solid 
(0.263g, 99 %). 1H NMR (400 MHz, cdcl3) δ 7.99 (d, 2H), 7.52 (d, 2H), 7.33 – 7.28 (m, 1H), 3.89 
(s, 3H), 0.28 – 0.20 (s, 9H). 13C NMR (101 MHz, cdcl3) δ 166.39, 131.76, 129.65, 129.26, 127.73, 
104.01, 97.53, 52.15, -0.26.  
Methyl 5-((trimethylsilyl) ethynyl) picolinate (6): A suspension of methyl 5-bromopicolinate 
(4) (2.650 g, 13.100 mmol), TMS-acetylene (3.700 ml, 26.200 mmol), Pd(PPh3)2Cl2 (0.460 g, 
0.660 mmol) and CuI (0.250 g, 1.310 mmol) in a acetonitrile (25 ml) in a reaction tube was heated 
while stirring at 90 0C overnight. The reaction was filtered through celite and solid residue was 
washed three times with ether. Filtrate was concentrated and the crude residue purified by column 
using Hexane: EtOAc (5:2) to give compound (6) as a brown solid (2.600 g, 85 %). 1H NMR (400 
MHz, cdcl3) δ 8.73 (s, 1H), 8.03 – 7.97 (m, 1H), 7.82 (ddd, J = 8.1, 2.0, 0.9 Hz, 1H), 3.94 (s, 3H), 
0.27 (s, 9H). 13C NMR (101 MHz, cdcl3) δ 165.13, 152.28, 145.99, 139.74, 124.26, 123.74, 
101.79, 100.50, 52.91, -0.45. 
Potassium 4-ethynylbenzoate (7): KOH pellets (2.040 g, 36.300 mmol) were added to a solution 




temperature. Reaction mixture was filtered and solid product allowed to dry to give compound 7 
as a light brown solid (2.200 g, 100 %). 1H NMR (400 MHz, meod) δ 7.87 (d, 2H), 7.42 (d, 2H). 
N-(2-(diethylamino) ethyl)-4-ethynylbenzamide (8): Potassium 4-ethynylbenzoate (7) (0.200 g, 
1.628 mmol) and TSTU (0.360 g, 1.200 mmol) were dissolved in 10ml DCM and left to stir for 
five minutes. DIPEA (0.200 ml, 1.200 mmol) and DEED (0.17 ml, 1.200 mmol) were then added 
to the reactive and left to stir at room temperature overnight. Solvent was evaporated and the crude 
purified by column using EtOAc: Ether: TEA (2:1:0.1) to give compound 8 as a viscous brown oil 
(0.200 g, 50%). 1H NMR (400 MHz, cdcl3) δ 7.74 (d, 2H), 7.52 (d, 2H), 7.19 (s, 1H), 3.44 (dd, J 
= 11.7, 5.3 Hz, 2H), 3.17 (s, 1H), 2.65 – 2.57 (m, 2H), 2.57 – 2.48 (m, 4H), 1.04 – 0.96 (m, 6H). 
13C NMR (101 MHz, cdcl3) δ 166.42, 134.48, 131.91, 126.88, 125.10, 82.71, 79.33, 51.28, 46.62, 
37.24, 11.58. HRMS (ESI) [M + H]+ calculated for [C15H21ON2]
+ was 245.1648, found 245.1647. 
N-(2-(diethylamino) ethyl)-5-ethynylpicolinamide (9): DEED (3 ml, 21.800 mmol) was added 
to a solution of methyl 5-((trimethylsilyl) ethynyl) picolinate (6) (2.520 g, 10.900 mmol) in MeOH 
(25 ml) and heated at 120 0C overnight. Solvent was evaporated off and the crude product was 
purified by column using Hexanes: EtOAc: TEA (2:1:1) to give a brown solid (1.380 g, 56 %).  1H 
NMR (400 MHz, cdcl3) δ 8.59 (dd, J = 2.0, 0.8 Hz, 1H), 8.30 (s, 1H), 8.10 (dt, J = 8.1, 1.8 Hz, 
1H), 7.88 – 7.82 (m, 1H), 3.47 (dd, J = 12.0, 6.3 Hz, 2H), 3.31 (s, 1H), 2.64 – 2.57 (t, 2H), 2.53 
(q, J = 7.1 Hz, 4H), 1.03 – 0.94 (m, 6H). 13C NMR (101 MHz, cdcl3) δ 163.53, 150.98, 149.18, 
140.24, 121.38, 82.40, 79.84, 51.32, 46.85, 37.23, 11.81. HRMS (ESI) [M + H]+ calculated for 
[C14 H20 O N3]
+ was 246.1601, found 246.1602. 
N-(2-(diethylamino) ethyl)-4-(1-(7-(hydroxyamino)-7-oxoheptyl)-1H-1, 2, 3-triazol-4-yl) 




trityl-protected 7-azidoheptanehydroxamic acid (0.140 g, 0.315 mmol) and DIPEA (0.090 ml, 
0.573 mmol) were dissolved in anhydrous THF (10 ml) and purged for 10 minutes at room 
temperature while stirring. CuI (0.027 g, 0.143 mmol) was then added while purging continued for 
another 20 minutes, after which the reaction was left to stir overnight. Reaction was concentrated 
and the crude purified by prep TLC using 10:4:0.1 DCM: Ether: TEA to give N-(2-
(diethylamino)ethyl)-4-(1-(7-oxo-7-((trityloxy)amino)heptyl)-1H-1,2,3-triazol-4-yl)benzamide 
(0.130 g, 67 %), which was used immediately for the next reaction (trityl deprotection) without 
characterization. 
Removal of trityl group was done by dissolving N-(2-(diethylamino)ethyl)-4-(1-(7-oxo-7-
((trityloxy)amino)heptyl)-1H-1,2,3-triazol-4-yl)benzamide (0.130 g, 0.193 mmol) in anhydrous 
DCM (10 ml) after which 1.0 ml TFA and 0.5 ml TIPS were added and the reaction was left to stir 
for 2 hours. Solvent and excess TFA were evaporated off, and 20 ml of anhydrous ether was added 
to the residue. Due to lack of success with ether precipitation, crude was purified using 10:1 
DCM:MeOH to give compound 10a as a white solid (0.010 g, 12 %). 1H NMR (500 MHz, MeOD) 
δ 8.46 (s, 1H), 7.95 (t, J = 6.5 Hz, 4H), 4.49 (t, J = 6.5 Hz, 2H), 3.59 (t, J = 6.4 Hz, 2H), 2.86 (d, J 
= 18.5 Hz, 2H), 2.81 (dd, J = 13.8, 6.8 Hz, 4H), 2.11 (t, J = 6.9 Hz, 2H), 2.00 (s, 2H), 1.65 (s, 2H), 
1.38 (d, J = 33.3 Hz, 4H), 1.17 (t, J = 7.0 Hz, 6H). 13C NMR (126 MHz, MeOD) δ 171.56, 168.50, 
146.37, 133.69, 133.47, 127.49, 125.18, 121.63, 51.22, 49.94, 36.59, 32.16, 29.56, 29.35, 28.00, 
25.69, 24.94, 9.75. HRMS (ESI) [M + H]+ calculated for [C22 H35 O3 N6]
+ was 431.2765, found 
431.2762. 
N-(2-(diethylamino) ethyl)-4-(1-(8-(hydroxyamino)-8-oxooctyl)-1H-1, 2, 3-triazol-4-yl) 




trityl-protected 8-azidooctanehydroxamic acid (0.400 g, 0.900 mmol) and DIPEA (0.28 ml, 1.636 
mmol) were dissolved in anhydrous THF (10 ml) and purged for 10 minutes at room temperature 
while stirring. CuI (0.080 g, 0.409 mmol) was then added while purging continued for another 20 
minutes, after which the reaction was left to stir overnight. Reaction was concentrated and the 
crude purified prep TLC using 10:4:0.1 DCM: Ether: TEA to give N-(2-(diethylamino)ethyl)-4-
(1-(8-oxo-8-((trityloxy)amino)octyl)-1H-1,2,3-triazol-4-yl)benzamide (0.170g, 31 %), which was 
used immediately for the next reaction (trityl deprotection) without characterization. 
Removal of trityl group was done by dissolving N-(2-(diethylamino)ethyl)-4-(1-(8-oxo-8-
((trityloxy)amino)octyl)-1H-1,2,3-triazol-4-yl)benzamide (0.170 g, 0.25 mmol) in anhydrous 
DCM (10 ml) after which 1.0 ml TFA and 0.5 ml TIPS were added and the reaction was left to stir 
for 2 hours. Solvent and excess TFA were evaporated off, and 20 ml of anhydrous ether was added 
to the residue. Precipitate obtained was filtered, and the residue washed sequentially with 20 ml 
anhydrous ether (twice), and 40 ml of 1:1 mixture of anhydrous ether and DCM. The resulting 
residue was left to dry to give compound 10b as a white solid (0.070 g, 64 %). 1H NMR (500 MHz, 
MeOD) δ 8.48 (s, 1H), 7.97 (d, J = 9.1 Hz, 4H), 4.49 (t, J = 7.1 Hz, 2H), 3.80 (t, J = 6.1 Hz, 2H), 
3.43 (t, J = 6.1 Hz, 2H), 3.40 – 3.34 (m, 4H), 2.10 (s, 2H), 2.02 – 1.94 (m, 2H), 1.66 – 1.57 (m, 
2H), 1.44 – 1.31 (m, 12H). 13C NMR (126 MHz, MeOD) δ 177.23, 169.39, 146.22, 134.20, 132.50, 
127.84, 125.24, 121.75, 51.60, 50.12, 35.06, 29.74, 28.45, 28.23, 25.87, 25.14, 7.76. HRMS (ESI) 
[M + H]+ calculated for [C23 H37 O3 N6]
+ was 445.2922, found 445.2918. 
N-(2-(diethylamino) ethyl)-5-(1-(6-(hydroxyamino)-6-oxohexyl)-1H-1, 2, 3-triazol-4-yl) 
picolinamide (11a): N-(2-(diethylamino) ethyl)-5-ethynylpicolinamide (9) (0.100 g, 0.408 mmol), 




0.815 mmol) were dissolved in anhydrous THF (10 ml) and purged for 10 minutes at room 
temperature while stirring. CuI (0.040 g, 0.204 mmol) was then added while purging continued for 
another 20 minutes, after which the reaction was left to stir overnight. Reaction was concentrated 
and the crude purified by prep TLC using 10:4:0.1 DCM: Ether: TEA to give N-(2-
(diethylamino)ethyl)-5-(1-(6-oxo-6-((trityloxy)amino)hexyl)-1H-1,2,3-triazol-4-yl)picolinamide 
(0.190 g, 71 %), which was used immediately for the next reaction (trityl deprotection) without 
characterization. 
Removal of trityl group was done by dissolving N-(2-(diethylamino)ethyl)-5-(1-(6-oxo-6-
((trityloxy)amino)hexyl)-1H-1,2,3-triazol-4-yl)picolinamide (0.110 g, 0.167 mmol)in anhydrous 
DCM (10 mL) after which 1.0 ml TFA and 0.5 ml TIPS were added and the reaction was left to 
stir for 2 hours. Solvent and excess TFA were evaporated off, and 20 ml of anhydrous ether was 
added to the residue. Due to lack of success with ether precipitation, crude was purified using 10:1 
DCM: MeOH to give compound 11a as a white solid (0.010 g, 14 %). 1H NMR (500 MHz, MeOD) 
δ 9.16 (s, 1H), 8.63 (s, 1H), 8.43 (d, 1H), 8.20 (d, 1H), 4.53 (t, J = 7.0 Hz, 2H), 3.83 (t, J = 6.2 Hz, 
2H), 3.51 (q, J = 7.3 Hz, 2H), 3.42 – 3.37 (m, 2H), 3.31 (t, J = 7.3 Hz, 4H), 2.14 (t, J = 7.3 Hz, 
2H), 2.06 – 1.98 (m, 2H), 1.72 (dt, J = 15.1, 7.4 Hz, 2H), 1.39 (dt, J = 7.2, 3.4 Hz, 6H). 13C NMR 
(126 MHz, MeOD) δ 171.22, 166.25, 148.30, 145.48, 143.54, 133.72, 129.67, 122.42, 122.17, 
52.20, 51.19, 49.99, 34.59, 32.03, 29.44, 25.47, 24.58, 7.95. HRMS (ESI) [M + H]+ calculated for 
[C20 H32 O3 N7]







N-(2-(diethylamino) ethyl)-5-(1-(7-(hydroxyamino)-7-oxoheptyl)-1H-1, 2, 3-triazol-4-yl) 
picolinamide (11b) 
N-(2-(diethylamino) ethyl)-5-ethynylpicolinamide (9) (0.100 g, 0.408 mmol), trityl-protected 7-
azidoheptanehydroxamic acid (0.190 g, 0.448 mmol) and DIPEA (0.150 mL, 0.815 mmol) were 
dissolved in anhydrous THF (10 mL) and purged for 10 minutes at room temperature while stirring. 
CuI (0.040 g, 0.204 mmol) was then added while purging continued for another 20 minutes, after 
which the reaction was left to stir overnight. Reaction was concentrated and the crude purified by 
prep TLC using 10:4:0.1 DCM: Ether: TEA to give N-(2-(diethylamino)ethyl)-5-(1-(7-oxo-7-
((trityloxy)amino)heptyl)-1H-1,2,3-triazol-4-yl)picolinamide (0.194 g, 71 %), which was used 
immediately for the next reaction (trityl deprotection) without characterization. 
Removal of trityl group was done by dissolving N-(2-(diethylamino)ethyl)-5-(1-(7-oxo-7-
((trityloxy)amino)heptyl)-1H-1,2,3-triazol-4-yl)picolinamide (0.194g, 0.288 mmol) in anhydrous 
DCM (10 mL) after which 1.0 mL TFA and 0.5 mL TIPS were added and the reaction was left to 
stir for 2 hours. Solvent and excess TFA were evaporated off, and 20 mL of anhydrous ether was 
added to the residue. Due to lack of success with ether precipitation, crude was purified using 10:1 
DCM: MeOH to give compound 11b as a white solid (0.015g, 12 %). 1H NMR (500 MHz, MeOD) 
δ 9.13 (d, J = 1.5 Hz, 1H), 8.59 (s, 1H), 8.38 (dd, J = 8.1, 2.0 Hz, 1H), 8.17 (d, J = 8.1 Hz, 1H), 
4.51 (t, J = 7.1 Hz, 2H), 3.57 (t, J = 6.9 Hz, 2H), 2.75 (t, J = 6.9 Hz, 2H), 2.67 (q, J = 7.2 Hz, 4H), 
2.09 (t, J = 7.4 Hz, 2H), 2.03 – 1.96 (m, 2H), 1.68 – 1.57 (m, 2H), 1.44 – 1.35 (m, 4H), 1.12 (t, J 
= 7.2 Hz, 6H). 13C NMR (126 MHz, MeOD) δ 178.94, 164.99, 148.88, 145.41, 143.64, 133.63, 
129.29, 122.25, 121.84, 51.17, 50.13, 36.58, 32.38, 29.67, 29.39, 28.07, 25.72, 25.33, 22.83, 10.38. 
HRMS (ESI) [M + H]+ calculated for [C21 H34 O3 N7]




N-(2-(diethylamino) ethyl)-4-(((6-(4-(6-methoxynaphthalen-2-yl)-1H-1, 2, 3-triazol-1-yl) 
hexanamido) oxy) carbonyl) benzamide (15): Compound (14) (0.050 g, 0.166 mmol) and TSTU 
(0.050 g, 0.166 mmol) were dissolved and left to stir at room temperature for 30 min. Afterwards 
compound 7u (0.058 g, 0.166 mmol) dissolved in 1ml DMF containing DIPEA (0.03 ml, 0.166 
mmol) was added to the reaction and left to stir overnight. Solvent was evaporated off and the 
crude purified by prep. TLC using 10:1 DCM: MeOH as an off white waxy solid (0.040 g, 40 %). 
1H NMR (500 MHz, DMSO) δ 8.80 (s, 1H), 8.67 – 8.61 (m, 1H), 8.32 (s, 1H), 8.11 – 8.02 (m, 
2H), 8.02 – 7.96 (m, 2H), 7.92 (dt, J = 13.4, 4.7 Hz, 1H), 7.87 (d, J = 9.2 Hz, 1H), 7.34 (d, J = 2.5 
Hz, 1H), 7.21 – 7.15 (m, 1H), 4.44 (dd, J = 14.7, 7.7 Hz, 2H), 3.89 (d, J = 4.3 Hz, 3H), 3.00 (d, J 
= 6.9 Hz, 2H), 2.75 (d, J = 6.4 Hz, 6H), 2.24 (t, J = 7.2 Hz, 1H), 1.65 (dt, J = 14.8, 7.3 Hz, 2H), 
1.37 (dt, J = 21.7, 10.8 Hz, 2H), 1.19 – 1.14 (m, 2H), 1.04 (dt, J = 20.3, 6.5 Hz, 6H). 13C NMR 
(126 MHz, DMSO) δ 186.16, 173.19, 170.41, 165.63, 157.82, 146.92, 134.33, 129.96, 129.56, 
128.99, 128.33, 128.05, 127.74, 126.61, 124.60, 123.82, 121.64, 119.63, 106.50, 70.30, 55.61, 
49.70, 47.41, 46.06, 32.19, 29.58, 25.70, 24.43, 11.30. HRMS (ESI) [M + H]+ calculated for [C33 
H41 O5 N6]
+ was 601.3133, found 601.3118. 
 
3.8.1. Cell viability assay  
 All cell lines used in this study (B16F10, A375 LNCaP and Vero) were maintained in the 
respective media recommended by ATCC. All the culture media used were supplemented with 10 
% fetal bovine serum (FBS) (Atlanta Biologicals, Atlanta, GA) and 1 % Pen. Strep. Prior to 
treatment with various drug concentrations and subsequent incubation for 72 hours, cells were 




as described by the manufacturer. For all drugs tested, DMSO concentration was maintained at 0.1 
% for experiments in LNCaP and at 1 % for experiments in other cell lines. Data was analyzed 
using GRAPHPAD prism software. 
 
3.8.2. Western blots analysis  
 B16F10 cells (106 cells/dish) were seeded in petri dishes 24 hour prior to treatment with 
various concentrations of compounds for 24h. Thereafter, media was removed and cells were 
washed with chilled 1X PBS buffer and resuspended in CelLyticM buffer containing a cocktail of 
protease inhibitor (Sigma-Aldrich, St. Louis, MO, USA). Protein concentration was determined 
through Bradford protein assay.  Equal amount of protein was then loaded onto an SDS-page gel 
(Bio-Rad, Hercules, CA, USA) and resolved by electrophoresis at a constant voltage of 100 V for 
2 h. The gel was transfered onto a nitrocellulose membrane and probed for acetylated tubulin, 
acetyl H4, and actin as loading control. 
 
3.8.3. HDAC inhibition  
HDAC inhibition study was done under contractual agreement by BPS Bioscience. 
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BIFUNCTIONAL CONJUGATES WITH POTENT INHIBITORY 




Aberrant epigenetic regulation and inflammation play significant roles in tumor 
development and progression. Posttranslational acetylation and deacetylation of histones, both 
epigenetic events regulated by histone acetyl transferases (HAT) and histone deacetylases 
(HDAC), respectively, control the expression and/or silencing of tumor suppressor genes.1 While 
these two epigenetic regulators exist in equilibrium in non-transformed cells, HDAC activity 
predominates in most malignant tumors, effectively leading to silencing of tumor suppressor genes 
and uncontrolled proliferation of cancer cells.2 Eighteen isoforms of HDAC are known, eleven of 
which depend on zinc for their catalytic activities and are group into: class I (HDACs 1-3 and 8); 
class II (subdivided into class II A (HDACs 4, 5, 7 and 9) and class IIB (HDACs 6 and 10)); and 
class IV (HDAC 11).3 Class III HDACs, also known as sirtuins, are non-zinc dependent and require 
NAD+ for their catalytic activity.3b The expression profiles of HDAC isoforms in different tumors 
vary with each isoform playing unique roles in driving tumorigenesis.4 The therapeutic potential 
of HDAC inhibition has been validated by the US food and drugs administration’s (FDA) approval 
of HDAC inhibitors (HDACi), vorinostat, romidepsin, belinostat and panabinostat (Figure 4.1) for 




Cardiotoxicity, short half-life, and inactivity towards solid tumors are few of many challenges 
faced by HDACi in the clinic.3a, 6 
Among the several drivers of inflammation in tumors, the inducible isoform of 
cyclooxygenases (COX), COX-2, plays a crucial role by ensuring a continuous supply of 
prostaglandin E2 (PGE2) to the tumors.
7 The other COX isoform, COX-1, is constitutively 
expressed in the body where it performs housekeeping functions.8 In contrast to COX-1, COX-2 
expression is short-lived9 and is upregulated in most tumors to meet up with the requirement for 
PGE2 in the rapidly proliferating cells.
7b Both COX isoforms facilitate the conversion of 
arachidonic acid to prostaglandin H2, which is in turn transformed to prostaglandins, by specific 
synthases, as required by the cells.7b, 10 Several COX inhibitors (Figure 4.2), also known as non-
steroidal anti-inflammatory drugs (NSAIDs), have been approved by the FDA for managing 
inflammation associated with pains and fever.  
Due to high expression of COX-2 in most tumors, it has been suggested that NSAIDs could 
someday find applications in the prevention and/or cure of some cancers, especially colon and 
prostate cancer.11 Several mechanisms of cytotoxicity of NSAIDs towards cancer cells have been 
reported; most are believed to be independent of COX-2 inhibition. In androgen dependent prostate 
cancer cell line (LNCaP), celecoxib exerts its cytotoxic effect via induction of c-jun12 and EP2 
signaling leading to suppression of androgen receptor (AR)13. Induction of apoptosis14, Wnt/beta-
catenin pathway suppression,15 cell cycle arrest16 and inhibition of angiogenesis17 are some of the 
other mechanisms through which NSAIDs exert their anticancer activity. In addition to being a 
possible therapeutic target, COX-2 upregulation in tumors has been exploited for tumor imaging 




Recently, there has been enormous interest in the development of dual-acting compounds 
comprising of an HDACi and another cytotoxic component.19 In such compounds, one of the 
components is usually the surface recognition group (cap) of the HDACi (see pharmacophoric 
model in Figure 4.1). While dual-acting compounds comprising NSAIDs and other agents exist,20 
none contain HDACi and NSAIDs combined as a single component. Moreover, results from in 
vitro studies suggest that enhanced cytotoxic effect could be achieved by combining NSAIDs and 
HDACi in cancer cell lines.21 In this study, we designed and synthesized bifunctional compounds 
with HDAC and COX-2 inhibitory activities. These compounds are capable of harnessing the 
cytotoxic effects of HDAC inhibition, COX-2 inhibition, and perturbation of other non-COX 
dependent pathways. Our design has indomethacin or celecoxib as the cap, methylenes as linkers, 
and hydroxamate as the zinc binding group (ZBG) (Figure 4.4 b-e). These compounds potently 
inhibited the HDAC isoforms tested and retained COX-2 inhibitory activity comparable to both 
celecoxib and indomethacin.  The potent HDAC and COX-2 inhibitory activities of these 
conjugates are reflected in their growth inhibitory activities in MCF-7 (breast cancer), A549 (non-
small cell lung cancer), HCT-116 (colon cancer), DU-145 (androgen independent prostate cancer) 
and LNCaP (androgen dependent prostate cancer) cell lines. They are also less toxic towards 





Figure 4.1: HDACi in use in the clinic  
 










4.2. Results and discussion 
 
Figure 4.3: Crystal structures showing (a) binding of celecoxib within COX-2 (PDB code 3LN1) 
showing SO2NH2 modification site, and (b) binding of celecoxib within COX-2 (PDB code 3LN1) 
showing CF3 modification site, (c) bindining of  indomethacin within COX-2 (PDB code 4COX) 
showing carboxylate modification site.   
 
4.2.1. Design rationale  
The residues presented at the outer rim of HDAC enzymes form rugged landscapes 
designed to flexibly accommodate a diverse class of substrates. This may explain the tolerance of 




structurally dissimilar HDACi.  Taking this into consideration, we hypothesized that incorporation 
of celecoxib (a COX-2 selective inhibitor) and indomethacin (a non-selective inhibitor of COX 
isoforms) into the surface recognition cap group of an HDACi may result in dual-acting agents 
that inhibit both HDAC and COX-2. Such agents are likely to show enhanced tumor cell 






Figure 4.4: (a) HDACi pharmacophoric model integrated in vorinostat structure. (b) Designed 
dual-acting COXi-HDACi compounds – (i) Celecoxib-based HDACi (series 1), (ii and iii) 




To determine which site to modify on celecoxib, we analyzed the orientation of celecoxib 
in the COX-2 active site. We found that the sulfonamide (SO2NH2) and trifluoromethyl (CF3) 
moieties of celecoxib are projected towards different solvent exposed regions of the enzyme 
(Figure 4.3 a-b). Based on this analysis, the sulfonamide and trifluoromethyl moieties could be 
suitable points for the attachment of HDAC-inhibiting pharmacophores. Modifications at these 
two ends should minimally perturb the binding of celecoxib-based conjugates to the COX-2 active 
site, as shown in previous studies.20b, 22 Because of the relaxed specificity for hydrophobic groups 
at the HDAC outer rims, the celecoxib aromatic moiety of the resulting dual-acting agents is 
expected to be accommodated as a surface recognition group when bound to HDAC enzymes. To 
test this deduction, we designed and synthesized celecoxib-HDACi conjugates in which: i) HDACi 
template is attached to the sulfonamide (Series 1, Figure 4.4) ii), the “CF3” is replaced by HDACi 
template (Series 2, Figure 4.4) and iii) the sulfonamide is replaced with a methyl sulfone (SO2Me) 
and “CF3” is replaced by HDACi template (Series 3, Figure 4.4). 
  Similarly for indomethacin, the carboxylic acid moiety is projected towards the solvent 
exposed region (Figure 4.3c) of COX-2. Modification of this moiety is known to convert 
indomethacin from a non-selective COX inhibitor to a COX-2 selective inhibitor.23 This prompted 
us to design and synthesize indomethacin-HDACi conjugates in which the HDACi template is 
attached to the carboxylic acid end (Series 4, Figure 4.4). Further modifications of indomethacin 
yielded conjugates in which the chlorobenzoyl is replaced by HDACi template, and carboxylic 




In all the NSAID-HDACi conjugates, linker lengths were restricted to five, six and seven 
methylenes separating the ZBG from the cap groups, in accordance with a previous study in our 
lab showing these lengths to be optimal for HDAC inhibition.24  
Scheme 4.1: Synthesis of series 1 celecoxib-HDACi conjugates  
 
 
4.2.2. Chemistry  
The sulfonyl chloride 1, a vital intermediate required in the synthesis of sulfonamide-
modified celecoxib-HDACi conjugates, was made according to a previously reported protocol25. 
The desired conjugates 2a-c were thereafter made by displacement of chloride from compound 1 
with trityl-protected primary amine having methylene linkers of appropriate lengths, followed by 




To access the series 2 conjugates, the 1-(4-sulfamoylphenyl)-5-(p-tolyl)-1H-pyrazole-3-
carboxylic acid intermediate 5 was made by hydrolysis of ethyl 1-(4-sulfamoylphenyl)-5-(p-tolyl)-
1H-pyrazole-3-carboxylate 4, whose synthesis had been previously reported,26 using lithium 
hydroxide (Scheme 4.2). Subsequent coupling of compound 5 to trityl-protected primary amine 
having methylene linkers of appropriate lengths followed by trityl deprotection furnished the 
desired celecoxib-HDACi conjugates 7a-c in decent yields. Likewise, the methyl sulfone analog 
8 (Series 3) was made from 6 using the same chemistry.  
Scheme 4.2: Synthesis of series 2 and 3 celecoxib-HDACi conjugates 
 
The first series of indomethacin-based COXi-HDACi conjugates (Series 4) were made 
from the NHS-activated indomethacin intermediate 10, which was obtained by reacting 
indomethacin with disuccinimidyl carbonate (Scheme 4.3). Displacement of NHS by trityl-
protected primary amine having methylene linkers of appropriate lengths and subsequent trityl 




Scheme 4.3: Synthesis of series 4 celecoxib-HDACi conjugates 
 
The esterified indole 12 required to synthesize the second series of indomethacin-HDACi 
conjugates was obtained by hydrolysis of indomethacin using NaOH followed by esterification 
using TMSCl in MeOH. Reaction of 12 with 4-ethynylbenzyl mesylate 13 in the presence of 
sodium hydride, gave the N-alkylated alkyne intermediate 14 (Scheme 4.4). Via Cu (I)-catalyzed 
azide-alkyne cyclo-addition reaction between alkyne 14 and trityl-protected azide having 
methylene linkers of appropriate lengths 15a-c, trityl-protected precursors to the final compounds 
16 and 17a-c were made. Ester hydrolysis with lithium hydroxide followed by trityl deprotection 
using TFA furnished the NSAID-HDACi conjugate 16 while methyl ester compounds 17a-c were 







Scheme 4.4: Synthesis of series 5 celecoxib-HDACi conjugates 
 
 
4.2.3. HDAC isoforms inhibition screening  
We screened all of the synthesized dual-acting COXi-HDACi compounds against all class 




inhibited all the HDAC isoforms screened. A closer look at the enzyme inhibitory activities reveals 
a linker length dependency which generally favors longer methylene linkers with few key 
exceptions (Table 4.1). Across all the five HDAC isoforms tested, these conjugates showed the 
strongest inhibitory effect towards HDAC 6, with IC50 as low as 5 nM for 17c. Among the 
celecoxib-based series (series 1-2), compounds 7a-c (series 2) showed more potency towards 
HDACs 1-3 compared to those of series 1 with the same linker lengths. This may be due to more 
favorable interaction of the 3’-amide and the free sulfonamide group, at the surface recognition 
group of conjugates, with potential H-bond donor/acceptor residues at the outer rim of the enzyme. 
In addition to the strong inhibitory effects towards HDAC 6 seen within the series 1 conjugates 
(compounds 2a-c), 2b also strongly inhibited HDACs 3 and 8, while 2c showed preference for 
HDAC 3 compared to 2a which has a strong inhibitory effect against HDAC 8.  The only member 
of series 3 conjugates, compound 8, is slightly more potent than compound 7b, the corresponding 
conjugate in series 2 with the same linker length. 
  In the indomethacin-based series, conjugates with triazolyl connecting the linker to the 
head group, compounds 17a-c (series 5), show greater inhibition of HDACs 1-3 and HDAC 6, 
compared to the amide-linked conjugates compounds 11a-c (series 4). Compounds 11a-c are 
equipotent towards HDAC 6, while they show varying activities towards other HDAC isoforms. 
We observed compounds 11a and 11c to be modestly active towards HDAC 1 (1810 nM and 1760 
nM respectively), with almost no activity towards HDAC 2. An important observation, considering 
the level of similarity in the sequence composition at the active site of the two HDAC isoforms. 
We probed this observation by molecular docking (see Appendix I, Figures 3 and 4), but did not 
see any obvious differences in the manner of interaction of the two compounds with HDAC 1 and 




similar activity in all the HDAC isoforms screened, suggesting that modifying the carboxylic acid 
group in the series 5 conjugates does not result in loss of enzyme inhibitory activity. The remaining 
members of this series, 17a and 17c, have vastly varied anti-HDAC activities. Compound 17a is 
moderately active against HDACs 3 and 8 with little activity against HDACs 1, 2 and 6.  
Conversely, 17c is broadly active against all HDAC isoforms tested and it is the most potent 
HDAC 6 inhibitor among the dual-acting COXi-HDACi compounds herein disclosed.    
 
Table 4.1: HDAC isoforms inhibition screening (IC50 in nM)
a of NSAIDs-HDACi conjugates  
 
Compound n HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 
2a 4 1870 ± 280 2060 ± 400 1020 ± 160 76 ± 26 226 ± 90 
2b 5 1030 ± 70 4050 ± 130 424 ± 53 66 ± 6 412 ± 43 
2c 6 968 ± 160 929 ± 164 256 ± 35 61 ± 11 989 ± 142 
7a 5 400 ± 60 232 ± 40 191 ± 44 92 ± 9 544 ± 76 
7b 6 208 ± 52 294 ± 46 333 ± 79 83 ± 8 520 ± 110 
7c 7 60 ± 7 32 ± 3 32.6 ± 7.5 183 ± 12 697 ± 55 
8 6 261 ± 35 163 ± 8 338 ± 130 50 ± 16 345 ± 43 




11b 5 980 ± 75 854 ± 280 356 ± 48 49 ± 9 109 ± 41 
11c 6 1760 ± 190 43 ± 3% 283 ± 54 50 ± 14 707 ± 86 
16 5 111 ± 15 302 ± 40 59 ± 10 22 ± 5 116 ± 32 
17a 4 778 ± 105 1360 ± 530 224 ± 60 6830 ± 430 672 ± 77 
17b 5 89 ± 13 407 ± 97 35 ± 6 10 ± 1 135 ± 35 
17c 6 251 ± 80 209 ± 18 181 ± 71 5 ± 3 394 ± 172 
% values refer to % inhibition at 10 μM. a average of three independent experiments. 
 
4.2.4. Molecular docking analysis 
To gain an insight into the specific interactions that may exist between our compounds and 
HDACs, which may explain the pattern of the observed HDAC inhibition, we docked all the 
compounds against HDAC 6. In all the series, we observed zinc chelation, typical of all 
hydroxamate-based HDACi, while the COX-binding moieties sit at surface of the enzyme 
(Appendix I, Figure 1).  
In all the celecoxib-based conjugates (series 1-3), the “para tolyl” group makes a 
stabilizing pi-stacking interaction with PHE 680 residue at the surface of the enzyme. We observed 
that compound 2a, analog with the shortest linker among the series 1 compounds, had the phenyl 
at the headgroup and the linker pushed further down the active site to maximize chelation with Zn 
at the bottom of the active site (Appendix I, Figure 1(i)). This slightly offset the pi-stacking 
interaction with PHE 680 at the surface of the enzyme, and may explain the slightly weaker activity 
against HDAC 6 compared to 2b and 2c. Compound 7b had a slightly different orientation at the 




still maintained pi-stacking interaction with PHE 680 and Zn chelation shown by compounds 7a, 
7c and 8 (Appendix I, Figure 1(iii)).  
Among the indomethacin-based compounds, the series 4 conjugates (11a-c) adopt a similar 
binding pose within the HDAC 6 active site, except for 11c (Appendix I, Figure 1(v)). Despite 
this, compounds 11a-c have similar inhibitory effects on HDAC 6 (Table 4.1). All the series 5 
conjugates, on the other hand, elicit a completely different interaction at the surface of the enzyme 
((Appendix I, Figure 1(vii)). 







   
                                                                           





Figure 4.5: Docking output of NSAID-HDACi conjugates overlaid with crystal structure of 
celecoxib and indomethacin in COX-2: i) series 1 conjugates: 2a (blue), 2b (magenta), 2c (yellow) 
and celecoxib (red); ii) series 2 and 3 conjugates: 7a (blue), 7b (magenta), 7c (yellow), 8 (green); 
iii) series 4 conjugates: 11a (blue), 11b (magenta), 11c (yellow), and indomethacin (red); iv) 
surface representation of series 4 conjugates: 11a (blue), 11b (magenta), 11c (yellow), and 
indomethacin (red); v) series 5 conjugates: 17a (blue), 17b (magenta), 17c (yellow), and 
indomethacin (red); vi) surface representation of series 5 conjugates: 17a (blue), 17b (magenta), 
17c (yellow), and indomethacin (red).  
 
We also docked the conjugates against COX-2 to confirm that the structural modifications 
made on celecoxib and indomethacin do not appreciably compromise their interactions with COX-
2. The selectivity of celecoxib towards COX-2 is attributed to its sulfonamide group forming four 
polar contacts (two H-bonding and two salt bridges) with His75, Arg499, Leu338 and Ser339 of 




site.27 Docking output of celecoxib-based series (series 1-3) show that the conjugates overlay 
perfectly with celecoxib in the COX-2 active site with the HDACi moiety projected towards the 
solvent exposed region. Among the series 1 conjugates, the “para tolyl” group is twisted 
perpendicularly to the plane of the “para tolyl” group of celecoxib (Figure 4.5 (i)), perhaps, to 
compensate for the modification at the sulfonamide end. The series 2 conjugates on the other hand, 
align perfectly with celecoxib in the COX-2 active site, with the appended HDACi template 
projecting towards the solvent exposed region (Figure 4.5 (ii)). All the conjugates bind COX-2 
similarly, irrespective of the length of the appended HDACi template. 
A similar observation was seen with the indomethacin-based series 4 conjugates, wherein 
all the conjugates align with indomethacin, except for compound 11c, with the HDACi appendage 
projected towards a pocket at the surface of the enzyme (Figures 4.5 (iii) and (iv)). We believe the 
misalignment of compound 11c, relative to indomethacin and other conjugates, is due to the length 
of the HDACi appendage. In order for the HDACi appendage to fit the pocket at the enzyme’s 
surface, there has to be a distortion in the binding mode within the active site leading to the 
misalignment (Figure 4.5 (iii)). The series 5 conjugates present a different binding mode, with the 
methyl ester group projected towards the hydrophobic region occupied by the chlorobenzoyl group 
of indomethacin. Consistent with previous observation in other series, all series 5 conjugates bind 







Table 4.2: COX isoforms inhibition study  




COX-1      
IC50 (µM) b 
COX-2  
IC50 (µM) b 
SI 
2a 16.25 97.69 ND ND - 
2b 61.43 100.00 3.57 ± 0.34 0.30 ± 0.03 >11 
2c 26.05 95.57 ND ND - 
7a NI 19.06 ND ND - 
7b 26.36 71.11 ND ND - 
7c NI 66.87 ND ND - 
8 NI 60.25 23.09 ± 0.70 4.44 ± 0.06 >5.20 
11a 40.22 95.13 ND ND - 
11b 22.81 98.13 21.00 ± 9.07 0.33 ± 0.06 >60 
11c 42.76 96.20 ND ND - 
16 NI 40.59 ND ND - 
17a NI 11.51 ND ND - 
17b NI 50.77 ND ND - 
17c 7.076 78.16 11.97 ± 1.10 4.58 ± 0.06 >2 
Celecoxib - - 7.7028 0.0728 >100 
Indomethacin - - 0.0529 0.2029 0.25 
a percent inhibition at 10µM; b average of three independent experiments; NI represents no 





4.2.5. COX inhibition study 
We performed a preliminary screening (at 10µM) of all the bifunctional compounds against 
COX-1 and COX-2 enzymes using Cayman fluorescent inhibitor screening assay kit. Based on the 
preliminary screen, representative members from each series were selected for IC50 determination 
in both COX isoforms (Table 4.2). In most cases, compounds within the same series showed 
similar percent inhibitory activities towards COX-1 and COX-2, validating our observation from 
docking which suggests that conjugates’ within the same series should have similar interactions 
with COX-2, independent of the length of the HDACi appendage. 
The celecoxib based conjugate 2b retained selectivity towards COX-2 akin to celecoxib, 
though with reduced potency. Compound 7c was surprisingly less potent compared to 2b in the 
preliminary screen, despite having a near perfect alignment with celecoxib in the COX-2 active 
site (Figure 4.4 (ii)) compared to the alignment of 2b (Figure 4.4 (i)). The only indomethacin-
based compound evaluated for IC50, 11b, shows comparable level of potency towards COX-2 as 
indomethacin. Interestingly, the COX-2 selectivity of 11b rivals that of celecoxib, an FDA-
approved COX-2-selective inhibitor. The COX-2-selectivity seen with compound 11b is 
consistent with observations in the literature on indomethacin modified at the carboxylic acid 
group.23 Despite the drastic structural modifications to celecoxib and indomethacin templates 
which furnished compounds 8 and 17c respectively, these compounds still showed decent activity 






Table 4.3: Cell growth inhibitory activity (IC50 in µM) of bifunctional COXi-HDACi conjugates 
in cancer and healthy cell lines.a 
Compound MCF-7 A549 HCT-116 LNCaP DU-145 Vero 




8.74 ± 0.23 8.88 ± 1.76 NT 6.83 ± 0.74 
2b 5.70 ± 
0.55 
8.00 ± 0.23 3.38 ± 0.09 2.19 ± 0.21 6.41 ± 0.51 5.53 ± 0.40 
2c 4.58 ± 
0.23 
8.15 ± 0.44 6.29 ± 0.15 2.11 ± 0.07 10.10 ± 
0.33 
6.61 ± 0.42 
7a >100 >100 NT NT NT >100 
7b >100 >100 24.97 ± 
1.95 
>20 NT >100 




7.12 ± 0.86 >20 NT 12.14 ± 
0.34 












>20 NT 40.67 ± 
2.67 






2.71 ± 0.52 7.26 ± 0.46 19.36 ± 
1.36 











16 47.84% NT 9.90 ± 1.95 NT NT NT 




9.31 ± 0.85 >20 NT 37.82 ± 
1.26 
17b 9.61 ± 
1.45 
8.22 ± 0.61 1.67 ± 0.09 1.35 ± 0.30 8.17 ± 0.05 5.82 ± 0.16 
17c 5.94 ± 
0.29 
4.43 ± 0.14 1.28 ± 0.13 1.53 ± 0.51 12.54 ± 
0.54 
5.73 ± 0.29 
SAHA 3.27 ± 
0.05 
5.00 ± 0.24 1.4 1.22 ± 0.06 3.45 ± 0.16 1.03 ± 0.09 
Celecoxib NT NT NT 32.6012 NT NT 
Indometha
cin 
5.20% NT NT >30012 NT NT 
% represents percent inhibition at 100µM, NT represents not tested, average of three independent 
experiments.a 
 
4.2.6. In vitro anticancer activity study 
Encouraged by the impressive HDAC and COX inhibitory activities of our conjugates, we 
tested their growth inhibitory activities in a panel of cancer cell lines: breast (MCF-7), lung (A549), 
colon (HCT-116), androgen-dependent (LNCaP) and -independent (DU-145) prostate cancer cell 
lines. Healthy monkey kidney epithelial cells (VERO) were used as a positive control. Our choice 
of cancer cell lines was based on the expression profiles of different HDAC isoforms and COX-2 




survival of the chosen cancer cell lines.2, 4 While COX-2 is ubiquitously expressed in the MCF-
718a and A54930 cell lines, its expression is barely discernible in the HCT-11622b cell line. Prostate 
cancer cell lines (LNCaP and DU-145) were chosen to evaluate the selectivity of our compounds 
towards androgen dependent prostate cancer. COX-2-specific NSAIDs perturb androgen receptor 
(AR)-mediated functions which are critical for the survival of LNCaP.12 Most of the conjugates 
show strong antiproliferative effects in all the cancer cell lines used in this study, and are less 
cytotoxic towards VERO compared to SAHA. More specifically, we observed the compounds to 
be considerably more potent towards androgen dependent prostate (LNCaP) and HCT-116 (with 
no COX-2 expression). 
Among the conjugates based on celecoxib (Series 1-3), compounds 2a-c show increasing 
activity with increase in methylene linker lengths in MCF-7 and A549 cell lines, consistent with 
the trend observed in their HDACs 1-3 and 6 inhibition activities. A different trend is observed for 
these series of compounds in HCT-116 and LNCaP cell lines, as compound 2b potently inhibit the 
proliferation of both cell lines while 2c is less potent against HCT-116 but equipotent as 2b against 
LNCaP (Table 4.3). Surprisingly, sulfonamide compounds 7a-c were barely cytotoxic across all 
cell lines (except for compound 7c), despite their impressive anti-HDAC activities. The inactivity 
of the sulfonamide-based compounds 7a-c may be due to lack of cell penetration to an appreciable 
extent. This deduction was supported by the fact that the methyl sulfone congener of inactive 
compound 7b, compound 8, showed anti-proliferative activity that is consistent with its HDAC 
inhibitory activity and with exquisite selectivity toward AR-positive LNCaP and HCT-116 cells.  
Most of the indomethacin-based conjugates potently inhibited the growth of all the cancer cell 




17c showed IC50 comparable to vorinostat in A549 cell line and it is more cytotoxic towards 
LNCaP and HCT-116 in similar manner to the other active celecoxib-based compounds.  
Considering their strong anti-HDAC and weak COX-2 inhibitory effect within the series 5 
conjugates, mechanism of cytotoxicity in HCT-116 could be attributed, predominantly, to HDAC 
inhibition. The series 4 conjugates 11b and 11c showed reduced anticancer effect in all cell lines, 
except LNCaP against which they are still potently active. Compound 11a, the other member of 
this series, is poorly active or inactive against all cell lines tested. The cytotoxic effects of 11b and 
11c towards LNCaP may be due to a combined effect of HDAC inhibition and inherent 
downregulation of AR associated with COX-2 selective NSAIDs.  
In healthy cells (VERO), these compounds are significantly less toxic when compared to 
vorinostat. Specifically, compound 8 is about ten-fold more selective towards prostate cancer cells 
(LNCaP) compared to VERO. Likewise, compounds 11b, 11c, 17b and 17c displayed varying 
level of selective cytotoxicity towards LNCaP compared to VERO.  
 
4.2.7. Comparison of antiproliferative activity of bifunctional compounds and combination 
therapy of NSAIDs and HDACi 
To investigate if there is an advantage in having bifunctional compounds compared to just 
a combination of the individual components (SAHA + Celecoxib; or SAHA + Indomethacin), we 
tested an equimolar concentration of the individual components, and compared their growth 
inhibitory activities to those of lead bifunctional compounds 2b and 11b in LNCaP, DU-145 and 





Figure 4.6: Antiproliferative activity of combination of equimolar concentration of respective 
NSAIDs and SAHA compared to equal concentration of appropriate bifunctional compounds in a) 
LNCaP; b) DU-145; and c) VERO cell lines. 
 
As shown in Figure 4.6a above, compound 2b, bifunctional compound derived from 
celecoxib template, is significantly more potent than a combination of celecoxib and SAHA in 
LNCaP, with no observable differences in DU-145 and VERO (Figures 4.6, b and c respectively). 
This confirms compound 2b as a more selective and potent compound to treat AR positive prostate 
cancer. Indomethacin derived compound 11b on the other hand, while equipotent to a combination 
of indomethacin and SAHA in both LNCaP and DU-147 (Figures 4.6 a and b respectively), is 




HDACi, 11b, has a superior therapeutic index when compared to a combination of equimolar 
concentrations of indomethacin and SAHA. 
Overall, compound 2b is more potent (Figure 4.6a) and selective towards LNCaP 
(Appendix I, Figure 3a) compared to compound 11b and a combination of SAHA and the 
respective NSAID, while compound 11b has the highest in vitro selective toxicity index.  
 
4.2.8. Intracellular target validation  
Using western blot, we probed for evidence of intracellular HDAC inhibition among our 
compounds in LNCaP. Inhibition of HDAC 6 is known to result in accumulation of acetylated 
tubulin in the cytosol.31 In this experiment, we chose compound 2b as a representative of all 
celecoxib-based conjugates (Series 1-3), while compounds 11b and 17b were selected as 
representatives of series 4 and 5 conjugates respectively. SAHA was used as the positive control. 
As expected, all the tested compounds showed accumulation of acetylated tubulin in a 
concentration dependent manner (Figure 4.6, panel 1). Compound 17b, a highly potent HDAC 6 
inhibitor (IC50 ≈ 10 nM), showed about the same level of acetyl tubulin at 1.5 μM (Figure 4.6, 
panel 1, lane 7) as SAHA at 10 μM (Figure 4.6, panel 1, lane 2). A similar trend was observed 
with histone H4 acetylation (a marker of class 1 HDAC inhibition) (see Appendix I, Figure 4). 
According to Yamaguchi et al,32 HDAC inhibition causes downregulation of PMA-
induced COX-2 expression in cancer cell lines. A similar observation was obtained when we 
treated LNCaP cells with SAHA at 10 μM (Figure 4.7, panel 3, lane 2). Our observation, following 




expression levels at the tested concentrations (Figure 4.7, panel 3, lanes 5-7). Compound 2b, on 
the other hand, showed COX-2 downregulation at low concentration (2 μM) and a slight 
upregulation a higher concentration (10 μM) (Figure 4.7, panel 3, lanes 3-4). The implication of 
this may be that the cytotoxic effect of these compounds in LNCaP may be less dependent on their 
effects on COX-2 expression. This is not without precedence, as other selective COX-2 inhibitors 
are known to induce apoptosis independent of COX-2 expression.14, 33 However, the sustained 
COX-2 expression level observed with our compounds, clearly distinguishes them from SAHA. 
This may prove to be advantageous in in vivo experiments with prostate cancer, as the COX-2 






Figure 4.7: Western blot analysis of acetylated tubulin, AR and COX-2 in LNCaP following 
treatment for 24hr. Lanes: 1, Control (DMSO); 2, SAHA (10 μM); 3, 2b (2 μM); 4, 2b (10 μM); 
5, 11b (2 μM); 6, 11b (10 μM); 7, 17b (1.5 μM); 8, celecoxib (10 μM); 9, indomethacin (10 μM). 
 
AR upregulation is critical to the survival of LNCaP34.  In our study with LNCaP, SAHA 
significantly suppressed AR expression at 10 μM (Figure 4.7, panel 2, lane 2), consistent with the 
literature.35 Compounds 2b showed a similar effect in a concentration dependent manner (Figure 
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4.7, panel 2, lanes 3-4). Quite unexpectedly, AR downregulation was much weaker for compound 
11b (Figure 4.7, panel 2, lanes 5-6), while compound 17b showed no noticeable effect at the single 
concentration tested (Figure 4.7, panel 2, lane 7). Both celecoxib and indomethacin showed no 
effects on AR regulation at 10 μM (Figure 4.7, panel 2, lanes 8 and 9). All together, these 
observations suggest that our compounds might be perturbing distinct pathways to elicit anti-
proliferative activities against LNCaP cells. Compound 2b acts more like a typical HDACi via 
induction protein acetylation and downregulation of AR. In contrast, 11b and 17b are atypical as 
they have no effect on AR expression. They most likely derived their potent anti-proliferative 
effect on LNCaP cells through a combination of COX-2-facilitated cell uptake, HDAC inhibition 
and perturbation of other pathways unique to prostate cancer.  
 
4.2.9. Effect of bifunctional compounds on PGE2 expression 
One of the consequences on intracellular COX inhibition is decreased production of 
prostaglandin E2 (PGE2).
36 To confirm that the strong COX-2 inhibitory effects of our compounds 
is maintained in cells, we treated HeLa cells with compounds 2b, 11b, celecoxib and indomethacin 
for 24 hours then measured the level of PGE2 produced in the cell culture supernatant. HeLa cell 
line was chosen for this study because it has been previously used for a similar study36 (see 
Appendix I, Table 1 for the IC50 of these compounds in HeLa cells). As shown in Figure 4.8, both 
compounds 2b and 11b significantly inhibited PGE2 production, confirming that these NSAID-





Figure 4.8: Intracellular COX-2 inhibition is evidenced by attenuation of prostaglandin E2 (PGE2) 
production. HeLa cells were treated with each of the tested compounds at 10X IC50 for 24hrs and 
PGE2 level was measured. *p<0.05. Statistical analysis was performed using Student’s t-test. Data 
are representative of three independent experiments.  
 
4.2.10. Effect of lead compound on cell cycle progression 
To determine if the potent cell proliferation inhibition activities of these compounds result 
from their perturbation of the cell cycle pattern, we evaluated the effect of compounds 2a, 8, 11b 
and 17b on LNCaP cell cycle progression using SAHA, celecoxib and indomethacin as controls. 
We observed that the effect of celecoxib and indomethacin (both at 40 μM) was not significantly 
different from the DMSO control. SAHA at 2.5 μM induced a G0/G1 phase arrest as reported 
previously in the literature35 (Figure 4.9). Compound 8, at 2.5 μM, displayed a similar G0/G1 phase 




weak inhibitory effect against COX- 2 (Table 4.2). Compared to 8, compounds 2a, 11b and 17b, 
have a distinct effect on cell cycle progression. At 2.5 μM, they induced a significant S phase 
arrest. This may be as a result of their combined HDAC and COX-2 inhibitory effects.  
 
 
Figure 4.9: Effect of SAHA, 2b, 8, 11b, 17b, celecoxib and indomethacin on LNCaP cell cycle 
progression.  




4.2.11. Bifunctional compounds suppress NTHi-induced NF-κB activation 
NF-κB activation drives inflammation and tumorigenesis in cancer. The two pathways 
involved in NF-κB activation (canonical and non-canonical pathways) are initiated by pro-
inflammatory cytokines such as TNFα and interleukins.37 We recently reported that HDACi 
downregulate inflammatory cytokines release and NF-κB activation.38 Likewise, there is evidence 
for non-COX inhibition dependent downregulation of NF-κB activation by NSAIDs.39 In view of 
these, we investigated the ability of our bifunctional compounds to suppress NF-κB activation in 
BEAS-2B cells treated with nontypeable Haemophilus influenzae (NTHi) using NF-κB luciferase 
assay. NTHi is a Gram-negative bacterium which causes infection in the human respiratory tract. 
NF-κΒ is potently activated upon NTHi infection in human epithelial cells, and induces pro-
inflammatory mediators such as IL-1β, IL-6 and TNF-α.  
We screened representative NSAID-HDACi conjugates with potent HDAC inhibition 
activities and observed that compounds 8 and 17b suppressed NTHi-induced NF-κB activation in 
BEAS-2B cells almost to the same extent as SAHA (Figure 4.10). In this assay, compound 2c, 
celecoxib and indomethacin also showed some level of suppression of NF-κB (Appendix I, Figure 
5). Considering the fact that compounds 8 and 17b have moderate COX and strong HDAC 
inhibitory activities, their ability to downregulate NF-κB activation is likely a consequence of their 
HDAC inhibitory capability. In summary, these results demonstrate that representative NSAID-





Figure 4.10: Representative NSAID-HDACi conjugates inhibit NF-κB activation. BEAS-2B cells, 
transfected with NF-κB luciferase construct, were pre-treated with compounds 8, 17b or SAHA at 
1 μM for 1hr and stimulated with NTHi for 5hr, and NF-kB promoter activity was then measured 
by performing luciferase assay. Data are mean ± SD (n=3). *p<0.05. Statistical analysis was 
performed using Student’s t-test. Data are representative of three independent experiments. CON 
= BEAS-2B cells treated with PBS control; NTHi = BEAS-2B cells treated with NTHi.  
 
4.3. Conclusion 
The clinical success of HDACi as a single agent in the treatment of solid tumors continues 
to remain elusive. Approaches currently exploited to make this achievable include: i) using a non-
hydroxamate ZBG40, ii) having a targeting group attached to the surface recognition group,19a iii) 
making dual acting conjugates comprising a cytotoxic component and HDACi template,19a and iv) 
using a prodrug approach.41 Herein, we described compounds that potently and selectively inhibit 
COX-2 while also maintaining strong anti-HDAC activity. In addition to exploiting the anticancer 




may show selective localization in tumors as seen with other conjugates comprising a COX-2-
selective inhibitor and a fluorophore.18a, 18c, 22b, 42 This approach has led to the discovery of 
compounds with strong growth inhibitory activities in various cancer cell lines with a strong 
preference for androgen-dependent prostate cancer cell line (LNCaP). While the selectivity 
towards LNCaP is not fully understood, we postulate that it could be a consequence of the effect 
of COX-2 and HDAC inhibition on AR functions. Previous studies on the effect of NSAIDs on 
AR in LNCaP suggest that COX-2 inhibition led to induction of the transcription factor c-jun, 
which in turn results in inhibition of AR activity.12 HDAC inhibition on the other hand, leads to 
decreased AR expression.35 
Compared to SAHA, our lead compounds (2b, 2c, 8, 11b, 17b and 17c) showed superior 
in vitro therapeutic index in all cancer cell lines relative to the positive control VERO. Compounds 
8 and 11b are particularly impressive in this regard, with about a ten-fold increase in selective 
cytotoxicity towards LNCaP relative to VERO. Lastly, we observed significant differences in the 
perturbation of cell cycle progression by compounds 2b, 11b and 17b, compared to SAHA, 
celecoxib and indomethacin that may be due to their combined effects on COX-2 and HDAC. 
 
4.4. Materials and methods  
All commercially available starting materials were used without further purification. 
Indomethacin was purchased from TCI America (OR, USA). Reaction solvents were either high 
performance liquid chromatography (HPLC) grade or American Chemical Society (ACS) grade 
and used without further purification. Analtech silica gel plates (60 F254) were used for analytical 




light was used to examine the spots. 200-400 mesh silica gel was used in column chromatography. 
For NMR spectra, Varian-Gemini 400 MHz or Bruker 500 MHz magnetic resonance spectrometer 
was used.  1H NMR spectra were recorded in parts per million (ppm) relative to the peak of CDCl3, 
(7.26 ppm), CD3OD (3.31 ppm), or DMSO-d6 (2.49 ppm). 
13C spectra were recorded relative to 
the central peak of the CDCl3 triplet (77.0 ppm), CD3OD (49.0 ppm), or the DMSO-d6 septet (39.7 
ppm) and were recorded with complete heterodecoupling. Multiplicities are described using the 
abbreviations: s, singlet; d, doublet, t, triplet; q, quartet; m, multiplet. High-resolution mass spectra 
were recorded at the Georgia Institute of Technology mass spectrometry facility in Atlanta. HPLC 
was used to establish the purity of the compounds to be >95 %. The HPLC analyses were done on 
a Beckman Coulter instrument with a Phenomenex RP C-18 column (250 mm × 4.6 mm), using 
0.1% TFA in water (solvent A) and 0.1 % TFA in acetonitrile (solvent B), starting with 70% B for 
5 min, then a gradient decrease of 70−10 % of B over 20 min. The flow rate was 1.0 ml/min and 
detection was at 280 nm. 4-Ethynyl-benzyl methylsulfonate 13, trityl-protected azide and amine 
linkers were made as previously described43. 
Du-145, LNCaP, Vero and A549 cell lines were purchased from ATCC (Manassas, VA), 
while MCF-7 and HCT-116 were generous a gifts from Dr. Al Merrill’s and Dr. Julia Kubanek’s 
laboratories respectively, at Georgia Institute of technology, Atlanta, GA. Cell cultures were 
maintained in an incubator at 37 0C under a 5 % CO2 atmosphere. Mouse antiacetylated α- tubulin 
antibody was obtained from Invitrogen (Life Technologies, Grand Island, NY, USA), rabbit 
antiactin, and rabbit antitubulin α antibodies were purchased from Sigma-Aldrich (St. Louis, MO, 
USA), AR antibody was purchased from Cell Signaling, while COX-2 antibody was purchased 
from Cayman chemicals. Secondary antibodies, goat antirabbit conjugated to IRDye680, and goat 




USA). The CellTiter 96 Aqueous One Solution Cell Proliferation assay (MTS) kit was purchased 
from Promega (Madison, WI, USA). 
 
4.4.1. Cell viability assay  
 All cell lines used in this study (Du-145, LNCaP, HCT-116, A549, MCF-7 and Vero) were 
maintained in the respective media recommended by ATCC. All the media used were 
supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologicals, Atlanta, GA) and 1% Pen. 
Strep. Prior to treatment with various drug concentrations and subsequent incubation for 72 hours, 
cells were incubated in a 96 well plate for 24 hours. Cell viability was measured using the MTS 
assay protocol as described by the manufacturer. For all drugs tested, DMSO concentration was 
maintained at 0.1% for experiments in LNCaP, HCT-116 and DU-145; and at 1% for experiments 
in other cell lines. Data was analyzed using the LOGIT function. GRAPHPAD prism software was 
used to generate all growth-inhibition curves. 
 
4.4.2. Cell cycle analysis  
 LNCaP cells were seeded onto 6-well plates at a density of 1×106 cells in 5 mL of media, 
and incubated in a humidified 5% CO2 atmosphere at 37 °C overnight. Following aspiration of 
media, fresh media containing drugs were added to the cells and incubated for 24 h. After 
incubation, cells were trypsinized, harvested and fixed with 70% EtOH. Fixed cells were stained 




FACS Acuri, BD Bioscience, San Jose, CA, USA). Unstained cells were used as control. Each 
experiment was performed in triplicate. 
 
4.4.3. Western blots analysis  
 LNCaP cells (106 cells/dish) were seeded in petri dishes 24 hour prior to treatment with 
various concentrations of compounds for 24h. Thereafter, media was removed and cells were 
washed with chilled 1X PBS buffer and resuspended in CelLyticM buffer containing a cocktail of 
protease inhibitor (Sigma-Aldrich, St. Louis, MO, USA). Protein concentration was determined 
through Bradford protein assay.  Equal amount of protein was then loaded onto an SDS-page gel 
(Bio-Rad, Hercules, CA, USA) and resolved by electrophoresis at a constant voltage of 100 V for 
2 h. The gel was transfered onto a nitrocellulose membrane and probed for acetylated tubulin, 
acetyl H4, AR, COX-2 and actin as loading control. 
 
4.4.4. HDAC inhibition  
The HDAC activity in presence of our compounds was assessed using the SAMDI mass 
spectrometry. As a label-free technique, SAMDI is compatible with a broad range of native peptide 
substrates without requiring potentially disruptive fluorophores. To obtain IC50 values, we 
incubated isoform-optimized substrates (20 M for HDACs 1-2, 6 and 50 μM for HDAC 8) with 
enzyme (70 nM (HDAC 1), 100 nM (HDAC 2), 50 nM (HDAC 3), 60 nM (HDAC 6), 500 nM 
(HDAC 8)) and inhibitor (at concentrations ranging from 10 nM to 1.0 mM) in 96-well microtiter 




8)). Solution-phase deacetylation reactions were quenched with trichostatin A (TSA) and 
transferred to SAMDI plates to immobilize the substrate components. SAMDI plates were 
composed of an array of self-assembled monolayers (SAMs) presenting maleimide in standard 
384-well format for high-throughput handling capability. Following immobilization, plates were 
washed to remove buffer constituents, enzyme, inhibitor, and any unbound substrate and analyzed 
by MALDI mass spectrometry using automated protocols44. Deacetylation yields in each triplicate 
sample were determined from the integrated peak intensities of the molecular ions for the substrate 
and the deacetylated product ion by taking the ratio of the former over the sum of both. Yields 
were plotted with respect to inhibitor concentration and fitted to obtain IC50 values for each 
isoform−inhibitor pair. 
 
4.4.5. COX inhibition assay  
In vitro COX inhibitory activity was evaluated using Cayman’s COX Fluorescent Inhibitor 
Screening Assay Kit (Cayman Chemical Company, Ann Arbor, MI, USA) following the 
manufacturer’s protocol. Briefly, ovine COX-1 and human recombinant COX-2 enzymes were 
incubated with stock solutions of our compounds and heme for 15 minutes at room temperature, 
after which a resorufin precursor was added and incubated for another 15 minutes at room 
temperature. The reaction was started by the adding arachidonic acid and left to proceed for 2 
minutes. Fluorescence was measured at a 530 nm excitation wavelength and a 595 nm emission 






4.4.6. Molecular Docking Analysis  
In silico docking was performed using Autodock Vina45 run through PyRx to manage the 
workflow and PyMol to visualize the results, as described previously.19d Briefly, ligands were 
prepared by first generating an energy minimized 3D structure in ChemBioDraw3D. This was 
followed by processing with Autodock Tools 1.5.4. Docking runs were performed within a 25−30 
Å cubic search space surrounding the binding pocket. 
 
4.4.7. Intracellular PGE2 measurement  
HeLa cells (3x105 cells/dish) were seeded in 6-well plates 24 hours prior to treatment with 
various concentrations of tested compounds. After incubation for 24 hours, the cell culture media 
was taken and centrifuged at 14,000 x g for 10 minutes, to remove cellular debris. PGE2 
concentration was determined by using PGE2 ELISA Kit-monoclonal (catalog number 514010). 
The assay was performed as recommended by the manufacturer. Briefly, serial dilution of PGE2 
standard and 50 µL of each sample were added to the recommended amount PGE2 antiserum and 
acetylcholinesterase tracer and incubated at 4 0C for 18 hours. The wells were emptied and washed 
five times with wash buffer. Thereafter, 200 µL of Ellman’s reagent containing substrate for 
acetylcholinesterase was added. The reaction was developed at room temperature for 2 hours on a 
slow shaker. Plates was read at 405 nm on a micro plate reader (Envision, PerkinElmer). Data was 
analyzed using the LOGIT function. GRAPHPAD prism software was used to generate graph and 





4.4.8. Anti-inflammatory activity assay  
NF-κB activity was measured using luciferase assay. BEAS-2B cells were transfected with 
NF-κΒ luciferase reporter construct in pGL3 basic vector46. Forty hours after transfection, the cells 
were treated with test compounds for 1 hour followed by stimulation with NTHi for 5 hours. The 
cells were then lysed with cell lysis buffer (250 mM Tris-HCl (pH 7.5), 0.1% Triton-X, 1 mM 
DTT) and luciferase activity was measured by using luciferase assay system (Promega). Relative 
luciferase activity (RLA) was determined using the following equation: RLA = luciferase unit of 
the cells treated with NTHi and inhibitors/ luciferase unit of the cells treated with mock. 
 
N-Hydroxy-6-((4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl) phenyl) sulfonamido) 
hexanamide (2a). Triethylamine (0.02 ml, 0.175 mmol) was added to a solution of trityl-protected 
6-aminohexanehydroxamic acid (0.05 g, 0.13 mmol) in CHCl3 (10 ml) and left to stir under argon 
for 5 minutes. Thereafter, a solution of 4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl) 
benzenesulfonyl chloride (0.05 g, 0.13 mmol) in anhydrous CHCl3 (5 ml) was added and the 
reaction left to stir overnight. Reaction was quenched with water (20 ml) and extracted with DCM 
(20 ml) three times. Combined organic layers were dried over anhydrous sodium sulfate and 
concentrated in vacuo. Residue was purified with prep TLC to give 6-((4-(5-(p-tolyl)-3-
(trifluoromethyl)-1H-pyrazol-1-yl) phenyl)sulfonamido)-N-(trityloxy)hexanamide an off-white 
solid (0.08 g, 0.10 mmol) which was immediately used for the next reaction without 
characterization.  
To a solution of 6-((4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl) 




were added TFA (1.5 ml) and TIPS (0.75 ml). Reaction was stirred at room temperature for one 
hour. Solvent was evaporated and the resulting residue purified by prep TLC using 
DCM:Acetone:AcOH (2:1:0.1) to give 2a as an off-white solid (0.03 g, 60%). HPLC retention 
time 16.22 minutes. 1H NMR (400 MHz, CD3OD) δ 7.90 (d, J = 8.5 Hz, 2H), 7.54 (d, J = 8.5 Hz, 
2H), 7.21 (q, J = 8.2 Hz, 4H), 6.94 (s, 1H), 2.90 (t, J = 6.8 Hz, 2H), 2.38 (s, 3H), 2.09 (m, 2H), 
1.60 (m, 2H), 1.54 – 1.45 (m, 2H), 1.34 (m, 2H).13C NMR (101 MHz, CD3OD) δ 145.7, 143.5, 
142.6, 142.1, 140.7, 139.8, 129.2, 128.6, 127.6, 125.7, 124.4, 122.3, 105.6, 42.5, 28.9, 25.8, 25.6, 
24.8, 19.9. HRMS (ESI) [M + H]+ calculated for [C23H26O4N4F3S]
+ was 511.1621, found 
511.1608. 
N-Hydroxy-7-((4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)sulfonamido) 
heptanamide (2b). Trityl-protected 7-aminoheptanehydroxamic acid (0.05 g, 0.14 mmol) was 
reacted with 4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl) benzenesulfonyl chloride (0.05 g, 
0.13 mmol) in anhydrous CHCl3 (5 ml) containing TEA (0.03 ml, 1.87 mmol) similar to compound 
2a above, to give 7-((4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)sulfonamido)-N-
(trityloxy) hexanamide as an off-white solid (0.08 g, 0.11 mmol) which was used for the next 
reaction (trityl deprotection) without characterization.  
Trityl deprotection was done as described for 2a in a DCM (10 ml) solution containing 
TFA (1.5 ml) and TIPS (0.75 ml). Purification was by prep TLC using DCM:Acetone:AcOH 
(2:1:0.1) to give 2b as an off-white solid (0.05 g, 92%). HPLC retention time 16.22 minutes. 1H 
NMR (500 MHz, CD3OD) δ 7.89 (d, J = 8.1 Hz, 2H), 7.53 (d, J = 8.1 Hz, 2H), 7.21 (dd, J = 18.5, 
7.7 Hz, 4H), 6.93 (s, 1H), 2.89 (t, J = 6.5 Hz, 2H), 2.37 (s, 3H), 2.10 (s, 2H), 1.60 (s, 2H), 1.47 (s, 




128.7, 127.7, 125.8, 122.4, 120.2, 105.5, 42.6, 29.1, 28.2, 27.8, 25.9, 25.2, 19.9. HRMS (ESI) [M 
+ H]+ calculated for [C24H28O4N4F3S]
+ was 525.1778, found 525.1771. 
N-Hydroxy-7-((4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)sulfonamido) 
octanamide (2c). Trityl-protected 8-aminooctanehydroxamic acid (0.06 g, 0.14 mmol) was 
reacted with 4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl) benzenesulfonyl chloride (0.05 g, 
0.13 mmol) in anhydrous CHCl3 (5 ml) containing TEA (0.03 ml, 1.87 mmol) similar to compound 
2a above, to give 8-((4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)sulfonamido)-N-
(trityloxy) octanamide an off-white solid (0.09 g, 0.11mmol) which was used for the next reaction 
(trityl deprotection) without characterization.  
Trityl deprotection was done as described for 2a in a DCM (10 mL) solution containing 
TFA (1.5 ml) and TIPS (0.75 ml). Purification was by prep TLC using DCM:Acetone:AcOH 
(2:1:0.1) to give 2c as an off-white solid (0.04 g, 71%). HPLC retention time 16.82 minutes. 1H 
NMR (400 MHz, CD3OD) δ 7.86 (d, J = 7.3 Hz, 2H), 7.50 (d, J = 7.6 Hz, 2H), 7.17 (dd, J = 14.9, 
8.0 Hz, 4H), 6.91 (s, 1H), 2.85 (s, 2H), 2.34 (s, 3H), 1.58 (m, 2H), 1.43 (m, 2H), 1.26 (m, J = 14.1 
Hz, 8H).13C NMR (101 MHz, cd3od) δ 145.7, 143.4, 143.1, 142.1, 140.7, 139.6, 129.2, 128.6, 
127.6, 125.7, 122.5, 119.9, 105.5, 42.6, 29.1, 28.5, 28.4, 26.2, 25.7, 19.9. HRMS (ESI) [M + H]+ 
calculated for [C25H30O4N4F3S]
+ was 539.1934, found 539.1928. 
1-(4-Sulfamoylphenyl)-5-(p-tolyl)-1H-pyrazole-3-carboxylic acid (5). Ethyl 1-(4-
sulfamoylphenyl)-5-(p-tolyl)-1H-pyrazole-3-carboxylate (1.33 g, 3.31 mmol) was dissolved in 
THF (30 ml) and LiOH.H2O (0.21 g, 4.97 mmol) was added followed by 6 ml of H2O. The reaction 
was left to stir at room temperature overnight. THF was evaporated off and product was 




with H2O to give (5) as a white solid (1.14 g, 96%). 
1H NMR (400 MHz, DMSO-d6) δ 13.15 (s, 
1H), 7.91 (d, J = 8.6 Hz, 2H), 7.56 (d, J = 8.8 Hz, 4H), 7.23 (q, J = 8.2 Hz, 4H), 7.09 (s, 1H), 2.34 
(s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 163.9, 146.2, 145.6, 144.5, 142.6, 139.7, 130.4, 129.7, 
127.8, 127.0, 126.8, 111.1, 21.8.  
1-(4-(Methylsulfonyl)phenyl)-5-(p-tolyl)-1H-pyrazole-3-carboxylic acid (6). Ethyl 1-(4-
(methylsulfonyl)phenyl)-5-(p-tolyl)-1H-pyrazole-3-carboxylate (0.42 g, 1.08 mmol) was reacted 
with LiOH.H2O (0.09 g, 2.16 mmol) following the same procedure for 5 above to give 6 as a white 
solid (0.38 g, 100 %). 1H NMR (400 MHz, DMSO-d6) δ 8.03 (d, J = 8.7 Hz, 2H), 7.61 (d, J = 8.6 
Hz, 2H), 7.26 – 7.17 (m, 4H), 7.09 (s, 1H), 3.31 (s, 3H), 2.33 (s, 3H). 13C NMR (101 MHz, DMSO-
d6) δ 163.4, 145.8, 145.1, 143.5, 140.6, 139.3, 129.9, 129.2, 128.7, 126.5, 126.3, 110.8, 43.7, 21.2.  
N-(6-(Hydroxyamino)-6-oxohexyl)-1-(4-sulfamoylphenyl)-5-(p-tolyl)-1H-pyrazole-3-
carboxamide (7a). EDCI (0.03 g, 0.17 mmol) and HOBT (0.02 g, 0.17 mmol) were added to a 
solution of 1-(4-sulfamoylphenyl)-5-(p-tolyl)-1H-pyrazole-3-carboxylic acid (5) (0.05 g, 0.14 
mmol) in CHCl3 (10 ml). The mixture was stirred at room temperature for 30 minutes after which 
trityl-protected 6-aminohexanehydroxamic acid (0.06 g, 0.154 mmol) was added, then left to stir 
overnight. The reaction was quenched with NaHCO3 (20 ml) and extracted three times with DCM 
(20 ml). Combined organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo. 
Crude product was purified by prep TLC using DCM:Acetone:AcOH (5:1:0.1) to give N-(6-oxo-
6-(trityloxy)amino)hexyl)-1-(4-sulfamoylphenyl)-5-(p-tolyl)-1H-pyrazole-3-carboxamide, which 
was used for the next reaction (trityl deprotection) without characterization. 
To a solution of N-(6-oxo-6-(trityloxy)amino)hexyl)-1-(4-sulfamoylphenyl)-5-(p-tolyl)-




TIPS (0.75 ml) were added. Reaction was stirred at room temperature for one hour. Solvent was 
evaporated and the resulting residue purified by prep TLC using DCM:MeOH:AcOH (10:1:0.1) 
to give 7a as an off white solid (0.03 g, 50 %). HPLC retention time 9.47 minutes 1H NMR (500 
MHz, DMSO-d6) δ 8.58 (s, 1H), 8.09 (d, J = 8.1 Hz, 2H), 7.75 (d, J = 8.4 Hz, 2H), 7.42 (dd, J = 
18.1, 7.9 Hz, 4H), 7.20 (s, 1H), 5.98 (s, 1H), 3.47 (d, J = 5.5 Hz, 2H), 2.54 (s, 3H), 1.73 (m, J = 
6.7 Hz, 3H), 1.47 (m, J = 14.0 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) δ 161.6, 148.7, 145.3, 
144.3, 142.6, 139.3, 130.2, 129.5, 127.4, 126.6, 108.8, 55.8, 30.1, 29.8, 27.5, 26.8, 25.7, 25.1, 21.7. 
HRMS (ESI) [M + H]+ calculated for [C23H28 O5N5S]
+ was 486.1806, found 486.1804. 
N-(7-(Hydroxyamino)-7-oxoheptyl)-1-(4-sulfamoylphenyl)-5-(p-tolyl)-1H-pyrazole-3-
carboxamide (7b). Trityl-protected 7-aminoheptanehydroxamic acid (0.08 g, 0.16 mmol) was 
reacted with a solution of 1-(4-sulfamoylphenyl)-5-(p-tolyl)-1H-pyrazole-3-carboxylic acid (5) 
(0.05 g, 0.14 mmol), HOBT (0.02 g, 0.17 mmol) and EDCI (0.03 g, 0.17 mmol)  in CHCl3 (10 ml) 
similar to compound 7a above, to give N-(7-oxo-7-((trityloxy)amino)heptyl)-1-(4-
sulfamoylphenyl)-5-(p-tolyl)-1H-pyrazole-3-carboxamide as an brown solid (0.08 g, 0.11 mmol) 
which was used for the next reaction (trityl deprotection) without characterization.  
Trityl deprotection was done as described for 7a. Purification was by prep TLC using 
DCM:MeOH:AcOH (10:1:0.1) to give 7b as a brown solid (0.02 g, 36 %). HPLC retention time 
10.13 minutes 1H NMR (500 MHz, DMSO-d6) δ 8.34 (s, 1H), 7.87 (d, J = 8.4 Hz, 2H), 7.53 (d, J 
= 8.4 Hz, 2H), 7.20 (dd, J = 18.1, 8.1 Hz, 4H), 6.98 (s, 1H), 3.25 (d, J = 3.3 Hz, 2H), 2.32 (s, 3H), 
1.95 (m, 2H), 1.50 (m, 4H), 1.26 (m, J = 19.3 Hz, 4H). 13C NMR (126 MHz, DMSO) δ 161.9, 




26.3, 26.2, 21.9. HRMS (ESI) [M + H]+ calculated for [C24H30O5N5S]
+ was 500.1962, found 
500.1956. 
N-(8-(Hydroxyamino)-8-oxooctyl)-1-(4-sulfamoylphenyl)-5-(p-tolyl)-1H-pyrazole-3-
carboxamide (7c). Trityl-protected 8-aminooctanehydroxamic acid (0.06 g, 0.15 mmol) was 
reacted with a solution of 1-(4-sulfamoylphenyl)-5-(p-tolyl)-1H-pyrazole-3-carboxylic acid (5) 
(0.05 g, 0.14 mmol), HOBT (0.02 g, 0.17 mmol) and EDCI (0.03 g, 0.17cmmol) in CHCl3 (10 ml), 
as described for compound 7a above, to give N-(8-oxo-8-((trityloxy)amino)octyl)-1-(4-
sulfamoylphenyl)-5-(p-tolyl)-1H-pyrazole-3-carboxamide as an brown solid (0.08 g, 0.11 mmol) 
which was used for the next reaction (trityl deprotection) without characterization.  
Trityl deprotection was done as described for 7a. Purification was by prep TLC using 
DCM:MeOH:AcOH (10:1:0.1) to give 7c as a brown solid (0.02 g, 36 %). HPLC retention time 
10.92 minutes. 1H NMR (500 MHz, DMSO-d6) δ 8.37 (s, 1H), 7.90 (d, J = 8.1 Hz, 2H), 7.56 (d, 
J = 8.1 Hz, 2H), 7.23 (dd, J = 18.1, 7.9 Hz, 4H), 7.01 (s, 1H), 3.28 (s, 2H), 2.35 (s, 3H), 1.97 (m, 
2H), 1.54 (m, 4H), 1.29 (m, J = 21.0 Hz, 8H). 13C NMR (126 MHz, DMSO) δ 161.3, 148.5, 144.9, 
143.8, 142.1, 139.1, 129.9, 129.1, 127.2, 126.7, 126.2, 108.4, 35.3, 31.9, 29.6, 29.0, 28.2, 26.8, 
21.3.  HRMS (ESI) [M + H]+ calculated for [C25H32O5N5S]
+ was 514.2119, found 514.2106. 
N-(7-(Hydroxyamino)-7-oxoheptyl)-1-(4-(methylsulfonyl)phenyl)-5-(p-tolyl)-1H-pyrazole-3-
carboxamide (8). Trityl-protected 7-aminoheptanehydroxamic acid (0.12 g, 0.31 mmol) was 
reacted with a solution of 1-(4-(methylsulfonyl)phenyl)-5-(p-tolyl)-1H-pyrazole-3-carboxylic acid 
(6) (0.10 g, 0.28 mmol), HOBT (0.04 g, 0.31 mmol) and EDCI (0.06 g, 0.30 mmol) in CHCl3 (10 




((trityloxy)amino)heptyl)-5-(p-tolyl)-1H-pyrazole-3-carboxamide as an brown solid (0.08 g, 0.11 
mmol) which was used for the next reaction (trityl deprotection) without characterization.  
Trityl deprotection was done as described for 7a. Purification was by prep TLC using 
DCM:MeOH:AcOH (10:1:0.1) to give 8 as a brown solid (0.02 g, 36 %). HPLC retention time 
11.13 minutes. 1H NMR (400 MHz, dmso) δ 8.41 (s, 1H), 8.03 (d, J = 8.4 Hz, 2H), 7.63 (d, J = 
8.4 Hz, 2H), 7.24 (q, J = 8.3 Hz, 4H), 7.01 (s, 1H), 3.31 (s, 3H), 2.35 (s, 3H), 2.04 (m, 2H), 1.93 
(m, 2H), 1.54 (m, 4H), 1.31 (m, 4H). 13C NMR (101 MHz, DMSO-d6) δ 156.2, 148.5, 144.9, 143.5, 
140.4, 139.2, 129.9, 129.1, 128.5, 126.6, 126.3, 109.0, 105.0, 43.8, 32.3, 29.6, 28.7, 26.6, 25.6, 
21.3.  HRMS (ESI) [M + H]+ calculated for [C25H31O5N4S]
+ was 499.2010, found 499.2010. 
NHS-activated indomethacin (10). Disuccinimidyl carbonate (0.86 g, 3.35 mmol) was added to 
a mixture of indomethacin (1.00 g, 2.79 mmol) and TEA (0.50 ml, 3.35 mmol) in DCM (20 ml). 
The reaction was stirred at room temperature overnight. Solvent was evaporated off and the residue 
purified by column chromatography using DCM: Acetone (10:1) to give 10 as a white solid (1.04 
g, 82 %). 1H NMR (400 MHz, CDCl3) δ 7.68 – 7.63 (m, 2H), 7.49 – 7.43 (m, 2H), 6.97 (d, J = 2.5 
Hz, 1H), 6.94 – 6.89 (m, 1H), 6.69 (dd, J = 9.0, 2.5 Hz, 1H), 3.96 (s, 2H), 3.85 (s, 3H), 2.80 (s, 
4H), 2.37 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 169.1, 168.6, 166.5, 156.4, 139.6, 136.6, 133.9, 
131.6, 130.9, 130.2, 129.3, 115.3, 112.8, 110.4, 100.9, 55.9, 27.4, 25.8, 13.7. 
6-(2-(1-(4-Chlorobenzoyl)-5-hydroxy-2-methyl-1H-indol-3-yl)acetamido)-N-
hydroxyhexanamide (11a). TEA (0.02 ml, 0.16 mmol) was added to a solution of NHS-activated 
indomethacin 10 (0.05 g, 0.11 mmol) and trityl-protected 7-aminoheptanehydroxamic acid (0.05 
g, 0.12 mmol) in DCM (10 ml). The reaction was left to stir at room temperature for 3 hours. The 




organic layer was dried over Na2SO4 and concentrated in vacuo. Residue obtained was purified by 
prep TLC using DCM: Acetone (10:1) to give 6-(2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-
1H-indol-3-yl)acetamido)-N-(trityloxy)hexanamide (0.07 g, 81 %) which was used for the next 
reaction (trityl deprotection) without characterization. 
Trityl group deprotection was done by dissolving 6-(2-(1-(4-chlorobenzoyl)-5-methoxy-2-
methyl-1H-indol-3-yl)acetamido)-N-(trityloxy)hexanamide in anhydrous DCM (10 ml) after 
which 1.5 mL TFA and 0.5 ml TIPS were added and the reaction was left to stir for 2 hours. 
Saturated NaHCO3 solution (40 ml) was added to the reaction and extracted three times with DCM 
(20 ml) after gas evolution had ceased. Combined organic layer was dried over Na2SO4 and 
concentrated in vacuo. Crude residue was purified by prep TLC using DCM:Acetone:AcOH 
(2:1:0.1) to give 11a as a light brown solid (0.07 g, 75 %). HPLC retention time 12.82 minutes. 1H 
NMR (400 MHz, CD3OD) δ 7.72 (d, J = 8.4 Hz, 2H), 7.58 (d, J = 8.4 Hz, 2H), 7.03 (d, J = 2.2 Hz, 
1H), 6.95 (d, J = 9.0 Hz, 1H), 6.70 (dd, J = 9.0, 2.3 Hz, 1H), 3.86 – 3.80 (m, 3H), 3.62 (s, 2H), 
3.22 (t, J = 6.7 Hz, 2H), 2.34 (s, 3H), 2.08 (s, 2H), 1.58 (d, J = 33.3 Hz, 4H), 1.32 (d, J = 9.7 Hz, 
2H). 13C NMR (101 MHz, CD3OD) δ 168.6, 164.9, 156.2, 138.7, 135.7, 134.3, 131.0, 130.7, 128.8, 
114.5, 113.5, 111.1, 104.4, 101.0, 54.8, 52.8, 39.1, 30.9, 28.6, 26.0, 24.9, 12.3. HRMS (ESI) [M 
+ H]+ calculated for [C25H29O5N3Cl]
+ was 486.1790, found 486.1782. 
7-(2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetamido)-N-
hydroxyheptanamide (11b). Reaction of NHS-activated indomethacin 10 (0.10 g, 0.22 mmol) 
with trityl-protected 7-aminoheptanehydroxamic acid (0.10 g, 0.24 mmol) in DCM (10 ml) 
containing TEA (0.04 ml, 0.26 mmol), as described for 11a, gave 7-(2-(1-(4-chlorobenzoyl)-5-




deprotection was achieved as described for 11a to give 11b as a light brown solid (0.14 g, 87 %). 
HPLC retention time 13.25 minutes. 1H NMR (400 MHz, DMSO-d6) δ 10.40 (s, 1H), 8.77 (s, 1H), 
8.09 (s, 1H), 7.70 (dd, J = 17.6, 8.5 Hz, 4H), 7.15 (d, J = 2.3 Hz, 1H), 6.97 (d, J = 9.0 Hz, 1H), 
6.74 (dd, J = 9.0, 2.4 Hz, 1H), 3.83 – 3.76 (m, 3H), 3.52 (s, 2H), 3.40 (s, 1H), 3.07 (d, J = 5.9 Hz, 
2H), 2.32 – 2.21 (m, 3H), 1.95 (t, J = 7.3 Hz, 2H), 1.46 (dd, J = 18.5, 11.6 Hz, 4H), 1.25 (m, 4H). 
13C NMR (101 MHz, DMSO-d6) δ 169.7, 169.1, 168.3, 156.0, 138.0, 135.6, 134.8, 131.6, 131.2, 
131.0, 130.7, 129.6, 114.9, 111.6, 102.4, 55.8, 49.9, 32.7, 31.6, 29.4, 28.9, 26.6, 25.7, 14.0. HRMS 
(ESI) [M + H]+ calculated for [C26H31O5N3Cl]
+ was 500.1947, found 500.1935. 
8-(2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetamido)-N-
hydroxyoctanamide (11c). Reaction of NHS-activated indomethacin 10 (0.05 g, 0.11 mmol) with 
trityl-protected 7-aminoheptanehydroxamic acid (0.05 g, 0.12mmol) in DCM (10 ml) containing 
TEA (0.02 ml, 0.16 mmol), as described for 11a, gave 8-(2-(1-(4-chlorobenzoyl)-5-methoxy-2-
methyl-1H-indol-3-yl)acetamido)-N-(trityloxy)octanamide (0.08 g, 91 %). Trityl deprotection was 
achieved as described for 11a to give 11c as a light brown solid (0.02 g, 47 %). HPLC retention 
time 13.95 minutes. 1H NMR (400 MHz, CD3OD) δ 7.69 (d, J = 8.1 Hz, 2H), 7.55 (d, J = 8.1 Hz, 
2H), 7.00 (s, 1H), 6.92 (d, J = 8.9 Hz, 1H), 6.67 (d, J = 8.7 Hz, 1H), 5.49 (s, 2H), 3.80 (s, 3H), 
3.59 (s, 2H), 3.19 (d, J = 5.5 Hz, 2H), 2.31 (s, 3H), 1.52 (m, J = 28.6 Hz, 4H), 1.26 (m, J = 14.7 
Hz, 8H). 13C NMR (101 MHz, CD3OD) δ 170.9, 169.2, 162.8, 158.5, 149.8, 147.4, 141.0, 138.0, 
136.6, 133.2, 131.1, 116.8, 115.7, 113.6, 103.3, 57.1, 55.7, 44.5, 43.8, 41.4, 33.4, 31.0, 30.8, 28.8, 
14.5. HRMS (ESI) [M + H]+ calculated for [C27H33O5N3Cl]





Methyl 2-(5-methoxy-2-methyl-1H-indol-3-yl)acetate (12). Indomethacin (3.00 g, 8.39 mmol) 
was dissolved in 1M NaOH (200 ml) and left to stir overnight. The reaction was acidified with 1M 
HCl and the precipitate filtered off. Filtrate was then extracted three times with DCM (100 ml). 
Combined organic layer was dried over Na2SO4 and concentrated in vacuo to give crude 2-(5-
methoxy-2-methyl-1H-indol-3-yl)acetic acid (1.12 g, 5.15 mmol). The crude intermediate was 
dissolved in MeOH (50 ml) and TMSCl (1.86 ml, 14.73 mmol) was added. The reaction mixture 
was left to stir at room temperature overnight. Water (50 ml) was added to quench the reaction and 
extracted three times with DCM (50 ml). Organic layer was combined, dried over Na2SO4 and 
concentrated in vacuo. Residue obtained was purified by column chromatography using 
CHCl3:EtOAc (10:1) to give 12 as a brown solid (0.99 g, 83 %). 
1H NMR (400 MHz, CDCl3) δ 
7.92 (s, 1H), 7.07 (d, J = 8.7 Hz, 1H), 7.01 (d, J = 2.0 Hz, 1H), 6.81 – 6.75 (m, 1H), 3.87 (d, J = 
1.1 Hz, 3H), 3.68 (d, J = 1.0 Hz, 5H), 2.32 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 172.8, 154.1, 
133.7, 130.2, 129.0, 111.1, 110.8, 104.1, 100.4, 55.9, 51.9, 30.3, 11.7. 
Methyl 2-(1-(4-ethynylbenzyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate (14). A solution of 
methyl 2-(5-methoxy-2-methyl-1H-indol-3-yl)acetate (12) (0.10 g, 0.43 mmol) and NaH (60 % 
dispersion in mineral oil) (0.03 g, 0.64 mmol) in anhydrous THF (10 ml) was cooled to 0 0C and 
left to stir for 20 minutes. The reaction was brought to room temperature, after which 4-
ethynylbenzyl methanesulfonate (0.11 g, 0.51 mmol) was added, and left to stir overnight. 
Reaction mixture was poured into sat. NH4Cl (10 ml) and extracted three times with DCM (15 
ml). Combined organic layer was dried over Na2SO4 and concentrated in vacuo. Purification was 
by prep TLC using CHCl3:Ether (20:1) to give 14 as a yellow solid (0.05 g, 31 %). 
1H NMR (400 
MHz, CDCl3) δ 7.41 (d, J = 8.0 Hz, 2H), 7.15 – 7.10 (m, 2H), 6.85 (d, J = 8.0 Hz, 2H), 6.80– 6.78 




(101 MHz, CDCl3) δ 172.8, 154.1, 138.1, 135.0, 133.7, 130.2, 129.0, 128.0, 125.0, 121.6, 111.1, 
110.8, 104.1, 100.4, 83.4, 55.9, 51.9, 46.8, 30.3, 11.7. HRMS (ESI) [M + H]+ calculated for 
[C22H21NO3]
+ was 347.1521, found 347.1529. 
2-(1-(4-(1-(7-(Hydroxyamino)-7-oxoheptyl)-1H-1,2,3-triazol-4-yl)benzyl)-5-methoxy-2-
methyl-1H-indol-3-yl)acetic acid (16). Methyl 2-(1-(4-ethynylbenzyl)-5-methoxy-2-methyl-1H-
indol-3-yl)acetate (14) (0.074 g, 0.21 mmol), trityl-protected 7-azidoheptanehydroxamic acid 
(0.11 g, 0.26 mmol) and DIPEA (0.07 ml, 0.43 mmol) were dissolved in anhydrous THF (10 ml) 
and purged for 10 minutes at room temperature while stirring. CuI (0.02 g, 0.11 mmol) was then 
added with purging continued for another 20 minutes. The reaction was left to stir overnight. 
Reaction was quenched with a solution of 4:1 sat. NH4Cl/NH4OH (20 ml) and extracted with a 
mixture of 10% MeOH in DCM (3X) (20 ml). Combined organic layer was dried over anhydrous 
Na2SO4 and concentrated in vacuo. Purification was by prep TLC using 10:1 DCM:MeOH to give 
methyl 2-(5-methoxy-2-methyl-1-(4-(1-(7-oxo-7-((trityloxy)amino)heptyl)-1H-1,2,3-triazol-4-
yl)benzyl)-1H-indol-3-yl)acetate (0.08 g, 51 %), which was used for the next reaction. 
The product of the first step above was dissolved in a 4:1 MeOH/H2O mixture (5 ml). 
LiOH.H2O (0.0065 g, 0.16 mmol) was added to the solution which was left to stir for 6 hours. 
Solvent was evaporated off and the residue purified by prep TLC using EtOAc:hexanes:AcOH 
(2:1:0.1) to give 2-(5-methoxy-2-methyl-1-(4-(1-(7-oxo-7-((trityloxy)amino)heptyl)-1H-1,2,3-
triazol-4-yl)benzyl)-1H-indol-3-yl)acetic acid (0.035 g, 45 %) as a yellow solid. Trityl 
deprotection was done as described for 11a. Purification was done using 10:1:0.1 
DCM:MeOH:AcOH to give 16 as a yellow solid (0.023 g, 96 %). HPLC retention time 10.62 




7.06 (d, J = 18.4 Hz, 3H), 6.70 (d, J = 7.5 Hz, 1H), 5.40 (s, 2H), 4.40 (s, 2H), 3.80 (d, J = 22.4 Hz, 
3H), 3.55 (s, 2H), 2.32 (s, 3H), 1.92 (d, J = 30.5 Hz, 2H), 1.49 (s, 2H), 1.28 (s, 5H). 13C NMR (126 
MHz, DMSO-d6) δ 184.2, 175.2, 171.2, 163.3, 156.1, 148.5, 144.5, 139.8, 136.8, 135.4, 131.5, 
129.9, 124.8, 120.1, 115.3, 110.8, 91.9, 65.6, 59.5, 56.1, 39.6, 35.9, 35.0, 22.4, 15.0. HRMS (ESI) 
[M + H]+ calculated for [C28H34O5N5]
+ was 520.2554, found 520.2549. 
Methyl 2-(1-(4-(1-(6-(hydroxyamino)-6-oxohexyl)-1H-1,2,3-triazol-4-yl)benzyl)-5-methoxy-
2-methyl-1H-indol-3-yl)acetate (17a). Reaction of methyl 2-(1-(4-ethynylbenzyl)-5-methoxy-2-
methyl-1H-indol-3-yl)acetate (14) (0.070 g, 0.20 mmol) with trityl-protected 6-
azidohexanehydroxamic acid (0.10 g, 0.24 mmol) in the presence of DIPEA (0.070 ml, 0.43 mmol) 
and CuI (0.019 g, 0.10 mmol) in THF (10 ml), as described above for 16, gave methyl 2-(5-
methoxy-2-methyl-1-(4-(1-(6-oxo-6-((trityloxy)amino)hexyl)-1H-1,2,3-triazol-4-yl)benzyl)-1H-
indol-3-yl)acetate (0.075 g,  49 %). Trityl deprotection was achieved as described for 11a. 
Purification was done by prep TLC using 10:1 DCM:MeOH to give 17a as a brown solid (0.042 
g, 40 %). HPLC retention time 12.88 minutes 1H NMR (400 MHz, CD3OD) δ 8.13 (s, 1H), 7.62 
(d, J = 8.1 Hz, 2H), 7.08 (d, J = 8.8 Hz, 1H), 6.96 (dd, J = 11.0, 5.2 Hz, 3H), 6.67 (dd, J = 8.8, 2.3 
Hz, 1H), 5.26 (s, 2H), 4.33 (t, J = 6.9 Hz, 2H), 3.76 (s, 3H), 3.71 – 3.65 (m, 2H), 3.62 (s, 3H), 2.25 
(s, 3H), 2.03 (t, J = 7.2 Hz, 2H), 1.60 (dt, J = 14.9, 7.3 Hz, 2H), 1.32 – 1.18 (m, 4H). 13C NMR 
(101 MHz, CD3OD) δ 173.2, 171.5, 153.9, 138.4, 134.9, 131.8, 128.1, 126.3, 125.3, 120.6, 110.1, 
109.3, 100.0, 54.8, 50.9, 49.9, 45.7, 31.7, 29.9, 29.7, 25.4, 24.5, 8.9. HRMS (ESI) [M + H]+ 
calculated for [C28H34O5N5]






2-methyl-1H-indol-3-yl)acetate (17b). Trityl deprotection of methyl 2-(5-methoxy-2-methyl-1-
(4-(1-(7-oxo-7-((trityloxy)amino)heptyl)-1H-1,2,3-triazol-4-yl)benzyl)-1H-indol-3-yl)acetate 
(0.074 g, 0.095 mmol), an intermediate obtained during the synthesis of 16 above, was achieved 
as described for 11a. Purification was done by prep TLC using 10:1 DCM:MeOH to give 17b as 
a brown solid (0.025 g, 49 %). HPLC retention time 8.48 minutes 1H NMR (500 MHz, CD3OD) δ 
8.24 (s, 1H), 7.69 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 8.8 Hz, 1H), 7.04 – 6.98 (m, 3H), 6.72 (dd, J = 
8.8, 2.1 Hz, 1H), 5.36 (s, 2H), 4.40 (t, J = 6.8 Hz, 2H), 3.81 (s, 3H), 3.75 (s, 2H), 3.67 (s, 3H), 2.32 
(s, 3H), 2.06 (m, 2H), 1.60 (m, 2H), 1.35 (m, 5H). 13C NMR (126 MHz, CD3OD) δ 173.4, 171.3, 
154.3, 147.3, 138.6, 135.0, 131.8, 129.4, 128.2, 126.3, 125.5, 120.7, 110.3, 109.5, 104.2, 100.2, 
55.0, 51.3, 50.0, 45.9, 29.7, 28.9, 28.0, 25.8, 25.1, 9.0. HRMS (ESI) [M + H]+ calculated for 
[C29H36O5N5]
+ was 534.2711, found 534.2705. 
Methyl 2-(1-(4-(1-(8-(hydroxyamino)-8-oxooctyl)-1H-1,2,3-triazol-4-yl)benzyl)-5-methoxy-
2-methyl-1H-indol-3-yl)acetate (17c). Reaction of methyl 2-(1-(4-ethynylbenzyl)-5-methoxy-2-
methyl-1H-indol-3-yl)acetate (14) (0.074 g, 0.21 mmol) with trityl-protected 8-
azidooctanehydroxamic acid (0.11 g, 0.26 mmol) in the presence of DIPEA (0.07 ml, 0.43 mmol) 
and CuI (0.02 g, 0.11 mmol) in THF (10 ml), as described above for 16, gave methyl 2-(5-methoxy-
2-methyl-1-(4-(1-(8-oxo-8-((trityloxy)amino)octyl)-1H-1,2,3-triazol-4-yl)benzyl)-1H-indol-3-
yl)acetate (0.026 g,  16 %). Trityl deprotection was achieved as described for 11a. Purification was 
done by prep TLC using 10:1 DCM:MeOH to give 17c as a brown solid (0.017 g, 92 %). HPLC 
retention time 9.92 minutes 1H NMR (500 MHz, CD3OD) δ 8.26 (s, 1H), 7.72 (d, J = 7.2 Hz, 2H), 
7.16 (d, J = 8.7 Hz, 1H), 7.04 (s, 3H), 6.74 (d, J = 8.6 Hz, 1H), 5.38 (s, 2H), 4.42 (s, 2H), 3.83 (s, 




13C NMR (126 MHz, CD3OD) δ 175.3, 170.3, 156.4, 149.2, 140.7, 137.1, 133.8, 131.5, 130.3, 
128.4, 127.5, 122.8, 112.4, 111.6, 106.2, 102.3, 57.1, 53.1, 52.1, 48.0, 31.8, 30.8, 30.3, 28.1, 27.4, 
24.7, 11.1. HRMS (ESI) [M + H]+ calculated for [C30H38O5N5]
+ was 548.2867, found 548.2855. 
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Targeting of drug delivery systems (DDS), using small molecules or antibodies, continues 
to be an attractive approach employed to improve on the bioavailability of drugs, and mitigate the 
toxic effects that may limit the clinical use of promising therapeutics. Liposomes are attractive as 
DDS because of their biodegradability and amphiphilic nature, which enables them to cross cell 
membranes with little resistance.  What used to be a major challenge in the field is making 
liposomes with long circulation time in systemic circulation, while resisting uptake by the 
mononuclear phagocyte system and still maintain structural integrity.1 This challenge was resolved 
with the introduction of stealth liposomes,2 having PEG coating on their surfaces.  Stealth 
liposomes get to tumor sites by leaching through defects in the tumor blood vessels, by a process 
known as enhanced permeability and retention effect (EPR).3  
To enhance the amount of liposomes getting to tumor sites, liposomes are often 
functionalized with ligands that have affinity for receptors ubiquitously expressed in tumors.4 Such 
liposomes are called actively-targeted liposomes, and have been proposed to get to tumors through 
a combination of EPR effect and receptor-facilitated uptake.4-5 In designing ligand targeted 
liposomes, the location of the ligand on the surface of the liposomes relative to the PEG coating is 




bind to their receptors with minimal hindrance6. On the other hand, ligands buried within PEG 
coating are likely to encounter hindrance in the ligand-receptor interaction needed to facilitate their 
uptake.6 
In continuation of our effort to assess the suitability of macrolides as targeting ligands on 
the surface of nanoparticles,7-8 we functionalized a phospholipid, 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine (DSPE), with clarithromycin and formulated liposomes with the 
functionalized DSPE. Three types of these clarithromycin-functionalized DSPE were made: one 
in which clarithromycin was directly attached to the phospholipid head group (compound 3), 
another one with a short linker (PEG8) as connecting unit between clarithromycin and DSPE 
(compound 6); and lastly, one with long linker (PEG2000) separating DSPE from clarithromycin 
(compound 10). Liposomes made with these compounds were used to encapsulate propidium 
iodide (PI), and their cellular uptake was assessed in macrophage cell line (RAW 264.7).  
Similarly, we appended tamoxifen, an estrogen receptor (ER) antagonist, to DSPE 
(compound 12), and formulated liposomes with the functionalized DSPE. Cellular uptake was also 
assessed in ER positive breast cancer cell line (MCF-7), with tamoxifen functionalized liposomes 
carrying propidium iodide. 
 
5.2. Materials and methods  
1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), DSPE-mPEG2000, DSPE-
mPEG2000-NHS, and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) were purchased from 




purchased via VWR from EMD Millipore (Biosciences. Murine macrophage cells RAW 264.7 
and breast cancer cell line MCF-7 were obtained from ATCC, USA. All solvents used in this study 
were either of HPLC grade or analytical grade, and were used without further purification. 
 






Clarithromycin-DSPE (3) was made using Cu (I) catalyzed Huisgen 1, 3-cycloaddition 
reaction between DSPE-azide (1) and clarithromycin benzyl alkyne (2) (scheme 5.1). The two 
intermediates (compounds 1 and 2) used in this synthesis were made as described previously.9  
Scheme 5.1: Synthesis of DSPE-clarithromycin (Compound 3) 
 
In making compound 6, we converted PEG-monoazide (4) to azide-PEG-carbonate, which 
was immediately reacted with DSPE to give azido-PEG-DSPE (5). The desired compound 6 was 
thereafter made by Cu(I)-catalyzed 1, 3-cycloaddition reaction between clarithromycin alkyne (2) 





Scheme 5.2: Synthesis of DSPE-PEG8-clarithromycin (Compound 6) 
 
Synthesis of compound 10 was achieved via a multistep synthesis involving making of 
intermediate compound 8. Access to compound 8 was achieved by Cu(I)-catalyzed cycloaddition 
reaction between azide-PEG-amine (7) and clarithromycin-alkyne compound 2 (scheme 5.3). 
Refluxing compound 8 with commercially available NHS-activated DSPE-PEG2000 (9) in CHCl3 
furnished the desired compound 10. Due to the polydispersed nature of the commercially available 
intermediate 9, compound 10 was also obtained in the polydispersed form. Product synthesis was 















Figure 5.2: Mass spec confirmation of synthesis of DSPE-PEG2000-clarithromycin (compound 10) 
 





Similar to compounds 3 and 6, tamoxifen-functionalized DSPE (12) was successfully made 
using Cu(I)-catalyzed cycloaddition reaction between compound 11 and compound 5 (scheme 
5.4).  
 
Table 5.1: Various liposome formulations 
Formulation Lipid composition Molar ratio 
C1 DSPC: DSPE-mPEG2000: cholesterol 11:1:7 
C2 DSPC: DSPE-mPEG2000: cholesterol: compound 3 11:1:7:0.1 
C3 DSPC: DSPE-mPEG2000: cholesterol: compound 6 11:1:7:0.1 
C4 DSPC: DSPE-mPEG2000: cholesterol: compound 10 11:1:7:0.025 
C5 DSPC: DSPE-mPEG2000: cholesterol: compound 12 11:1:7:0.1 
 
 
5.4. Preparation of liposomes 
Liposomes were prepared were prepared by the thin film hydration method.10 Briefly, 
DSPC, DSPE-mPEG2000, cholesterol and the respective clarithromycin- or tamoxifen-modified 
DSPE, in molar ratios shown in table 4.1, were dissolved in chloroform in a round bottom flask to 
give a clear solution. If a clear solution is not obtained, a mixture of chloroform and methanol (2:1) 
was used to dissolved the components. Organic solvents were removed using the rotary evaporator 
until a thin film is obtained, and the flask is left on the high vacuum overnight to remove residual 




containing 10 µM propidium iodide (PI) at 550 C, followed by intermittent sonication, in a bath-
type sonicator, for 10 minutes at 100W. The resulting suspension was extruded seventeen times 
through an extruder (Avanti mini extruder, Avanti Lipids) with a polycarbonate membrane (100 
nm) to obtain a clear solution of unilamellar liposomes. Dialysis through Slide-A-Lyzer dialysis 
cassette G2 (Thermo Scientific) (with molecular weight cut-off 10 KDa) was used to removed 
unencapsulated PI and unincorporated lipids. Pure liposomes were stored at 4 0C until used. 
 
5.5. Characterization of liposomes 
The sizes of liposomes (Table 5.2) were measured using dynamic light scattering. 
 
5.6. Encapsulation efficiency (EE) of liposomes 
EE was determined by lysis followed by absorbance measurement. To determine the 
amount of PI encapsulated in liposomes, 50µL of liposome was lysed using Triton-X (Sigma, 
USA) and absorbance of the solution measured. This was then compared to a standard curve of 
absorbance vs varying concentrations of PI. Encapsulation efficiency was calculated using the 
equation: 








Table 5.2: Characteristics of various liposome formulations 
Formulation Radius (nm) Polydispersity EE (%) 
C1 55.7 0.08 10.3 
C2 51.7 0.19 ND 
C3 54.5 0.11 15.3 
C4 ND ND ND 
C5 54.9 0.21 10 
ND= not determined 
 
5.7. In vitro cellular uptake 
RAW 264.7 and MCF-7 cells were grown in DMEM supplemented with 10% fetal bovine 
serum (FBS) and 1% pen. Strep. in a humidified incubator with 5% CO2 at 37 
0C in petri dishes. 
Prior to experiment, cells were seeded in a 12-well plate containing a cover slip at 5*105 plating 
density. The following day, media was aspirated and replaced with fresh media containing 
appropriate concentrations of PI or liposomes encapsulating PI. 24 hours after incubation at 37 0C, 
media was aspirated and the wells washed twice with chilled PBS, pH 7.4. Cells were thereafter 
fixed with 4% paraformaldehyde. For MCF-7 experiment, 300 nM solution of DAPI was added to 
the wells, after which cover slips were removed from the wells and mounted on slides using 





5.8. Results and discussion 
5.8.1. Characterization: clarithromycin-functionalized liposome 
 Liposomes were successfully formulated using the molar ratios of individual components 
shown in Table 5.1. For a typical stealth liposome (C1), molar ratio of 11:1:7 of DSPC: DSPE-
mPEG2000: cholesterol was sufficient to give the desired formulation, and this formed the basis on 
which other liposomes were made. The major challenge in making ligand-bearing liposomes is 
determining the optimum amount of ligand-functionalized DSPE that can be incorporated into the 
lipid mix. For each of the clarithromycin-targeted liposomes, we added varying amounts of each 
of the three clarithromycin modified DSPE, and chose the optimum ratio that gave a stable 
liposome formulation. As shown in Table 5.1, compounds 3 (without linker) and 6 (with PEG8 
linker) (Figure 5.1) were doped into the lipid mix at 0.1 mol equivalent of DSPE-mPEG2000 to give 
formulations C2 and C3 respectively. This was the optimum level of incorporation of the two 
compounds that gave a stable formulation. For formulation C4, however, we could not exceed 
0.025 mol (relative to DSPE-mPEG2000) of compound 10 to form liposomes. The reason for this is 
not very clear. 
 The hydrodynamic radius was determined for three of our formulations (C1-C3), as a 
measure of size of liposomes. For a typical unilamellar liposome for tumor drug delivery purpose, 
sizes in the range of 50-100 nm (radius) are desirable11. All the three liposomes analyzed have 
radius of 55.7, 51.7 and 54.5 nm for C1, C2, and C3 formulations respectively (Table 5.2). The 
two ligand functionalized liposomes, C2 and C3, have radii within the 50-100 nm range, 
suggesting that they may be suitable for cancer drug delivery applications. Comparing the sizes of 




there was no significant difference in the size of C1 and C3, suggesting that incorporating 
clarithromycin-PEG8-DSPE into the liposome do not lead to visible change in size of the liposome. 
Liposome formulation C2, on the other hand, appear to be smaller than the formulation without 
ligand, C1. This is an unusual observation, as most ligand functionalized liposomes turn out to be 
bigger in sizes that the non-functionalized ones. Since clarithromycin is directly attached to the 
lipid’s phosphate group for compound 3 (incorporated into C2), it is quite possible that 
clarithromycin in this location compresses the liposome, which then leads to the decrease in size 
compared to non-modified liposome.  
 Analysis of EE for the stealth liposome, C1, and one of the clarithromycin-functionalized 
liposomes, C3, showed that they both have low EE (Table 5.2) 15.3 and 10.3 respectively. The 
low EE obtained could be due to the thin film hydration method used in formulating these 
liposomes. 
 
5.8.2. Characterization: tamoxifen-functionalized liposome 
 The liposome formulation containing tamoxifen-PEG8-DSPE (12), C5, was made by 
doping the lipid mix with compound 12 at a 0.1 mol equivalent of DSPE-mPEG2000 (Table 5.2). 
This formulation gave liposome with a radius (54.9 nm) not significantly different from the size 
of liposome without ligand, C1, (55.7 nm). This also suggests that tamoxifen-PEG8-DSPE do not 
significantly affect the size of the liposome made, and that the liposome obtained may be suitable 




 Similar to the clarithromycin-based liposome, tamoxifen functionalized liposome also had 
a low EE (Table 5.2), though about the same as that for stealth liposome. 
 
5.8.3. Cellular uptake study: uptake of clarithromycin-functionalized liposomes in RAW 
264.7 macrophage cells 
 Having successfully made and characterize liposomes encapsulating PI with 
clarithromycin on their surfaces, we evaluated the effect of having clarithromycin on the surface 
of liposomes on cell uptake. For this, we used confocal microscopy to track the fluorescence due 
to PI within the liposomes in murine macrophage cell line, RAW 264.7. For this study, we treated 
RAW 264.7 cells with free PI and liposomes from C1 and C3 formulations for 24 hours. Confocal 
images obtained are shown in Figure 5.3. We can clearly see that cells treated with liposome having 
clarithromycin-PEG8-DSPE incorporated (formulation C3) have the highest amount of PI 
internalized compared to cells treated with free PI and liposome without ligand (formulation C1). 
This observation is consistent with our previous study7, where we showed that macrolides facilitate 
substantial accumulation of gold nanoparticles in RAW 264.7 cells. Although this data is 
preliminary, we can safely assume that clarithromycin could be used as a targeting ligand on the 





Figure 5.3: Confocal microscope images of RAW 264.7 cellular uptake of PI encapsulated in non-
targeted- and targeted liposomes, as well as unencapsulated PI (free dye) 
 
 Further evaluation is required to reproduce this observation, and also explore other 
formulations (C2 and C4) to see which one will give the highest amount of intracellular liposomal 
PI. 
 
Figure 5.4: Confocal microscope images of MCF-7 cellular uptake of PI encapsulated in non-




5.8.4. Cellular uptake study: uptake of tamoxifen-functionalized liposomes in MCF-7 cells 
 Tamoxifen is an ER-binder currently FDA approved for ER+ breast cancer. Our lab and 
others have exploited tamoxifen’s affinity for ER to facilitate delivery of gold nanoparticles12 and 
liposomes13 to ER-expressing breast cancer cell line, MCF-7. Though the previous study using 
tamoxifen as ligand to guide liposome13 showed some promise, tamoxifen was not covalently 
linked to any of the lipids that constitute the liposome. In our study, we treated MCF-7 cells with 
tamoxifen-functionalized liposome and non-targeted liposome (both encapsulating PI) for 10- and 
24 hours, after which the cells nuclei were stained with DAPI. The images taken with confocal 
microscope are shown in Figure 5.4 above. At 10 hours, we saw more of PI in the cells treated 
with Tamoxifen-functionalized liposome compared to the non-functionalized one, with some of 
the dye already in the nucleus. The observation was more pronounced at 24 hours. 
 
5.9. Conclusion 
 We have reported our synthetic efforts towards making phospholipids carrying targeting 
ligands. With our approach, we were able to make DSPE functionalized with clarithromycin and 
tamoxifen. Liposomes made with phospholipids having clarithromycin attached showed some 
promise in facilitating delivery of PI to RAW 264.7 macrophage cells. Likewise, liposome made 
with DSPE functionalized with tamoxifen was assessed for cellular uptake in RAW 264.7 
macrophage cells. Though promising, it is not very clear from the current study if there is an 
advantage to having tamoxifen-DSPE incorporated into liposomes. A more extensive study will 




5.10. Description of compound synthesis 
Compounds 1, 4 and 7 were made following literature protocols7.  
Clarithromycin triazolyl DSPE (3): 
DSPE azide 1 (0.30 g, 0.39 mmol) and ethynyl benzyl clarithromycin 2 (0.36 g, 0.43 mmol) are 
dissolved in anhydrous THF (20 ml) and purged with argon for 10 min. DIPEA (0.13ml, 0.78 
mmol) and CuI (0.04 g, 1.94 mmol) were then added to the mixture and purged further for another 
20 minutes. The resulting suspension was stirred at room temperature for 12 h. Reaction was 
quenched with a solution of 4:1 satd. Aqueous NH4Cl/NH4OH and extracted with a mixture of 
10% MeOH in DCM. Combined organic layer was dried over anhydrous Na2SO4 and concentrated 
in vacuo. The crude was purified by prep. TLC using CHCl3: MeOH: NH4OH (10:2:0.1) to give 
compound 3 as an off white solid (0.46g, 72 %). 1H NMR (400 MHz, cdcl3) δ 8.10 (s, 1H), 7.74 
(d, J = 7.8 Hz, 2H), 7.38 (s, 2H), 5.17 (d, J = 18.5 Hz, 1H), 4.84 (d, J = 15.8 Hz, 1H), 4.60 (d, J = 
20.2 Hz, 2H), 4.44 – 4.36 (m, 1H), 4.25 (d, J = 28.4 Hz, 3H), 4.07 (d, J = 29.5 Hz, 1H), 3.93 (d, J 
= 20.6 Hz, 4H), 3.78 – 3.66 (m, 3H), 3.66 – 3.54 (m, 2H), 3.47 (d, J = 7.1 Hz, 2H), 3.42 – 3.32 (m, 
1H), 3.17 (s, 1H), 3.09 (s, 2H), 3.04 – 2.91 (m, 7H), 2.80 (d, J = 30.7 Hz, 1H), 2.57 (s, 1H), 2.41 
(s, 2H), 2.31 – 2.13 (m, 7H), 1.98 – 1.72 (m, 2H), 1.61 – 1.42 (m, 5H), 1.36 (d, J = 11.8 Hz, 3H), 
1.32 – 1.14 (m, 97H), 1.08 (dd, J = 28.3, 6.2 Hz, 27H), 0.90 – 0.77 (m, 16H). HRMS (ESI) m+z 
Calcd. for C87H154O21N4P [M+H







DSPE-PEG8 azide (5): 
PEG azide 4 (0.57 ml, 1.43 mmol), TEA (0.60 ml, 4.29 mmol), and disuccinimidyl 
carbonate (0.73 g, 2.86 mmol) were dissolved in acetonitrile (20 ml) and left to stir at room 
temperature overnight. Solvent was evaporated and azido-PEG-carbonate was recovered by prep 
TLC using DCM:Acetone (1:2) as a colorless viscous liquid (0.70 g, 90 %) and used for the next 
step without characterization. The recovered azido-PEG-carbonate (0.24 g, 0.44 mmol), DSPE 
(0.25 g, 0.34 mmol) and TEA (0.14 ml, 1.02 mmol) were dissolved in CHCl3 (15 ml) and stirred 
at 40 0C overnight. Solvent was evaporated off, and the crude purified by prep TLC using DCM: 
MeOH (10:1) to give compound 5 as a waxy solid (0.17 g, 56 %). 1H NMR (400 MHz, cdcl3) δ 
6.23 (s, 1H), 5.14 (s, 1H), 4.31 (d, J = 9.5 Hz, 2H), 4.18 (s, 2H), 4.12 – 4.03 (m, 2H), 3.92 – 3.81 
(m, 5H), 3.69 – 3.59 (m, 30H), 2.68 (s, 6H), 2.25 (dd, J = 12.8, 7.4 Hz, 5H), 1.53 (s, 5H), 1.19 (d, 
J = 12.5 Hz, 74H), 0.84 (t, J = 6.8 Hz, 7H). 31P NMR (162 MHz, cdcl3) δ -1.98. 
Clarithromycin triazolyl PEG8 DSPE (6): 
DSPE-PEG8 azide 5 (0.17 g, 0.15 mmol), ethynyl benzyl clarithromycin 2 (0.14 g, 0.16 mmol), 
DIPEA (0.06 ml, 0.29 mmol) and CuI (0.01 g, 0.07 mmol) were reacted in anhydrous THF (10 
ml) as described for compound 3 above. Due to PEG’s solubility in water, no aqueous workup was 
done. Solvent was evaporated and the crude was purified by prep. TLC using CHCl3: MeOH: 
NH4OH (10:2:0.1) to give compound 6 as an off white solid (0.16 g, 53 %). 
1H NMR (400 MHz, 
cd3od) δ 8.28 (s, 1H), 7.78 (d, J = 8.2 Hz, 2H), 7.41 (d, J = 8.1 Hz, 2H), 5.42 – 5.38 (m, 1H), 5.17 
(d, J = 19.1 Hz, 1H), 5.06 (dt, J = 16.2, 8.1 Hz, 1H), 4.86 (t, J = 11.1 Hz, 1H), 4.61 (t, J = 5.0 Hz, 
2H), 4.48 (t, J = 8.5 Hz, 1H), 4.40 (dt, J = 12.6, 6.4 Hz, 1H), 4.21 – 4.11 (m, 3H), 4.09 – 4.00 (m, 




3.51 (m, 39H), 3.37 – 3.26 (m, 8H), 3.20 – 3.10 (m, 7H), 3.04 – 2.96 (m, 5H), 2.94 – 2.85 (m, 1H), 
2.76 (d, J = 24.4 Hz, 1H), 2.53 (d, J = 30.4 Hz, 1H), 2.37 (s, 1H), 2.36 – 2.23 (m, 10H), 1.94 – 
1.76 (m, 5H), 1.69 (d, J = 12.9 Hz, 1H), 1.63 – 1.49 (m, 8H), 1.42 – 1.31 (m, 31H), 1.31 – 1.16 
(m, 100H), 1.16 – 1.06 (m, 18H), 0.85 (dt, J = 13.8, 7.1 Hz, 12H). 31P NMR (162 MHz, cdcl3) δ 
0.85. HRMS (ESI) m+2/2z Calcd. for C104H188O30N5P [M+2H
+]: 1009.1533, found 1009.1544. 
Clarithromycin triazolyl PEG8 amine (8): 
Azide PEG amine 7 (0.11 g, 0.27 mmol) and ethynyl benzyl clarithromycin 2 (0.15 g, 0.18 
mmol), DIPEA (0.06 ml, 0.35 mmol) and CuI (0.02 g, 0.09 mmol) were reacted in anhydrous THF 
(10 ml) as described for compound 6. The crude was purified by prep. TLC using DCM: MeOH: 
NH4OH (10:2:0.1) to give compound 8 as a light yellow viscous liquid (0.12g, 37 %). 
1H NMR 
(400 MHz, cdcl3) δ 8.17 (s, 1H), 7.96 (d, J = 8.2 Hz, 2H), 7.51 (d, J = 8.1 Hz, 2H), 5.21 (dd, J = 
11.1, 2.0 Hz, 1H), 5.05 (t, J = 8.4 Hz, 1H), 4.76 (t, J = 4.9 Hz, 2H), 4.58 (t, J = 10.3 Hz, 1H), 4.14 
– 4.03 (m, 3H), 3.98 – 3.84 (m, 3H), 3.85 – 3.72 (m, 36H), 3.70 (dd, J = 15.2, 10.0 Hz, 5H), 3.67 
– 3.52 (m, 4H), 3.52 – 3.42 (m, 2H), 3.31 (d, J = 9.2 Hz, 2H), 3.31 (d, J = 11.7 Hz, 4H), 3.23 – 
3.11 (m, 6H), 3.09 – 2.99 (m, 4H), 2.85 – 2.64 (m, 5H), 2.50 – 2.37 (m, 5H), 2.33 (d, J = 0.7 Hz, 
1H), 2.08 (dd, J = 13.3, 6.5 Hz, 3H), 2.02 – 1.80 (m, 4H), 1.73 – 1.63 (m, 2H), 1.54 (d, J = 16.0 
Hz, 3H), 1.41 (dt, J = 18.5, 9.3 Hz, 9H), 1.38 – 1.20 (m, 31H), 1.00 (t, J = 7.4 Hz, 3H).  
Clarithromycin triazolyl PEG2000 DSPE (10): 
DSPE-PEG2000-NHS 9 (0.35 g, 0.15 mmol) and compound 8 (0.12 g, 0.10 mmol) were 
dissolved in CHCl3 and stirred at 70 
0C overnight. Solvent was evaporated off and the crude 
purified by prep TLC using DCM: MeOH: NH4OH (12:1:0.1) to give compound 10 (0.24 g, 40 




Tamoxifen triazolyl PEG8 DSPE (12): 
DSPE-PEG8 azide 5 (0.59 g, 0.50 mmol), tamoxifen alkyne 2 (0.20 g, 0.50 mmol), DIPEA 
(0.16 ml, 0.914 mmol) and CuI (0.04 g, 0.23 mmol) were reacted in anhydrous THF (20 ml) as 
described for compound 3 above. Due to PEG’s solubility in water, no aqueous workup was done. 
Solvent was evaporated and the crude was purified by prep. TLC using DCM: MeOH (10:1) to 
give compound 12 as an off white solid (0.51 g, 63 %). 1H NMR (400 MHz, cdcl3) δ 7.50 (t, J = 
9.6 Hz, 1H), 7.25 (dd, J = 9.7, 4.9 Hz, 2H), 7.19 – 7.10 (m, 2H), 7.11 – 7.05 (m, 2H), 7.05 – 6.97 
(m, 3H), 6.89 (t, J = 6.7 Hz, 1H), 6.82 – 6.73 (m, 1H), 6.69 (d, J = 8.7 Hz, 1H), 6.44 (d, J = 8.7 
Hz, 1H), 6.33 (s, 1H), 5.13 (s, 1H), 4.71 (s, 1H), 4.46 – 4.35 (m, 2H), 4.28 (d, J = 11.5 Hz, 2H), 
4.05 (d, J = 19.4 Hz, 5H), 3.83 (d, J = 31.8 Hz, 4H), 3.76 (t, J = 4.7 Hz, 3H), 3.57 – 3.44 (m, 33H), 
3.28 (s, 3H), 3.13 (s, 1H), 2.99 (q, J = 7.5 Hz, 2H), 2.85 (s, 1H), 2.69 – 2.61 (m, 3H), 2.59 (s, 2H), 
2.42 – 2.29 (m, 1H), 2.19 (dd, J = 13.4, 6.7 Hz, 4H), 1.63 (t, J = 16.9 Hz, 3H), 1.46 (d, J = 19.4 
Hz, 5H), 1.43 – 1.28 (m, 15H), 1.16 (s, 65H), 0.81 (dt, J = 13.5, 7.3 Hz, 9H). 31P NMR (162 MHz, 
cdcl3) δ -3.98. HRMS (ESI) m+z Calcd. for C89H149N5O18P [M+H
+]: 1607.0635, found 1607.0629. 
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With the recent US FDA approvals of Belinostat and Panobinostat, the future of HDACi 
drug discovery field looks promising. Several other HDACi are in different stages of preclinical 
and clinical development to address the shortcomings of the clinically approved HDACi.  
In my thesis work, I have successfully explored different approaches to making new series 
of HDACi with exceptional in vitro therapeutic index (a measure of toxicity towards cancer cells 
relative to healthy cells). In chapter two, I described effort towards expanding the SAR studies on 
macrolide-based HDACi derived from clarithromycin, as a continuation of studies in our lab 
towards making lung tissue- selective HDACi.1-2 In this project, SAR studies were focused on the 
points of attachment of HDACi template to clarithromycin and the zinc binding group (ZBG). In 
the former, modifications were made on both desosamine and cladinose sugars of clarithromycin. 
Among the new series of compounds made, the cladinose-modified series afforded us the lead 
compound (with six methylenes as connecting unit between the triazolyl end and hydroxamate), 
thereby justifying modification at this end of clarithromycin. However, it is yet to be shown that 
synthetic transformations on cladinose sugar do not significantly affect lung tissue accumulation 
profile of clarithromycin. Hence, future studies will focus on the in vivo bio-distribution study and 
therapeutic effect of my lead compound in animal models of lung cancer.  In the latter part of this 
project, I adopted a biaryl ZBG into the design of clarithromycin-based HDACi as an extension of 
the SAR studies. This resulted in compounds that potently and selectively inhibit HDAC 1 and 
HDAC 2, consistent with previous studies that adopted the same ZBG.3 Surprisingly though, none 




maximum concentration tested. The lack of cytotoxicity observed might be due to the inability of 
the compounds to efficiently penetrate the cell membrane, hence the modest to moderate changes 
to the acetylation status of H4, a marker of intracellular class I HDAC inhibition observed in the 
cells. Studies that shed light on efflux of these compounds from the cells may help explain the 
discrepancy observed between the in vitro HDAC inhibition and the antiproliferative activities of 
these compounds. 
 Using design-multiple ligands approach, I also explored the beneficial effects of having 
bifunctional compounds as compared to combination therapy. It is a common clinical practice for 
patients to be prescribed two or more drugs with the goal of achieving synergistic therapeutic 
effects resulting from the action of the individual drugs. In such cases though, there is the challenge 
of dealing with issues such as the individual toxicity associated with each drugs, different 
pharmacological profiles of each drugs also requires that the dosage be optimized, which further 
makes combination therapy complicated. To avoid these bottlenecks, the bifunctional approach 
that incorporates two “warheads” into a single compound is currently being explored as a safer 
and probably more cost-effective approach.4 In my approach, I generated bifunctional COX-
HDAC inhibitors, that showed impressive cytotoxic effects in prostate cancer cell lines, with 
selectivity towards AR-dependent prostate cancer cell line. Lead compounds from this study 
showed unprecedented selective cytotoxicity towards prostate cancer cell lines relative to healthy 
control cell line Vero. What makes this concept more appealing is that some of the bifunctional 
compounds significantly downregulate activation of NF-kB, a driver of inflammation in tumors. 




 While the roles of individual HDAC isoforms in melanoma progression has not been fully 
characterized, some studies have shown that upregulation of HDAC 5 and HDAC 6 are important 
in melanoma survival.5-6 Using a targeted approach, I made HDACi by incorporating a group with 
high affinity for melanin to further study the roles of HDACs in melanoma survival. High melanin 
production is a common phenomenon in many melanoma cases. The lead compound from this 
work is about ten-fold more potent than SAHA towards HDAC 1, and has about the same activity 
towards HDAC6 as SAHA. Surprisingly, none of the compounds were significantly cytotoxic 
towards melanoma cell lines, B16F10 and A375. In order to improve on the cellular potency of 
the compounds, I made a prodrug bearing the benzamide template linked by a labile bond to a 
hydroxamate-based HDACi. The prodrug showed some promise, but did not show the anticipated 
benefit in melanoma cell lines. Both the benzamide HDACi and the prodrug may be redesigned in 
future studies to optimize for potency in cell lines.  
 Lastly, lipid nanoparticles have emerged as important drug delivery systems for drugs with 
poor pharmacokinetic profiles, and those with significant off-target toxicities. One approach to 
improve the specificity of nanoparticle for tumors is to have targeting ligands appended to their 
surface to further enhance their ability to localize in tumors. I carried out preliminary studies 
evaluating the suitability of clarithromycin and tamoxifen as targeting ligands on liposomes. 
Liposomes incorporating clarithromycin-functionalized phospholipid showed promising results in 
terms of uptake into macrophage cells. However, this needs to be reproduced and optimized to 
improve on the cellular uptake. Likewise, phospholipid functionalized with tamoxifen showed 
some promise in facilitating uptake of liposomes into MCF-7, an estrogen receptor positive breast 




clarithromycin- and tamoxifen-   functionalized liposomes to deliver chemotherapeutic agents to 
cancer cells, and ultimately to tumors in vivo. 
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Table 1: Growth inhibitory activity of selected bifunctional compounds in HeLa cells 



































Figure 1: Docking against HDAC6; i) series 1 in HDAC6: 2a= light blue, 2b= yellow, 2c= 
magenta; ii) space fill model representation of (i), iii) series 2 & 3 in HDAC6: 7a= light blue, 7b= 
magenta, 7c= yellow, 8= brown; iv) space fill model representation of (iii); v) series 4 in HDAC6: 
11a= blue, 11b= magenta, 11c= yellow;  vi) space fill model representation of (v); vii) series 5 in 








Figure 2: Docked structures of compounds 11a-c in the HDAC 1 active site: 11a= yellow, 11b= 




Figure 3: Docked structures of compounds 11a-c in the HDAC 2 active site: 11a= yellow, 11b= 







Intracellular target validation: 
 
Figure 4: Western blot analysis of histone H4 acetylation in LNCaP cell line. Lanes: 1, Control 
(DMSO); 2, SAHA (10 μM); 3, 2b (2 μM); 4, 2b (10 μM); 5, 11b (2 μM); 6, 11b (10 μM); 7, 17b 
(1.5 μM); 8, 17b (10 μM); 9, indomethacin (10 μM). 
 
 
Figure 5: Comparison of antiproliferative activities of compounds 2b and 11b, and combinations 























Figure 7: BEAS-2B cells, transfected with NF-κB luciferase construct, were pre-treated with 
tested compounds at 1 μM for 1hr and stimulated with NTHi for 5hr, and NF-kB promoter activity 
was then measured by performing luciferase assay. Data are mean ± SD (n=3). *p<0.05. Statistical 
analysis was performed using Student’s t-test. Data are representative of three independent 
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